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ABSTRACT 
The complement system consists of -30 proteins involved in a series of cascading 
reactions ultimately resulting in the destruction of invading pathogens. Central to the 
pathway are three paralogous proteins, C3, C4 and C5. Furthermore, pivotal to the 
successful functioning of this system are five proteins belonging to the regulators of 
complement activation (RCA) family - they ensure that a complement-mediated immune 
response is proportionate and targeted against infection. RCA proteins are characterised 
by numerous occurrences of a single module-type; the complement control protein (CCP) 
module. In this work, comprehensive bioinformatics analyses of sequence and structure 
of CCP modules was undertaken. Through extensive database and literature searches 
CCP module sequences and structures were retrieved and large-scale all-against-all 
sequence and structure comparisons performed; analysis of intermodular orientations for 
pairs of modules and larger fragments was performed. These analyses revealed 
interesting consensus and novel trends. Based upon optimal use of experimentally 
determined CCP module structures as templates, an automated large-scale protein 
structure comparative modelling procedure was implemented for a set of 203 CCP-
module sequences. The accuracies of models produced were validated, and the models 
are publicly available online at "The CCP module model database" 
(http://www.bru.ed.ac.uk/—dinesh/ccp-db.html), which also serves as a comprehensive 
resource for information on CCP modules. By way of example, surface electrostatic 
analyses were undertaken for the first 28 CCP module models of complement receptor 
type 1 (CR1). This revealed a striking case of adaptive evolution - assignments to 
clusters based on surfaces differ from assignments to clusters based on sequences and 
sheds light on mutagenesis studies. Overall, the models provide a rich vein of 
information for design of mutants, interpretation of phenotypic consequences of 
polymorphisms, and prediction of function. This wider utility of models is discussed in 
relation to inferring consequences of several disease-associated sequence variations for 
complement proteins - CR1, factor H, MCP, and another CCP-containing protein, 
SRPX2. Finally, homology models of CS and C5b were created on the basis of the recent 
landmark publication of C3 and C3b structures. This revealed presence of a novel 
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putative disulfide bond in C5, and additionally helped revisit previous functional peptide 
and mutant data and provides insight into the latter stages of complement assembly. 
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Chapter 1 
The Complement System: Function, Regulation and 
Role in Disease 
ti 	The Complement System 
The complement system is an evolutionary ancient, essential molecular component of 
innate immunity that consists of a set of approximately 30-plasma and cell-
membrane-attached proteins (See Table 1.1 for a complete list). These proteins act in 
an orchestrated fashion (Figure 1. 1), to eliminate infectious organisms and other 
unwanted particles from the body, elicit inflammatory responses, and facilitate 
adaptive immune responses (Walport 2001b; a; Carroll 2004b; a). 
No. Complement Approximate No. of Approximate Cleavage 
component protein molecular chains plasma or fragments 
mass (kDa) serum 
concentrations 
(jtg/inl) 
1 Clq 410 18 70-300 
2 Cir 83 1 34-100 
3 Cis 85 1 30-80 
4 C2 102 1 15-30 C2a,C2b 
5 C3 190 2 1200-1500 Oa, C3b,C3c, 




6 C4 205 3 350-600 C4a, C4b, C4c, 
C4d, C4dg 
7 CS 196 2 70-85 C5a, C5b 
8 C6 125 1 60-70 
9 C7 120 1 55-70 
10 C8 150 3 55-80 
11 C9 66 1 50-160 
12 Factor B 100 1 140-240 Ba, Bb 
13 Factor D 24 1 1-2 
14 Properdin 224 4 20-30 
15 MBL 540 18 1 
16 MASP-1/MASP-3 94 1 
17 MASP-2 76 1 
18 Cl inhibitor (Clinh) 105 1 180-275 
19 C4131? 550 7 250 
20 Factor H 150 1 300-560 
21 Factor 1 100 2 34-50 
22 CR1 (CD35) 160-250 1 
23 CR2 (CD2I) 140 1 
24 CR3 (CDIIb/18) 265 2 
25 CR4(CD11c/18) 245 2 
26 DAF (CD55) 70 1 
27 MCP (CD46) 45-70 1 
28 CIqR 65 1 
29 C3aR 54 1 
30 C5aR(CD88) 45 1 
31 CD59 20 1 
32 Carboxypeptidase N 280 4 
Table 1.1: Proteins involved in the complement system. The table provides a summary ot 
information on the complement proteins. 	Most values derive from the Merck manual 
(http://www.merck.com/mrkshared/nirnanual/), others from literature. Abbreviations used in table: C 
(except where stated otherwise) = complement component; MBL = mannose- or mannan-binding 
lectin; MASP = mannose-binding lectin-associated serine protease; C4BP = C4b-binding protein; CR = 
complement receptor; DAF = decay accelerating factor; MCP = membrane cofactor protein; CD = 
clusters of differentiation; cleavage fragments are denoted with a small letter after the component. 
Even though its principal function is supposed to be protective, inappropriate 
complement activation or overzealous complement activity have been linked to a 
2 
wide variety of inflammatory conditions - reviewed in Section 1.5. In this sense, the 
complement system has been referred to as a "double-edged sword" (Colten 1994). 
The complement system can be activated via three routes namely, the 
alternative pathway, classical pathway, and lectin pathway. All three activation 
pathways result in formation of bimolecular convertase enzymes (Figure 1.1) that 
drive a cascade of proteolytic events, providing a basis for amplification. 
Classical Pathway 	Lectin Pathway 	 Alternative Pathway 
Ci q,r,s 	MBP, MASP-i ,2 	
initial C3 Convertase 
	
Activator I C4 	 CR1 	 C3b + C3(H20)Bb 
Clqrs 	C2 	Factor H R(Factor B) 
MCP 




C3 Convertase C4b2a 	 Loop 	 C3 Convertase 
Opsonisation 	 Opson:sation 
4 * Ijft 




Membrane Attack Complex 
V 
Lysis 
Figure 1.1: Schematic diagram to summarise the complement "cascade" system. The classical and 
lectin pathways are triggered by binding of antibodies to complement component Cl (consisting of 
Clq and two copies of Cir and Cis), or specific sugars to the maimose-binding proteinlmannose-
binding protein-associated serine protease (MBP/MASP) complex. The alternative pathway runs in 
continuous "tick-over" mode because C3 undergoes spontaneous conversion to C3(H20). The five 
RCAs are C4b-binding protein (C4BP), MCP, DAF, CR1, and factor H. All act in subtly different 
ways upon the convertases. See text for a description of pathway and explanation of abbreviations. 
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1.1.1 The Alternative pathway 
The alternative pathway of complement activation provides a first line of defence 
because it is permanently switched on at a low level (i.e. it operates in "tick-over" 
mode), but is kept in check by regulators that act only on self-surfaces. The presence 
of any unprotected, "non-self' surface thus induces rapid escalation of the system. In 
the alternative pathway (Figure 1. 1), the complement component protein C3 
undergoes slow, spontaneous hydrolysis to yield C3(H20). C3(H20) associates with a 
second protein, factor B. Factor B, bound to C3(H20), is a substrate for factor D. In 
this context factor B is cleaved to form Bb, and the resultant C3(H20).Bb complex is 
a proteolytically active entity. It cleaves 0 into Oa and C3b. C3b attaches 
covalently to surfaces, and like C3(H20), associates with factor B, ultimately forming 
the alternative pathway convertase, C3b.Bb. This surface-associated bimolecular 
enzyme converts more molecules of 0 to C3b, thus contributing to the formation of 
extra convertases and the creation of a positive feedback loop. 
1.1.2 The Classical and Lectin pathways 
The complement system may additionally be activated by antibodies bound to 
polyvalent antigens. This is referred to as the classical pathway (linking the innate 
and adaptive immune systems). In the lectin pathway, sugars on bacterial surfaces 
activate complement. The classical and lectin pathways involve cleavage of 
complement component C4, a homologue of C3, resulting in formation of CO. CO 
also binds to surfaces and it forms a convertase through association with C2, creating 
the bimolecular, proteolytically active complex C4b.2a. Like the alternative pathway 
convertase, the classical/lectin pathway convertase thus formed cleaves C3 to C3b and 
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C3a. The C3b product is available for formation of more alternative pathway 
convertase complexes (i.e., C3b.Bb). 
1.1.3 The common-Lytic pathway 
Both alternative and classical pathway convertases can associate with further 
molecules of C3b to form trimolecular complexes, C3b.Bb.C3b and C4b.2a.C3b, 
which have CS convertase activity, i.e. they cleave complement component C5 into 
C5a and C5b. C5b may subsequently act as a nucleation site for assembly of C6, C7, 
C8 and several molecules of C9 to form a multiprotein membrane attack complex 
(MAC, or C5-C9) that penetrates cell membranes, causing lysis, leakage and cell 
death. 
A further consequence of complement activation, which is independent of 
MAC formation, is deposition of multiple molecules of C3b and C4b on the target 
surface. This is called opsonisation and provides the basis for immune clearance, an 
important process by which C3b/C4b-coated particles are cleared from the 
bloodstream (Ross and Medof 1985). Furthermore, the cleavage products of C3b - 
C3d and C3dg - are ligands for other receptors, able to trigger signalling pathways 
that bring about, for example, enhanced levels of antibody production by B-cells 
(Dempsey et al. 1996). Finally, the small fragments, C3a, C4a, and C5a, cleaved 
from C3, C4, and C5 during complement activation, are the anaphylatoxins (also 
referred to as the anaphylotoxins) - i.e. chemotactic peptides that mediate a series of 
proinflammatory phenomena. Thus, activation of complement disrupts the membrane 
of the target cell, removes foreign and other unwanted particles to the liver for 
destruction, enhances the adaptive immune response, and, via anaphylatoxins, recruits 
lymphocytes and macrophages to the site of infection. 
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1.2 The Regulators of Complement Activation 
Not only is the complement system effective in immune defence, but it also has 
potential for damage to self. It is therefore vital that complement activation is both 
capable of being rapidly triggered, and tightly regulated. These properties are 
achieved largely as a result of assembly and decay of the aforementioned C3 
convertase enzymes, C3b.Bb and C4b.C2a, which occupy pivotal positions within the 
pathway. It is the positive feedback loop involving C3b production and convertase 
formation that provides complement with the potential to act in a rapid (explosive) 
fashion. The bimolecular convertases (C3b.Bb and C4b.C2a) have a half-life in the 
order of minutes. Once they have decayed into their components, they cannot 
reassemble; for example, C3b must associate with a fresh molecule of intact factor B 
to produce a new convertase complex. Consequently, there is the potential for a 
complement response to die out when the stimulus to activation is destroyed and/or 
subject to immune clearance. 
In addition, a critical set of five proteins are dedicated to regulation of the 
complement cascade via interactions with the convertases. These are known as the 
regulators of complement activation (RCA) family, and consist of C4b-binding 
protein (C4BP), complement receptor type I (CR1, CD35), decay accelerating factor 
(DAF, CD55), factor H (fl-1) and membrane cofactor protein (MCP, CD46) (Table 1.1 
and Figure 1.2). The RCA proteins have two principal activities in terms of their 
action on the convertases. Some of the RCAs accelerate the decay of the convertases, 
reducing their half-life from minutes to seconds. This is decay accelerating activity 
(DAA). The mechanism is unknown. Some RCAs act as cofactors for the protease, 
factor I (cofactor activity, CA); factor I cleaves C3b and C4b to generate C3dg and 
C4dg, thus further reducing potential for convertase formation. The five human 
RCAs have overlapping functional profiles. Molecules of at least one of DAF, MCP, 
and CR1 are expressed on the surfaces of every cell in the body where they play a 
protective role. The soluble regulators, C4BP and fl-I, are particularly important for 
preventing activation at self-surfaces that lack membranes, because such surfaces, are 
unlikely to possess the cell-bound regulators DAF, MCP, and CR1. 
The RCA family is exceptional amongst the complement proteins in that each 
of the five proteins are composed almost entirely of multiple examples of a single 
type of domain or module known as the complement control protein (CCP) module 
(analysed in detail in the following chapter). 	RCA-mediated protein-protein 
interactions occur via binding sites extending on one or over several adjacent CCP 
molecules. 
As a consequence of its potential for inflicting damage on invaders, a large 
range of complement evasion strategies have evolved amongst microorganisms 
(Lindahl et al. 2000). The most widespread anti-complement measure involves 
"hijacking" of RCAs. Many bacteria express proteins that act as virulence factors 
through their ability to sequester RCAs. Another approach is to "steal" an RCA gene 
and adapt it for the purposes of the invader. Thus one or more pox viruses, like 
Vaccinia virus, produce proteins that closely mimics the mammalian RCAs (VCP) 
both in sequence and function (Ciulla et al. 2005). The following section briefly 
describes the main functions of each RCA (and VCP) in terms of their 
activities/interactions with other complement components, and additionally lists 
interactions with all other known ligands to date. The structures of these proteins are 
discussed in depth in Chapter 2. 
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1.2.1 Complement Receptor type 1 
Complement receptor type 1 is a transmembrane, single polypeptide chain 
glycoprotein containing 30 CCP modules in its most common allotype, expressed 
primarily on erythrocytes and other blood cells (Klickstein et al. 1987). It is unique in 
having both DAA and CA and acting on both the alternative and classical pathway 
convertases. in CR1 (Krych-Goldberg and Atkinson 2001b) there are three functional 
regions, each extending over three modules, within the extracellular domain: one copy 
of "site 1" and two near-identical copies of "site 2". Site 1 resides within the N-
terminal, membrane-distal, three CCP modules of CR1 (CCPs 1-3). It has convertase 
DAA along with the ability to bind C4b (and C3b weakly). Each copy of site 2 (CCPs 
8-10 and CCPs 15-17) has high affinity for C3b and C4b, and has CA. 
Ligand Binding site References 
Complement component C3b CCPs 8, 9, 10 + CCPs 15, 16, 17 (Krych et at. 1991; Krych 
Binds CCPs 1, 2, 3 weakly et al. 1994; Krych et al. 
1998) 
Complement component C4b CCPs 1,2,3 + CCPs 8, 9, 10 + CCPs (Krych et at. 1991; Krych 
15,16,17 et al. 1994; Krych et al. 
1998) 
Complement component iC3b CCPs 1, 2, 3 + CCPs 8, 9, 10 + CCPs (Krych et al. 1991; Krych 
15, 16, 17 et at. 1994; Krych et at. 
1998) 
Clq and mannan-binding lectin CCPs 22-28 (Klickstein et al. 1997; 
Ghiran et at. 2000) 
P1asmodiumfa1cparum adhesin CCPs 8, 9, 10 + CCPs 15, 16, 17 (Rowe etal. 1997; Rowe 
Erythrocyte Membrane et al. 2000) 
Protein I (PfEMP1) 
Leishmania major - (da Silva et al. 1988; Da 
Silva etal. 1989) 
Mycobacterium tuberculosis - (Schlesinger et al. 1990) 
Table 1.2: Binding sites on CR1 for various ligands. 
1.2.2 Factor H 
Factor H is an abundant, soluble single-chain, plasma glycoprotein composed from 20 
CCP modules. It has both DAA and CA, but it acts exclusively upon the alternative 
pathway convertase. The four N-terminal CCP modules (CCPs 1-4) harbour a C3b-
binding site and this region is the locus of the CA and DAA of factor H, while the two 
C-terminal modules (CCPs 19-20) form another C3b-binding site (specifically for the 
C3d component of C3b) and are crucial for self and non-self discrimination. A third 
set of modules involving CCPs 12-14 are thought to bind another region of C3b 
(C3c). 
Ligand Binding site References 
Complement component C3b CCPs 1. 2,3,4 + CCPs 12, 13, 14 (Jokiranta etal. 2000) 
(0c) + CCPs 19, 20 (0d) 
Glycosaminoglycans (GAGs) CCP 7 + CCP 9 + CCPs 12, 13, 14 + (Pangburn et al. 1991; 
CCPs 19, 20 Blackmore etal. 1996; 
Blackmore et al. 1998b; 
Prodinger etal. 1998; 
Ormsby et al. 2006) 
Sialic acid CCPs 16 --20 (Ram et al. 1998b) 
L-selectin - (Ma!hotra et al. 1999) 
C-Reactive Protein (CRP) CCPs 7 - 11 (Jarva etal. 1999) 
Adrenomedu!!in (AM) CCPs 15-20 + CCPs 8-11 (Martinez et al. 2003) 
Borrelia afzelii 
BaCRASP-1, -2 CCPs I - 7 (Kraiczy et al. 2001a) 
BaCRASP-4, -5 CCPs 19, 20 
Borrelia burgdorferi 
BbCRASP-1, -2, -3, -4, CCPs 19,20 (Alita!o etal. 2001; 
-5 CCPs 15 - 20 Hellwage et al. 2001; 
OspE CCPs 19, 20 Kraiczy etal. 2001a; 
p21 CCPs 19, 20 Kraiczy et al. 2001b; 
ErpA (BBL39) CCPs 19, 20 Alitalo et al. 2002; 
ErpC CCPs 19, 20 Stevenson etal. 2002; 
ErpP (BBN38) - McDowell et al. 2003; 
Metts et at. 2003) 
35kDa protein 
Borrelia hermsii 
FhbA (FHBPI9) CCPs 1-7 + CCPs 16-20 (Hovis et al. 2004; Hovis 
FHBP28 et al. 2006) 
Borrelia recurrent/s - (Meri et al. 2006) 
Borrelia duitonii - (Meri et at. 2006) 
Borrelia parkeri - (McDowell et al. 2003; 
McDowell et al. 2004) 
Borrelia garinii - (Alitalo et al. 2005) 
Candida albicans 
CaCRASP-1, -2 CCPs 6, 7 + CCP 19 (Meri etal. 2002a) 
Streptococcus pneumoniae 
Hic CCPs 8 	11 (Duthy et al. 2002; Jarva 
PspC CCPs 6-10 + CCPs 13- 15 et al. 2002; Dave et al. 
2004a; Dave et al. 2004b; 
Quin et al. 2005) 
Streptococcus pyo genes 
M-Proteins CCP 7 (Blackrnore etal. 1998a; 
Fba CCP 7 Kotarsky etal. 1998; 
Pandiripa!!y et al. 2002; 
Pandiripa!ly et al. 2003; 
Perez-Caballero et al. 
2004; Wei et al. 2005) 
Streptococcus agalactiae 
P protein CCP 13 or CCP 20 (Areschoug etal. 2002; 
Jarva et al. 2004) 
Echinococcus granulosus - (Diaz et al. 1997) 
HIV 
gp41, gpl2O - (Stoiber et al. 1996; 
Stoiber et al. 1997) 
Neisseria gonorrhoeae 
PorinlA CCPs 16-20 (Ram et al. 1998a; Ram 
LPS - etal. 1998b) 
Neisseria men/n gitidis 
Class 3 PorB - (Ram etal. 1999) 
Onchocerca volvulus 
Microfi!ariae (ml) CCPs 8 - 20 (Meri et al. 2002b) 
Yersin ia enterocolitica 
YadA - (China eta]. 1993) 
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T,'ypanosorna cruzi - (Tomlinson et al. 1994) 
Treponema denticula CCPs 1-7 (McDowell et al. 2005) 




LthA CCPs 18-20 (Verma et al. 2006) 
Table 1.3: Binding sites on Factor H for various ligands 
1.2.3 Decay-accelerating factor 
Decay accelerating factor (DAF, also called CD55), is a single-chain glycoprotein 
(Medof et al. 1987a; Medof et al. 1987b) attached to the membrane by a glycosyl-
phosphatidylinositol (GPI)-anchor (Medof et al. 1986), and possesses only DAA. It 
has four CCP modules and its classical pathway convertase regulation has been 
mapped to CCP modules 2 and 3, while alternative pathway convertase regulation is 
encompassed by CCPs 2-4 
Ligand Binding site References 
Complement 
convertases/componentS 
C3bBb CCPs 2, 3,4 (Brodbeck etal. 1996; 
C4b2a CCPs 3, 4 Kuttner-Kondo et al. 
C3b - 2001; Harris et al. 2005) 
Factor B - 
Bb subunit - 
CD97 CCP 1 (Hamann etal. 1996; 
Hamann etal. 1998; Qian 
et al. 1999) 
Echo virus 
7 CCPs 2, 3,4 (Clarkson et al. 1995; 
11 CCP 3 + 20% contribution from CCPs Lea et al. 1998; Bhe!!a et 
12 1, 2, 4 at. 2004; Pettigrew et al. 
CCPs 2, 3, 4 2006) 
Coxsackievirus 
B3 CCP 2 (Bergelson et al. 1995; 
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A21 CCP 1 Shafren et al. 1997) 
Enterovirus 70 CCP 1 (Karnauchow et al. 1998) 
Escherichia co/i 
Dr adhesins CCPs 2, 3 (Nowicki et al. 1993; 
X adhesins CCPs 3, 4 Pham et al. 1995; Le 
Afa adhesins CCPs 2, 3,4 Bouguenec et al. 2001; 
P1845 adhesins CCPs 2, 3, 4 Hasan etal. 2002; 
Anderson et al. 2004) 
Helicobacterpylori CCPs I -4 (O'Brien et al. 2006) 
Table 1.4: Binding sites on DAF for various ligands 
1.2.4 Membrane cofactor protein 
Membrane cofactor protein (MCP, also called CD46) is expressed on the surface of 
nucleated human cells (Lublin et al. 1988) and contains four CCP modules. MCP 
exhibits only CA, i.e. acts as a cofactor for factor 1-catalysed proteolysis of C3b and 
C4b molecules that are deposited on host cell surfaces and hence regulates both 
pathways of complement. Domain deletion/swap experiments in MCP indicate that 
for C4b-binding and CA, CCPs 2-4 are essential, although module 1 also contributes. 
CCP modules 3 and 4 bind C3b, but the additional presence of module 2 is required 
for C3bCA. 
Ligand Binding site References 
Complement component C3b CCPs 2-4 (Adams etal. 1991; Iwata 
etal. 1995) 
Complement component C4b CCPs 1-4 (Adams et al. 1991; Iwata 
et al. 1995; Liszewski et 
al. 2000) 
31integrins - (Lozahic et al. 2000) 
Measles virus 
. 	Hemagg!utinin CCPs 1,2 (Dorig etal. 1993; 
Naniche et al. 1993; 
Manchester etal. 1997) 
Human herpesvirus 6 
12 
Complex 	of CCPs 2, 3 (Santoro et al. 1999; 
glycoprotein H, L and Greenstone et al. 2002; 
Q Mori et al. 2003) 
Group B and D adeno viruses 
Fiber knob domain CCPs 1, 2 (Gaggar et al. 2003; 
Segerman et at. 2003; 
Wu et al. 2004; Gaggar et 
at. 2005) 
Neisseria 	gonorrhoeae 	and 
meningitidis CCP 3, 4 + serine-threonine-proline (Kallstrom et al. 1997; 
Type iv pili domain Kalistrom et at. 1998; 
Kalistrorn et al. 2001) 
Group A Streptococcus 
M-Protein CCPs 3,4 (Okada et at. 1995; 
Giannakis et at. 2002) 
Table 1.5: Binding sites on MCP for various ligands 
1.2.5 C4b-binding protein 
C4b-binding protein (C413P) is a soluble glycoprotein, which performs a parallel role 
to factor H, but acts predominantly upon the classical pathway convertase. It is the 
only polymeric member of the RCAs, having seven a-chains, each containing eight 
CCP modules and a single 13-chain containing three CCP modules. In the case of 
C4BP, the three N-terminal CCP modules of the a-chain are required for C4b-binding 
and these are also the site for DAA and CA, whereas modules 1-4 have been 
implicated in weak C3b-binding. 
Ligand Binding site References 
Complement 	component 	C4b CCPs 1, 2, 3 of a-chain, (Ogata et al. 1993; 
(C4c and C4dg fragments) cluster of charged AAs on interface Accardo etal. 1996; 
CCP I-2 Hardig et al. 1997; Blom 
et al. 1999; Blom et al. 
2001a; Leung et al. 2006) 
Complement component C3b CCPs 1-4 of a-chain, (Blom etal. 2003) 
cluster of charged AAs on interface 
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CCP 1-2 
Glycosaminoglycans (GAGs) CCPs 1, 2, 3 of a-chain, (Blom et al. 1999; Blom 
cluster of charged AAs on interface et al. 2001 a) 
CCPI-2 
Protein S CCPs 1, 2 of 13-chain (Hardig et al. 1993; 
Hardig and Dahlback 
1996; Blom et al. 1998; 
van de Poel et al. 1999; 
Webb et al. 2001) 
CD40 CCP 8 of a-chain + core region (Brodeur et al. 2003) 
Serum amyloid P component CCP 8 of a-chain H- core region (Garcia de Frutos et al. 
(SAP) 1995) 
DNA, RNA and necrotic cells CCPs 1, 2 of a-chain, (Trouw et al. 2005) 
cluster of charged AAs on interface 
CCP I-2 
Streptococcus pyogenes 
M-proteins CCPs 1, 2 of a-chain (Thern et al. 1995; 
Accardo et al. 1996; 
Blom et al. 2000a; Perez- 
Caballero et al. 2004; 
Jenkins et al. 2006) 
Bordetella pert ussis 
Filamentous Cluster of charged AAs on interface (Berggard et al. 2001) 
hemagglutinin CCP 1-2 
Neisseria gonorrhoeae 
Type iv pili CCPs 1, 2 of a-chain (Blom etal. 2001b; Ram 
PorlA CCP 1 of a-chain et al. 2001) 
PorIB CCP 1 of a-chain 
Escherichia coli K] 
OmpA CCP 3 of a-chain (Prasadarao et al. 2002) 
Moraxella catarrhalis 
UspAl CCPs 2, 5, 7 of a-chain (Nordstrom etal. 2004) 
UspA2 CCPs 2, 5, 7 of a-chain 
Candida albicans CCPs 1, 2 of a-chain (Meri et al. 2004) 
Borrelia recurrentis - (Meri et al. 2006) 
Borrelia duttonii - (Meri et al. 2006) 
Table 1.6: Binding sites on C4BP for various ligands 
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1.2.6 Complement receptor type 2 
Complement receptor 2 is a glycoprotein of 15 or 16 CCP modules that does not 
regulate complement activation, but is located in the same gene cluster as the 
remaining five RCAs. It connects the innate and acquired immune responses 
(Matsumoto et at. 1991); C3d becomes covalently attached to antigens, and the 
subsequent recognition of C3d by CR2 on the surface of a B cell enhances induction 
of the immunoglobulin IgG response by three to four orders of magnitude (Dempsey 
et al. 1996). 
Ligand Binding site References 
Complement components C3d, 
C3dg 
CCPs 1, 2 (Care! etal. 1990; Martin 
etal. 1991; Szakonyi et 
al. 2001) 
Complement component i0b CCPs 1, 2 (Schwendinger etal. 
1997) 
CD23 CCPs 1, 2 + CCPs 5-8 (Aubry et al. 1994) 
Interferon-a (117N-a) CCPs 1-4? (Delcayre et al. 199 1) 
DNA CCPs 1, 2 (Holers and Kulik 2006) 
Epstein-Barr virus 
Gp350, gp220 CCPs 1, 2 (Fingeroth etal. 1984) 
Table 1.7: Binding sites on CR2 for various ligands 
1.2.7 Vaccinia virus complement control protein 
VCP was the first microbial protein identified to have complement inhibitory activity 
(Kotwal and Moss 1988; Kotwal et al. 1990), and is the smallest and simplest 
complement control protein (244 residues, four CCP modules), lacking glycosylation 
or other modifications. It has been reported to act as a cofactor for factor I cleavage 
of C3b and C4b (Kotwal et al. 1990; McKenzie et al. 1992) inhibiting both alternative 
and classical pathways of complement (Sahu et al. 1998) and also weak DAA activity 
(Mullick et al. 2005). Through this ability, VCP secreted from virally infected cells, 
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protects the host cell and released viral progeny from host complement attack (Isaacs 
et al. 1992; Howard et al. 1998). 
Ligand Binding site References 
Human complement component CCPs 1-4 (Rosengard et al. 1999; 
C3b (C3dg) Bernet et al. 2004; 
Mullick etal. 2005) 
Human complement component CCPs 1-4 (Bernet etal. 2004; 
C4b (C4c) Mu!!ick et al. 2005) 
Complement convertases 
C3bBb CCPs 1- 4 (McKenzie etal. 1992; 
C4b2a CCPs I -4 Mu!Iick et al. 2005) 
G!ycosaminoglycans (GAGs) CCPs 1,2 + CCP 4 (mainly) (Smith etal. 2000; 
Murthy et al. 2001; Smith 
et al. 2003; Ganesh et al. 
2004) 
Suramin CCP 4 (Ganesh et al. 2005) 
Table 1.8: Binding sites on VCP for various ligands 
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1.3 Complement components C3, C4 and C5 
Fundamental to the complement pathway are three large paralogous proteins C3, C4 
and C5. These proteins emerged over 700 million years ago (Sunyer et al. 1998) and 
belong to the a2-macroglobulin (a2M) family, whose other members include the 
proteinase inhibitor a2M, the insect and nematode thioester-containing proteins 
(TEPs), and CD109 (Chapter 5). These proteins (1400 - 1800 amino acid-residues) 
are characterised by homologous sequence features - including a unique thioester 
motif (not present in C5) - and have important roles in the immune response in 
metazoans, predating the emergence of immunoglobulins (Budd et al. 2004). These 
proteins are now recognised as being multiple-domain in nature (discussed further in 
Chapter 5). 
During and following complement activation, C3, C4 and CS are cut 
selectively by specific proteases at analogous Arg residues in the a-chain to create the 
anaphylatoxins, C3a, C4a and CSa, and the larger C3b, C4b and C5b fragments. 
Otherwise, despite high sequence similarities, these three proteins have distinct 
functions. The thioester allows activated C3b and C4b molecules to bind covalently 
to other molecules. Complement components C3, C4 and CS are synthesised as 
single chains, but post-translational processing results in disulfide-linked multichain 
structures (two chains in C3 and C5, a and 0; three chains in C4 a, P and y  via an 
additional tetra-arginine site). 
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1.4 Terminal components 
The membrane attack complex is a large, membrane-bound protein complex that is 
the ultimate product of complement activation. It is assembled from five distinct 
soluble plasma proteins (C5b-C9). The terminal components C6 (125 kDa), C7 (120 
kDa), C8 (150 kDa) and C9 (66 kDa) have almost entirely modular structures. C6 is 
composed of nine modules or domains, whereas C7, the C8ct and C8J3 subunits, and 
C9, all resemble truncated forms of C6, with successively fewer modules (eight, four, 
four, and three, respectively) (Figure 1.3). 
The five proteins are incorporated in a sequential process that begins with 
proteolytic activation of CS at the target cell surface (see above, and Chapter 5). This 
generates a metastable activated C5b that forms the nucleus for subsequent addition of 
single molecules of C6, C7, C8, and finally, multiple copies of C9 to yield the lytic 
MAC. in addition to the irreversible post-cleavage complex (i.e. C5b.C6), CS also 
binds reversibly to C6 forming the pre-activation complex (i.e. C5:C6), and to C7 via 
its FIMAC (Factor I membrane attack complex) domains (Arroyave and Mullereb.Hj 
1973; Thai and Ogata 2004). 
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1.5 Complement and Disease 
Despite the actions of the RCA protein family and other inhibitory proteins, such as 
CD59, that act elsewhere within the complement system, there remain numerous 
situations in which complement-mediated damage to self-tissues is pathologic. A 
particularly graphic example of complement's destructive power is provided by the 
events that follow xenotransplantation. Naturally occurring xenoreactive antibodies 
trigger a complement-mediated "hyperacute rejection", resulting in decimation of the 
xenograft within minutes. This phenomenon remains one of the major hurdles to a 
potentially revolutionary strategy for overcoming the chronic shortage of donor-
organs. 
Complement has also been implicated in the debilitating symptoms of a very 
long list of clinical conditions (Morgan and Harris 2003; Mizuno and Morgan 2004). 
Varying amounts of evidence exists for complement involvement in the following 
diseases: rheumatoid arthritis, systemic lupus erythematosus, most types of 
glomerulonephritis, atypical haemolytic uraemic syndrome (see Chapter 4, Section 
4.1.1), autoimrnune myocarditis, multiple sclerosis, myasthenia gravis, 
antiphospholipid syndrome, noncardiac myositis, type I diabetes mellitus, age-related 
macular degeneration (see Chapter 4, Section 4.1.2) and asthma. There is also 
evidence for an important role of complement in degenerative diseases, such as 
Alzheimer's disease, and in reperfusion following ischemia during myocardial 
infarction and stroke. Inappropriate complement activation can also be triggered by 
burns and by treatments such as cardiopulmonary bypass and haemodialysis. One in 
five people, according to some estimates, will have a complement-mediated symptom 
at some stage in their lives. Considerable effort has been invested in the search for 
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safe and effective agents to use in the therapeutic downregulation of the complement 
system. 
1.5.1 Inhibiting Complement 
Several candidate anti-complement drugs have made it as far as clinical trials. Only 
brief mention will be made here of the majority of the contenders, the focus of this 
thesis are the natural regulators (and their engineered derivatives). 
1.5.1.1 Small molecule inhibitors 
An excellent example of this approach is compstatin, a cyclic peptide derivative that 
is the product of a painstaking design process (Soulika et al. 2003), although the exact 
mechanism whereby compstatin acts is unknown. It is, however, a good convertase 
inhibitor, and its efficacy in this respect is manifested in several potential clinical 
applications - it is beneficial in animal models of cardiac surgery and 
cardiopulmonary surgery; it also shows promise in ex vivo models of 
xenotransplantation. 
The 74-amino acid C5a fragment - produced upon cleavage of C5 by the C5 
convertases - is an anaphylatoxin. This very potent proinflammatory peptide is one of 
the strongest chemotactic substances known. Acting via specialised receptors on their 
surfaces, it recruits neutrophils and macrophages to a site of complement activation. 
The potential for antagonising its receptor is obvious, and this has been explored most 
successfully using novel, small cyclic molecules derived from the C-terminus of C5a. 
Administration of such compounds to rats or mice by oral and other routes exhibited 
a broad range of anti-inflammatory activities (Woodruff et al. 2005). This work 
nicely demonstrates the therapeutic potential of anticomplement therapies. 
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1. 5.1.2 Antibody-based therapies 
An alternative approach is to block CS cleavage production by means of derivatives 
of antibodies to CS. Two antibody-derived molecules - eculizumab and pexelizumab 
(Kaplan 2002; Whiss 2002) - are at an advanced stage of development for 
cardiopulmonary bypass (Fleisig and Verner 2005), myocardial infarction and stroke, 
as well as chronic conditions such as rheumatoid arthritis, dermatomyosis and 
pemphigus. For example, a study showed that patients with the rare, occasionally 
fatal, blood disease, paroxysmal nocturnal haemoglobinuria (PNH), who received 
eculizumab maintained statistically significant reductions in red blood cell destruction 
and blood transfusions (Hillmen et al. 2004). 
1.5.2 Exploiting the RCAs 
A possible advantage of therapy based on inhibition at the level of CS is that it leaves 
intact earlier stages of complement, including the generation of opsonins and immune 
clearance. 	Thus a patient taking anti-CS therapy would not be entirely 
immunocompromised. If, on the other hand, the goal is to suppress all the principal 
outcomes of complement activation - immune clearance, the generation of all three 
anaphylatoxins, and the formation of the membrane attack complex - then the 
regulators of complement activation represent an excellent starting point. 
An early, thoroughly investigated, example is soluble CR1 (sCR1) or TP1O 
(Rioux 2001). This recombinant protein contains all 30 of CR1's CCP modules 
encompassing functional site 1 and two copies of site 2. Nanomolar concentrations of 
TP1O are able to down-regulate C3 and CS convertases, in both alternative and 
classical pathways of complement, via decay acceleration and cofactor activities. 
Thereby it diminishes production of opsonins, anaphylatoxins and membrane attack 
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complexes. In an exciting initial report (Weisman et al. 1990), TP1O reduced 
infarction size by 44% in a rat model of reperfusion injury of ischemic myocardium. 
Seventeen years later, the efficacy of TP 10 in ischemia-reperfusion injury associated 
with cardiopulmonary bypass - the most promising application so far - is still the 
subject of ongoing investigation. A placebo-controlled, double-blind study involving 
564 high-risk patients (Lazar et al. 2004) showed that TP 10 significantly inhibited 
complement activity immediately after cardiopulmonary bypass, and this inhibition 
persisted for several days. While TP 10 was clinically ineffective when considered 
over the entire population of patients, it did significantly decrease the incidence of 
mortality and myocardial infarction in male patients. In a much smaller (n = 15), 
related, phase I/Il trial, the possible use of TP1O in infants undergoing 
cardiopulmonary bypass was investigated and no adverse events were attributable to 
TP 10. 
Another possible application of TP10 is in xenotransplantation: in pig-to-
primate heart transplantation, a survival time of up to seven days (compared to 30-40 
minutes for the control) under continuous treatment with TP 10 was reported (Pruitt et 
al. 1997). 	On the other hand TP1O was apparently less successful in 
xenotransplantation when administered in conjunction with the use of transgenic 
donor pigs expressing human DAF (Azimzadeh et al. 2003; Lam et al. 2005), 
probably reflecting the multilayered complexity of the immune response and our lack 
of detailed knowledge of how complement is regulated in various tissues. 
The very large size (-490 kDa) of TP1O, the expense of its production, and its 
complexity mean it is unlikely to find wide application in humans. A smaller, more 
elegant solution might lie in a molecule termed APT070 (Smith 2002). This 
therapeutic compound consists only of the N-terminal three CCP modules of CR1, 
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followed by a positively charged peptide sequence (known as an "addressin"), and a 
myristoyl group. The peptide and fatty acid moieties help to direct the CCP module 
component to the phospholipid bilayer and hold it there - their addition significantly 
enhances the complement inhibitory properties of the triple CCP module fragment 
alone. In some respects therefore, APT070 resembles GPI-anchored DAF. Indeed, 
the three CCP modules encompass functional "site 1" of CR1. APT070 prevents 
complement-mediated tissue damage in animal models of rheumatoid arthritis, renal 
transplant reperfusion injury and vascular shock (Smith 2002). Most recently 
(Halstead et al. 2005), it has been investigated as a possible therapy in Guillain-Barré 
syndromes. Despite these promising results, the company that currently possesses the 
rights to APT070 (Inflazyrne Pharmaceuticals, http://www.inflazyme.com) is no 
longer pursuing its development. 
Building on the idea that engineered complement regulators are effective anti-
complement agents, the possible uses of hybrids with antibodies have been explored 
(Morgan and Harris 2003). In some cases, the antibody Fab arms are attached to the 
complement regulator in the hope that they will target the attached regulator to a 
specific site. Alternatively, regulator molecules may be attached to the Fe portion of 
an antibody, thus they form the equivalents to the Fab arms, and the Fc helps to 
extend the plasma half-life. Some fusion proteins act as prodrugs in that the full 
inhibitory potential of the attached regulator may only be revealed by proteolysis, thus 
providing an additional opportunity for targeting specific sites. 
Finally, mention must be made of VCP and its relative from the small pox 
(variola) virus inhibitor of complement enzymes (SPICE). Neither VCP nor SPICE is 
glycosylated - both consist entirely of four CCPs. Of all the RCAs, VCP and SPICE 
therefore have the simplest composition. VCP is also the best-characterised RCA 
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from a structural standpoint, initially from NMR studies (Wiles et al. 1997; 
Henderson et al. 2001), and latterly by X-ray crystallography (Murthy et al. 2001). 
Furthermore, 3D structures have been determined of VCP in complex with two 
ligands - heparin (Ganesh et al. 2004) and suramin (Ganesh et al. 2005). 
Unfortunately, a commensurate body of site directed mutagenesis data is not 
available. Nonetheless, domain deletion experiments (Smith et al. 2003) demonstrate 
that all four CCP modules are required, while module 4 contains the main heparin-
binding site. Also of interest is a functional and sequence comparison with SPICE 
(Rosengard et al. 2002). Neither VCP nor SPICE possess potent decay accelerating 
activity, but they both have cofactor activity for factor 1-catalysed proteolysis of C3b 
and CO. SPICE is a better cofactor than VCP, and the cofactor activity of SPICE is 
-25-50% that of sCR1. Thus the putative, single functional site in SPICE is 
comparable in potency with each of the three functional sites in sCR1. There are 
eleven amino acid residue differences between SPICE and VCP, all located in CCPs 
2, 3 and 4. None of the amino acid residues that differ between the two proteins are 
near inter -nodular junctions and all are surface exposed, implying no significant 
structural differences between the two. 	Clearly, some or all of the eleven 
substitutions in SPICE compared to VCP are contact residues - either for C3b/C4b or 
factor I and they warrant further inspection. It is striking that VCP can bind heparin 
and simultaneously inhibit complement activation via its DAA and CA, implying that 
it has the ability to protect surfaces (Murthy et al. 2001). SPICE binds heparin 
equally well. These properties have encouraged the hope that VCP (and SPICE) 
could be used therapeutically in humans, despite their probable immunogenicity. In 
support of this, the possible benefits of VCP in numerous animal models of disease 
has been shown (Jha and Kotwal 2003). 
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1.5.3 Future of A nti-comple;nent Therapy 
Engineered RCA proteins (or viral proteins used without modification) have great 
therapeutic potential as a consequence of their efficacy in blocking all the major 
outcomes of a complement activation event, and their specificity. This is illustrated to 
some extent by the relative success of sCR1, although it looks as if this agent will 
only be used in limited and specific circumstances where it can be physically 
delivered to where it is needed - e.g. during cardiac surgery. The -490 kDa sCR1 
was not rationally designed; since the entire extracellular portion of CR1 was used, no 
knowledge of structure or function was applied. A significant advance was the 
truncation of sCR1 to three CCP modules and attachment of a targeting entity to 
create APT070. Although this product is not currently being developed for the clinic, 
it very nicely illustrates the benefits of rational design based on knowledge of the 
location of functional sites in CR1, and on understanding of the improved 
effectiveness of surface associated complement regulators. APT070 additionally 
exemplifies the advantages of a targeting strategy, as was also evident from the 
improved efficacy of RCA-antibody fusions. 
That SPICE (and to a lesser extent, VCP) can encapsulate much of the (so-far 
identified) activity of sCR1 in just four CCP modules suggests that a simple 
truncation, as was done in the creation of APT070, does not go far enough. Indeed, a 
strategy not yet well explored, is the use of knowledge-based site directed 
mutagenesis as a means of tailoring the activities of the CCP modules within the 
regulatory portions of hybrid molecules such as TP1O and APT070. This lack of 
progress is probably attributable to the dearth of knowledge regarding mechanism at 
the atomic level despite a wealth of structural information. 	The results of 
mutagenesis, however, while they are not easy to interpret for reasons described 
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earlier, are tantalising. For example, single amino acid residue swaps between 
functional sites 1 and 2 of CR1 were sufficient to delete the cofactor activity in site 2 
and introduce it into site 1 (Krych-Goldberg and Atkinson 2001a). Numerous other 
mutagenesis studies support the suggestion that significant decreases and increases in 
inhibitory activity may be brought about with a few judiciously selected amino acid 
substitutions. Because there appear to be different sites (in CR1 for example) for 
cofactor activity and decay accelerating activity, and non-identity of C3b- and C4b-
interaction sites (for example, in DAF), it is also possible to tailor an RCA to 
selectively inhibit a specific step in the complement cascade. The fusion of much 
more powerful and selective complement regulatory components with the elegant 
solutions for targeting and extending plasma half-lives described above could yield a 
new generation of powerful complement inhibitors able to act at much lower plasma 
concentrations than the present ones. Currently, however, there are far too many gaps 
in our knowledge of how the RCAs work at the atomic level, and this is holding back 
rational design of highly potent and specific inhibitors. 
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1.6 Structure determination of proteins in complement 
Even though the complement system was discovered more than a century ago, the 
first three-dimensional (3D) structure of a complement component, that of a fragment 
of human C3a and desArg-C3a, was determined only in 1980 by Huber et al., by X-
ray diffraction (Huber et al. 1980). Since then there has been good progress in 
determining 3D structures of complement proteins (Table 1.9; RCAs shown in Figure 
1.2). 
Protein' PDB ID Species Reference 
Clq !PK6' Homo sapiens (Gaboriaud et al. 2003) 
CIq 1C28 Mus inusculus (Shapiro and Scherer 1998) 
Cir 1GPZ 1 7, 1MD7,, 1MD8 2, 1APQ Homo sapiens (Bersch et al. 1998; 
Budayova-Spano et al. 
2002a; Budayova-Spano et 
al. 2002b) 
Cis 1ELV 2, 1NZI Homo sapiens (Gaboriaud et al. 2000; 
Gregory et al. 2003) 
MASP-2 1Q3X 2, 1ZJK 12  Homo sapiens (Harmat et al. 2004; Gal et 
al. 2005) 
MASP-2 INTO Ratios (Feinberg et at. 2003) 
norvegicus 
C3 2A73' Homo sapiens (Janssen et al. 2005) 
C3 2B39 Bos taurus (Fredsiund et at. 2006) 
C3b 2HR0, 2107, 2ICE, 2ICF Homo sapiens (Abdul Ajees et al. 2006; 
Janssen et al. 2006; 
Wiesmann et al. 2006) 
C3c 2A74 Homo sapiens (Janssen et al. 2005) 
C3d 1C3D, lGHQ(b 
complex  svth) Homo sapiens (Nagar et al. 1998; Szakonyi 
etal. 2001) 
C3dg 1QQF, 1QSJ Ratios (Zanotti et al. 2000) 
norvegicus 
C4Adg 1HZF Homo sapiens (van den Eisen et al. 2002) 
C5ac 1KJS Homo sapiens (Zhang et al. 1997) 
C5a-desArg IC5A' Sus scrofa (Williamson and Madison 
1990) 
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C5-C345C 1XWE°  Homo sapiens (Brarnham et al. 2005a) 
C87 1IW2 (pH 7), 1LF7 (pH 4) Homo sapiens (Ortlund et al. 2002) 
Crry 1NTL 5 Mus nnisculus (Aslam et at. 2003) 
Crry INTJ'1-5  Rat! us (Aslam et al. 2003) 
norvegicus 
Factor B IDLE, 1Q0P Homo sapiens (Jing etal. 2000; 
Bhattacharya et al. 2004) 
Factor D 1DSU, 1HFD, 1BIO, 1DFP', Homo sapiens (Narayana etal. 1994; Kim 
1DIC, 1DST, 1FDP et at. 1995a; Cole etal. 
1997; Cole et al. 1998; Jing 
et al. 1998; Jing et al. 1999) 
CR! IGKN°1516, 1GKG*1617,  IPPQ°!6 Homo sapiens (Smith et al. 2002; O'Leary 
et at. 2004) 





contplcx with C3d) et al. 2002; Gilbert et at. 
2005; Gilbert et al. 2006a) 
CR3 1 D2L Homo sapiens (Dolmer et al. 2000) 
Factor H  1HFH 15,16, 1HF1 15, !HCC 16, Homo sapiens (Norman etal. 1991; 
2BZM*19,20,  1HAQ# Barlow etal. 1993; Aslam 
and Perkins 2001; Herbert et 
al. 2006c) 
DAF 1H03 34, 1H04 34, 1H2P 3,4, Homo sapiens (He etal. 2002; Uhrinova et 
1H2Q 3,4, 1UOT 34, 1OJV 4, at. 2003; Williams etal. 
1OJW 1 .4, 1OJY 4, 1OK1 14, 2003; Bhel!a etal. 2004; 
1OK2 14, 1OK3 1 .4, 1OK9 1 .4, Lukacik etal. 2004; 
1NWV 2,3, liv!! ll.4 	
complex with Pettigrew et al. 2006) 
echovirus) & 	(in complex with echovirus) 
-4 
2C81&1-4 (in complex with echovirus) 
MCP 1CKL 12  Homo sapiens (Casasnovas et at. 1999) 
C4BP 2A55 1 ,2  Homo sapiens (Jenkins et al. 2006) 
CD59 1CDQ, 1CDR*,  1CDS°, 1ERG°, Homo sapiens (Fletcher et at. 1994; Kieffer 
1ERH* etal. 1994) 
VCP 1G40 14, 1G44 4, 1VVC°34, Vaccinia virus (Wiles et al. 1997; 
1VVD°3,4, 1VVE*34, IE5G*23, Henderson etal. 2001; 
1RID14, 1Y8Ev1.4 Murthy etal. 2001; Ganesh 
et al. 2004; Ganesh et al. 
2005) 
Table 1.9: Structures of complement proteins deposited in the PDB (as on Dec, 2006). 
Superscripts used in table: No  discrimination is made between intact whole proteins or fragments. In 
the case of CCP-module-containing complement proteins, CCP modules solved are indicated as 
subscript. b  Factor H CCP module 5 has been determined by NMR (Barlow et al. 1992), but not 
deposited into the PDB. C  C3a and desArg-C3a fragments have been determined by X-ray diffraction 
(Huber et al. 1980), but not deposited into the PDB. Structures solved by X-ray diffraction, 
Structures solved by NMR, 4 Structure solved by X-ray and neutron scattering, & Structure solved by 
cryo-electron microscopy. 
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Figure 1.2: Available structural information for the RCA family (including CR2) and the viral 
mimic, VCP. Where they are known, 3D structures of modules are shown as backbone traces, and 
their relative positions within the protein are shown diagrammatically. Figure adapted from (Brook et 
al. 2005). 
Most structures have been determined using high resolution techniques, X-ray 
diffraction and nuclear magnetic resonance (NMR), however very few structures are 
derived from the complete native intact protein. Many have been determined by more 
than one technique, and in some cases by the same technique in different conditions. 
Some structures have been solved as complexes and multimers, while others as 
smaller fragments, domains or modules, mutants, structures with various bound 
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ligands or inhibitors, structures with various sample or crystallisation conditions (e.g. 
pH), structures of proteins crystallised in various space groups, proteins from various 
species, or NMR structures deposited as ensembles of low-energy structures or in one 
case as an average minimised structure. There have also been low resolution X-ray 
and neutron solution scattering structures and cryoelectron microscopy structures 
deposited in the Protein Data Bank (PDB). There still however remain large gaps in 
our structural knowledge and understanding of various proteins. Modelling can play 
an important role in filling these gaps. In particular, the work on the structure of RCA 
proteins over the last 15 years (Figure 1.2), and the very recent structural 
breakthroughs on C3 and its fragments, afford the opportunity to apply homology 
modelling to a sizeable proportion of proteins in the complement system. This thesis 
describes efforts in this direction and discusses the utility of the models thus created. 
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1.7 Summary aims of Ph.D. project 
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immunoglobulin-like 
[_TrpSP ] Trypsin-like serine protease 
cct C-type lectin 	4 Thrombospondin type I 
Factor IJMAC 	LDLra 	I Transmembrane 
Figure 1.3: Complement protein targets for modelling. Modular architecture of the main 
complement components are shown and labelled. The target proteins for modelling; i.e. the CCP 
modules within the complement system and the C3, C4 and C5 proteins are shown boxed. Unless 
labelled on the figure, all domains are shown within key. Abbreviations for the complement 
components are explained in text. 
To undertake comprehensive bioinformatics analysis on the sequence and 
structure of CCP modules, including analyses of intermodular orientations 
among experimentally determined structures; to discover consensus and novel 
trends (Chapter 2). 
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To develop and implement a large-scale comparative modelling protocol for 
individual human CCP-modules (Chapter 3). 
. To undertake surface analyses of CCP module structures, using complement 
receptor type 1 as an example (Chapter 3). 
To set up and maintain an up-to-date online resource on CCP modules and 
store and make publicly available the models (Chapter 3). 
To infer the consequence of numerous disease-associated sequence variations 
on the basis of the models derived from the large-scale protocol, and 
additionally through other newly created ones (Chapter 4). 
To provide novel insights into the latter stages of complement through 
comparative models of complement component C5 and C5b (Chapter 5). 
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A bioinformatics analysis of the sequence, structure 
and dynamics of CCP-modules 
2.1 	Preamble to survey 
A very striking feature of proteins that belong to the "regulators of complement 
activation" (RCA) family (Chapter 1, Section 1.2) is the presence of numerous 
examples of a repeating motif of -60 amino acids that was originally called the "short 
consensus repeat" (SCR) (Morley and Campbell 1984; Reid and Day 1989). We now 
know that each repeat corresponds to a structural unit called a "complement control 
protein" (CCP) module. The CCP module has also been called the "sushi domain" 
reflecting the limited knowledge of its three-dimensional (313) structure in the past 
(Ichinose et al. 1990). In addition to its pre-eminence in the RCA family, the CCP 
module is found in other proteins within the complement system, and in a wide range 
of non-complement proteins (http://smart. embl-heidelberg.de). 
Strings of between four and 30 CCP modules joined by short linking segments 
are found within all members of the RCA family. These proteins are expressed by a 
cluster of genes located on the long arm of chromosome 1 (1q32). Their primary role 
is to ensure a complement-mediated response to infection is targeted and 
proportionate (as discussed in Chapter 1, Section 1.2). They interact, via binding sites 
that entail between two and four CCP modules, with components of the C3 and C5 
35 
convertase complexes (Chapter 1, Tables 1.2 to 1.6). By blocking formation of new 
convertases, accelerating the dissociation of existing convertases, and acting as 
cofactors for proteolytic degradation of the dissociated components, the RCA proteins 
negatively regulate the complement cascade. All host cells exposed to serum have 
RCA proteins embedded in, attached to, or associated with, their surfaces to protect 
themselves against complement. Many of the RCA proteins have numerous 
additional binding partners (listed in Chapter 1). In some cases these include proteins 
expressed by pathogens in an effort to anchor themselves to a host cell, to subvert the 
host's complement system, or to exploit the signal transduction properties of several 
membrane-associated RCAs. 
To date, no large-scale bioinformatics analysis has been performed on this 
family of proteins and their component CCP modules. Hence, several questions 
remain unanswered. Just how widespread are CCP modules among humans and non-
humans? Are there any functional correlations among the proteins that contain them? 
How do the "many" experimentally-determined CCP module structures compare with 
one another? Where do the most significant structural differences among them lie? 
It has been established that many RCA proteins are predominantly extended 
molecules that have a large surface area relative to their molecular weight available 
for potential interactions with binding partners. In general, each RCA protein has 
multiple binding sites (Chapter 1), and each binding site encompasses surface 
elements from two or more neighbouring CCP modules. Hence, simultaneous 
occupation of two or more binding sites on the same protein molecule, and interplay 
between them, may be required for biological function of some RCA proteins. In the 
light of these observations, it is also important to consider the way in which each CCP 
module is attached to its neighbours. This raises several further important questions - 
are there well-structured "junctions" between modules that result in rigid, defined 
intermodular angles? Or are junctions open and flexible allowing unrestricted 
inter -nodular movement? Do the modules that contribute surface elements towards a 
common binding site rearrange themselves during binding to a ligand? These issues 
bear upon mechanisms of binding and biological action. They could also contribute 
to the design of therapeutic versions of the RCAs (see Chapter 1, Section 1.5.2 and 
1.5.3). 
In the current work, for the first time, the above questions are addressed in the 
context of an overview of the literature and comprehensive "all-against-all" sequence 
and structure comparisons of CCP modules. 	Analyses of the inter-module 
orientations within module pairs and larger fragments of CCP modules are also 
performed; these are useful for the design of mutagenesis experiments and the 
interpretation of functional data. The emphasis of this survey is on CCP modules of 
the following RCA proteins: decay accelerating factor (DAF, CD55), complement 
receptor type 1 (CR1, CD35), membrane cofactor protein (MCP, CD46), the factor H 
(IN) family, C4-binding protein (C4BP); and on a viral mimic of the mammalian 
RCA proteins, Vaccinia virus complement control protein (VCP). Another CCP-
containing complement protein - complement receptor type 2 (CR2, CD21) - is 
encoded by a gene in the same region, and normally regarded as a member of the 
RCA family even though it is not involved in regulation of complement activation. 
The blood-clotting factor XIII b subunit (FXIIIb) is built from CCP modules, and its 
gene is also located in the 1q32 cluster; but it is not regarded as an RCA since it does 
not interact with complement proteins, and hence it will not be dealt with in this 
chapter. 
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2.2 Materials and methods 
2.2.1 CCP module sequence retrieval, analysis and alignment 
CCP modules were identified using a combination of literature and database searches. 
The main database that was queried was the Simple Modular Architecture Research 
Tool (SMART) (http://smart.embl-heidelberg.de) (Schultz et al. 1998; Letunic et al. 
2002; Letunic et al. 2004), which identifies, annotates and presents domain 
architecture from sequence information. Several hundred sequences were identified 
as putative CCP modules on the basis of this search. This list of sequences was then 
manually rendered non-redundant, to discard duplicates, and fragments of modules 
were also eliminated. Splice variants were identified. The highly curated sequence 
database, SwissProt and its supplement, TrEMBL (http://www.expasy.org/sprot/)  
(Boeckmann et al. 2003) were then used to retrieve sequences corresponding to the 
identified putative CCP-modules from humans and non-humans. Domain boundaries 
were defined, on the basis of inspection of CCP 3D-structures, as one residue before 
the first Cys and three residues after the fourth Cys. 
The multiple sequence alignment for the 84 individual human RCA CCP-
modules was created using ClustalX (Thompson et al. 1997). The resultant alignment 
was further manually edited. Editing was based upon conservation of amino acid 
residues and secondary structure elements as predicted by PsiPred (McGuffin et al. 
2000), and as determined from 3D-structures of CCP modules in the Protein Data 
Bank (PDB) (Berman et al. 2000) to place gaps most appropriately. 
2.2.2 All-against-all pairwise sequence comparison amongst CCP 
modules 
Two sets of pairwise sequence comparisons were performed. The first set (88 
sequences) of comparisons included sequences from the 84 individual CCP modules 
of the six proteins in the RCA family- CR1 (30 CCPs), CR2 (15 CCPs), C4BPct (8 
CCPs) and P (3 CCPs), DAF (4 CCPs), MCP (4 CCPs), factor H (20 CCPs), and 
additionally four CCPs from Vaccinia virus, VCP. The second set (48 sequences) 
encompassed sequences from the factor H family, including the 20 individual CCP 
module sequences from factor H, and additionally, 28 CCP module sequences from 
factor H-related proteins (FHRs); FHR1 (5 CCPs), FHR2 (4 CCPs), FHR3 (5 CCPs), 
FHR4 (5 CCPs), and FHRS (9 CCPs). 
The sequences (SwissProt Accession Nos.; CR1: P17927, CR2: P20023, 
C4BPa: P04003, C4BPf3: Q9BS25, DAF: P08174, MCP: P15529, factor H: P08603, 
FHR1: Q03591, FHR2: P36980, FHR3: Q02985, FHR4: Q92496, FHR5: Q9BXR6, 
and VCP: P10998) were downloaded from SwissProt and saved into two files locally 
in FASTA format. The CCP-module specific sequence files were then formatted 
using the 'formatdb' program, which comes as part of the stand-alone BLAST 
executable (Altschul et al. 1990; Altschul et al. 1997) (http://www.comparative-
legumes. org/Iis/blast/AboutBLAST2 .html#standalone). The 'form atdb' command 
must be used in order to format protein source databases before these databases can be 
searched by 'blastall', i.e. it turns FASTA files into BLAST readable databases. 
form atdb —i /usr/progs/BLAST/data/*fsa  
(where "i" = any database filename in FASTA format) 
An automated BLAST was run separately for the 88- and the 48-sequence 
databases such that each sequence was compared against every other sequence in the 
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respective databases. The 'blastall' command, which incorporates the 'blastp' 
program, was implemented and the output file 'OUTPUT' saved after the search was 
performed on the 'INPUT'. 
blastall —p blastp —d *fsa  —i INPUT—e 10.0> OUTPUT 
[where '*fsa' = database of 88 or 48 sequences; 'INPUT' = input file (same as 
database file); 'OUTPUT' = output file; '—e 10.0' =  evalue cut-off] 
The results obtained were then parsed and extracted using a PERL script 
(Appendix X). To enable this PERL script to run, a Boulder-BLAST package, which 
is an already available program to aid in parsing and reading of BLAST files, was 
installed. The results were then saved in a Microsoft Excel Workbook (Appendix 
CD). 
2.2.3 Structural comparisons among experimentally determined CCP 
modules 
Combinatorial Extension (CE) was used to compare individual CCP modules against 
each other. CE is a method for calculating pairwise structure alignments using 
characteristics of their local geometry as defined by vectors between Ca positions 
(Shindyalov and Bourne 1998). Thirty-four individual experimentally determined 
CCP module structures were first parsed from their parent protein using coordinates 
downloaded from the PDB. In the case of those modules where more than one 
structure exists, or structures have been solved by more than one technique, the 
highest resolution crystal structure was used. In the case of NMR ensembles, the 
closest-to-mean, lowest energy or average minimised structure was used. In cases 
where both liganded and unliganded structures existed, the unliganded structure was 
adopted. For each module, domain boundaries were considered from one residue 
before the first Cys to three residues after the last Cys (as with the sequence 
comparisons), where available in the structural co-ordinates. A PERL script 
(Appendix X) was used to automate CE to compute an all-against-all pairwise 
structure alignment, among individual CCP module structures. 
The global overlay of all 34 individual CCP-modules was performed using the 
program, Multiprot (Shatsky et al. 2002; 2004). MultiProt superposes the input PDB 
files based on the common geometrical cores between them, and derives multiple 
alignments from simultaneous superpositions of input molecules. It is a sequence-
independent method of multiple structure alignment. 
2.2.4 Calculation of buried surface area 
Module I 	Module 2 
normally 	xC-C-C-C-xx xx-C-C-C-Cx 
DAF-I,2 and FH-19,20 	xC-C-C-C-xx x-C-C-C-Cx 
CR2-I ,2 	xC-C-C-C-xxxxxxxx-C-C-C-Cx 
Figure 2.1: Schematic showing module and bimodule boundaries. The schematic indicates the 
individual module and bimodule pair boundaries considered for surface area calculation, where x = any 
residue; the four cysteine residues in each module are shown (C); and the dashed line indicates the 
position within the linker where the modules are separated. The scheme for the exceptions to the 
general case, i.e. DAF-1,2, FH-'19,20 and CR2-1,2 are shown. 
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This was estimated by first calculating the Surface Area (SA) of a CCP module pair 
12 (SA Bimodule'2), then repeating the calculation for each of the modules in turn 
(SA Module' and SA Module 2). The web server "GETAREA 1.1" (Fraczkiewicz and 
Braun 1998) (http://www.sesb.utmb.edu/cgi-bin/get-a-form.tcl) was used for surface 
area calculations, using default parameters (radius of water probe in Angstroms = 1.4; 
output level = only total area). The surface area (SA) that was buried was calculated 
as: (SA Module' + SA Module 2) - SA Bimodule'2, and therefore includes contacts 
between atoms belonging to the two halves of the linker. For Module 1 (in a four-
residue linked module pair), module boundaries were considered to encompass one 
residue before the first CYS to two residues after the last CYS; and for Module 2 (in a 
four-residue linked module pair), from two residues before the first CYS until one 
residue after the last CYS. For a module pair, boundaries were considered from one 
residue before the first CYS of Module ito one residue after the last CYS of Module 
2 (Figure 2.1). All the linker lengths for the set of solved structures have four 
residues, except in the cases of CR2-4,2 (where linker length = 8 residues) and 
DAF-4,2 and factor H'-49,20 (where linker length = 3 residues). For CR21,2, four 
residues after the last CYS of Module 1 and four residues before the first CYS of 
Module 2 were taken as boundaries for individual modules. For DAF-1,2 and factor 
H-49,20, two residues after the last CYS of Module 1 (and one residue before the 
first CYS); and one residue before the first CYS of Module 2 (and one residue after 
the last CYS) were taken as boundaries for individual modules (Figure 2.1). 
As with CE (Section 2.2.3), for structures solved by X-ray diffraction, the 
highest resolution crystal structure was used, or in cases where both unliganded and 
complexed structures were available, the unliganded form was used for surface area 
calculation. In the case of structures solved by NMR, the closest to mean, average 
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minimised structure or the lowest energy structure was used. X-ray structures were 
protonated before calculations. The IL-2Ra module pair (PDB code: 2B51) was 
excluded from this analysis, because of its unique, irregular appearance (discussed in 
Chapter 3). 













Figure 2.2: Intermodular arrangements. Schematic of skew, tilt and twist angles that define the 
orientation of module 2 (grey) with respect to module 1 (black). These three angles are necessary and 
sufficient to reproduce, in three steps, the experimentally determined orientation of module 2 relative to 
module 1 starting from a theoretical conformation in which the two modules are aligned, with module 2 
above and module I below (see left-hand panel). 
Intermodular orientations may briefly be described by a tilt angle and an angle of 
twist. These two angles are sufficient to describe how one module may be rotated 
relative to its neighbour about two defined (with respect to some feature that is 
common to both modules) orthogonal axes in such a way that the two modules 
become aligned end-to-end with one another (Bork et al. 1996). These two angles 
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alone are not, however, sufficient to describe the reverse process - how to restore a 
unique arrangement of two CCP modules starting from the case where both are 
aligned end-to-end. This is because it would be impossible to know on the basis of 
just that information in which direction to tilt the second module with respect to the 
first even though the angle of the tilt itself is known. The direction may be defined by 
a third angle - skew (Barlow et al. 1993) (see Figure 2.2). Finally, because the linker 
varies in length another parameter - distance (between centres of neighbouring 
modules) - is sometimes helpful in describing an inter -nodular orientation. 
Tilt, twist and skew angles were calculated using the program 'mod22' 
(written by Bruno Kieffer, University of Strasbourg - first applied in (Barlow et al. 
1993)) for all experimentally determined pairs and larger fragments of CCP-module 
containing proteins, where one, or more structures were available - i.e. for an 
ensemble of NMR-derived structures or where several molecules present in the unit 
cell of a crystal exist. Where several X-ray structures are in the database for the same 
protein, the structure of highest resolution was used. This program was first applied 
to the module pair of factor H15,16 (Barlow et al, 1993), and was hence used in this 
exercise to assess intennodular angles in a uniform manner for all module pairs and 
larger fragments. Module boundaries were considered as Cys 1 and 4 for each 
module, and the Ca-atom of the consensus Trp in each module. In each case, the z-
axis was defined by the principal inertia tensor, and the x-axis was defined with 
reference to the Ca-atom of the consensus Trp residue in each module (Leu in the 
case of FH20). 
MAI 
2.3 Results and discussion 
2.3.1 	Occurrence of CCP modules 
2.3.1.1 	Modular composition of the RCA proteins 
Many proteins of the complement system are built up from a limited range of module-
types. The CCP module is very strongly represented with 69 occurrences amongst the 
most common allotypes of the five proteins that have been shown to regulate 
complement and belong to the RCA family: MCP, CR1, fH, DAF, and C413P (see 
Figure 2.3). If all 19 CCP module-containing complement proteins arising from 
unique genes (including the fl-I-related proteins - see below) are included, the total is 
130. 
0x1.X000W0000000000000WOUD0I CR! 	 OAF 
4000I- CR2 	OY)fl 	C4!tPa mcp 
-0000c00000D000000000 Factor H 
-00000 FHRt -Q3Q FHR-3 40))0O0DO(  FHR5 	 100LTSP_] Clr 
-0000 FHR-2 0009'j FHR-4 	 U0{ TIpSP 
CS 	 .2 FactorS 	 OO    
3QQ—[jSP C2 	C7 	ICJO4 TrpSP } MASt'-! 
-000Q 	0009 	-0000 1 DAF-transntentbrane -CYIY)0000l Crry/512 antigen (rat) 
KCP (Horpesvinca) 	 VCP (Vaccrnia vtruc) 
_) 	!LISR J 	!L2R a 	ctI000000.I.- 






0 	CCP 	 • LINK (hyaluronan-binding) 
A von Willebrand factor type A • 	(Ca2'-binding) EGF-like 
CUB 	 pentaxin 
immunoglobulin-like 	 PP MAC/perform 
TrpSP ) Trypsin-like serine protease 
Cct C-type lectin 	4 Thrombospondirt type I 
Factor I/MAC 	4 LDLra 	Transmembrane 
Figure 2.3: Occurrence of CCP modules in complement and other proteins. This figure was 
compiled on the basis of information from the SMART database (Schultz et al. 1998; Letunic et al. 
2002; Letunic et al. 2004) (http://smart.embl-heidelberg.de/). The upper part shows proteins of the 
human complement system, and a small selection of non-human complement regulatory proteins. The 
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lower part illustrates just a few of the numerous mammalian non-complement system proteins that 
contain CCP modules. Abbreviations used: FHR - factor H-related protein; VCP and KCP - Vaccinia 
and Kaposi's virus complement control proteins; IL2R and ILl 5R - interleukin 2 and 15 receptors (a-
chain); GABA-BR1a - GABAB receptor type 1 a-chain; CSMD - CUB and sushi multiple domain 
protein 1; other abbreviations are explained in the text. 	Symbols are explained in the key 
(abbreviations used in key: CUB = first found in CIr, Cis, uEGF and bone morphogenetic protein; 
LDLa = low density lipoprotein receptor domain class A; EGF = epidermal growth factor; MAC = 
membrane attack complex.) 
The five complement regulators listed above, along with the fH-related 
proteins and CR2, are unusual in that they consist entirely, or almost entirely, of a 
single module type. Other CCP module-containing complement proteins, such as 
Cir, Cls, C2, factor B, mannan-binding lectin-associated serine protease (MASP) 1, 
MASP 2, C6 and C7, are more typical of extracellular multiple-module proteins since 
they contain mixtures of several module-types (see Figure 2.3) and are said to be 
"mosaic" (Bork et al. 1996). 
2.3.1.2 	Splice variants 
Figure 2.3 shows only the most common splice-variants of each human protein. A 
fl1-like protein (FHL- 1) contains the seven N-terminal CCP modules of fl-I and a C-
terminal extension of four residues (Zipfel et al. 1999). CR1 exists as shorter (23 
modules) and longer (37 and 44 modules) versions that differ by the presence or 
absence of seven-module-long blocks called long homologous repeats (LHRs) - thus 
in the most common variant there are four such LHRs (LHR-A - LHR-D) plus two 
additional modules close to the C-terminus and the membrane. CR2 exists as a 15 
CCP-module variant (shown in Figure 2.3) and as a 16-module version with an 
additional module, number 11 (Barel et al. 1998). Splice variants of human MCP and 
DAF differ in their serine-threonine-proline extension, and in the nature of their 
membrane attachment, not in the number of CCP modules (Post et al. 1990; 
Liszewski et al. 1994). There do not appear to be any splice-variants of human C4BP 
a- or n-chains, but two minor forms have been observed with different combinations 
of a- and n-chains (Criado Garcia et al. 1995). The most common form of C413P exist 
in the blood as a complex with protein S (Dahlback et al. 1983; Hillarp and Dahlback 
1988). 
2.3.1.3 	Other forms of RCAs in non-humans 
There is variation, even between closely related species, in the set of proteins used for 
immune adherence (a function of erythrocyte-borne CR1 in humans) and to regulate 
complement. For example baboon and chimp erythrocytes carry versions of CR1 
composed of seven and eight CCP modules respectively (Birmingham and Hebert 
2001). The first five modules of baboon CR!, and the first six of chimp CR1, are 
highly similar to the equivalent modules of human CR1; the sequence of the last 
module in both cases resembles that of human CR! module 21. Mouse versions of 
CR1 and CR2 are encoded by the same gene, alternatively spliced to generate a form 
of CR1 (21 modules) or CR2 (15 modules) (Kurtz et al. 1990). Mouse tissues also 
express complement receptor-1 related gene/protein Y (Crry) that has decay 
accelerating and membrane cofactor activities (Kim et al. 1995b) but does not have an 
immune adherence role (Molina et al. 1992). It has five CCPs that are similar in 
sequence to the five N-terminal modules of human CR1. Crry-knock out mouse 
embryos are killed by maternal complement (Xu et al. 2000). The rat equivalent to 
mouse Crry has six or seven CCP modules (Takizawa et al. 1994) (Figure 2.3). 
Rodent versions of both MCP and DAF are expressed, but MCP expression is 
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restricted to testis (Miwa et al. 1998). There are two mouse DAF genes, I and II, 
producing predominantly transmembrane and GPI-anchored versions, respectively 
(Miwa et al. 1998). GPI-linked, transmembrane, and secreted versions of rat, guinea 
pig and pig DAF are probably splice variants (Nonaka et al. 1995; Miwa et at. 2000; 
Perez de la Lastra et al. 2000). Pig DAF is unusual in having only three CCPs (Perez 
de la Lastra et al. 2000). Chickens produce a transmembrane complement regulatory 
protein Cremp (also called Crem) that has five CCP modules and an additional CCP-
like module (Inoue et al. 2001). The first two modules resemble modules 2 and 3 of 
DAF, and the third and fourth modules are very similar to the equivalent modules of 
MCP. The locus of the first non-mammalian RCA gene cluster to be reported was 
recently identified in chickens (Oshiumi et al. 2005), revealing two additional 
proteins; Cres, a secretory protein consisting of 10 CCP modules, modules 2-to-4 
displaying homology to the equivalent modules of the a-chain of C4BP in humans, 
while the remaining modules do not show marked similarity to any other RCA 
module; and Creg, a GPI-anchored membrane protein, consisting of seven CCP 
modules, with high homology to modules of an LHR of CR1 in humans (CCP5 1-4, 8-
11, 15-18, and 22-25). A protein, SBP1, from the bony fish barred sand bass has 17 
CCP modules, which resemble factor H in humans and was demonstrated to bind both 
C3b and C4b and to act as a cofactor for their enzymatic cleavage by factor I (Kemper 
et al. 1998). A family of large transmembrane receptors and adhesive proteins, 
CSMD (CUB and sushi multiple domain) 1, 2 and 3 each contain more than 25 CCP 
modules (Lau and Scholnick 2003; Shimizu et al. 2003). CSMD1 from rat was 
recently shown to possess complement regulatory activity, thus raising the possibility 
that a similar feat is performed by its human orthologue (Kraus et al. 2006). 
	
2.3.1.4 	Viral versions of RCAs 
Several viruses in the Herpesviridae and Poxviridae families have genes for CCP 
module-containing proteins, presumably acquired through a process of horizontal 
gene transfer. Pox viruses generally produce a soluble four-CCP module complement 
inhibiting protein (Figure 2.3), although the monkeypox version has only three 
modules (Uvarova and Shchelkunov 2001). The best-studied example is VCP, from 
Vaccinia virus (Kotwal and Moss 1988) that has four CCPs. Vaccinia virus has an 
additional gene encoding a distinct four CCP-module containing protein - VB05 - 
that has a transmembrane domain and reportedly plays a role in plaque-size and host-
range (Takahashi-Nishimaki et al. 1991). Another virus, variola encodes a smallpox 
inhibitor of complement enzymes (SPICE) protein, which also functions as a 
complement regulator (Dunlop et al. 2003). Within the herpes family, some members 
of the rhadinovirus genus have been found to produce a four CCP module-protein 
with a transmembrane domain (Albrecht and Fleckenstein 1992). The version 
expressed by Kaposi's sarcoma-associated herpesvirus ("KCP", also known as 
"Kaposica") (Figure 2.3) has been shown to inhibit complement effectively and 
contribute significantly to virulence (Mullick et al. 2003; Spiller et al. 2003). 
2.3.1.5 	Other proteins that contain CCP modules 
Several other human proteins that interact with C3b and/or C4b contain two or three 
CCP modules - these are factor B and C2, Cir and Cis, MASP 1/3 and MASP 2 
(Figure 2.3). The late complement components, C6 and C7, contain pairs of tandem 
CCP modules that may interact with the C5b*  fragment generated by C5 convertase 
(DiScipio et al. 1999). The '' refers to the unstable, transitory nature of this 
EEO 
fragment that is able to interact with C6 to form C5b.C6 in an initial irreversible step 
along the pathway to formation of the membrane attack complex (DiScipio et al. 
1999) (discussed further in Chapter 5). 
There are also a large and very diverse range of non-complement mammalian 
proteins that contain CCP modules. Illustrative examples of note are: clotting FXIIIb; 
the adhesive extracellular matrix proteins - aggrecan, neurocan and brevican that each 
contain a single CCP module; the selectin family - whose stalks are composed of 
trains of CCPs; a subunit of the heterodimeric metabotropic G-protein linked GABA 
receptor - GABAB receptor type la (Blein et al. 2000) (type lb lacks the two CCP 
modules (Kaupmann et al. 1997)); the a-chain of the IL-2 and IL-15 receptors - the 
single CCP module of the IL-is receptor, together with a C-terminal Pro/Thr region, 
is necessary and sufficient for IL-15 binding (Wei et al. 2001); J3-2-glycoprotein I also 
known as apolipoprotein H (132GP1,  ApoH) for which two crystal structures have been 
solved (Bouma et al. 1999; Schwarzenbacher et al. 1999); polydom, a 387 kDa 
placentally expressed protein with 34 CCP modules (Gilges et al. 2000), also referred 
to as SEL-013 (selectin-like osteoblast derived) and SVEP1 (sushi, von Willebrand 
factor type A (vWA), EGF, and pentraxin 1) in humans (Shur et al. 2006). Perhaps 
the most primitive eukaryote known to possess a CCP module to date is Plasmodium 
falciparum (OKeeffe et al. 2005). 
This widespread use of CCP modules underlines the versatility of a structural 
scaffold that can be adapted by evolution to suit many purposes, both "architectural" - 
endowing on specific proteins an appropriate reach and level of flexibility or rigidity - 
and "functional" i.e. providing specific surfaces that are directly involved in binding 
(Kirkitadze and Barlow 2001). In recent years there has been increasing evidence 
suggesting that complement components, particularly complement component C3 
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may also participate in non-inflammatory and developmental processes, such as tissue 
regeneration, neuron development, wound healing and reproduction (Mastellos and 
Lambris 2002; Mastellos et al. 2003; Mastellos et al. 2005), indicating that it has a 
broad role in cell differentiation. It is plausible that several of the non-complement 
CCP modules could interact with C3 in its developmental role. 
2.4 	Sequences of CCP modules 
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Figure 2.4: Multiple sequence alignment of CCP modules in RCA proteins. The 84 individual 
CCP modules of the six proteins in the RCA family- CR1 (30 CCPs), CR2 (15 CCPs), C4BPct (8 
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CCPs) and fI (3 CCPs), DAF (4 CCPs), MCP (4 CCPs) and factor H (20 CCPs) aligned using ClustaiX 
(Thompson et al. 1997). 	Consensus residues generated by WebLogo version 2.8.2 
(http://weblogo.berkeley.edu!) (Crooks et al. 2004) are indicated at the bottom of the alignment (the 
greater the height of the residue letter, the greater the conservation for that residue at that position). 
This alignment differs slightly from the one published in (Soares and Barlow 2005), in light of new 
structural information. 
Historically, the existence of CCP modules was inferred from inspection of the 
emerging primary sequence information for RCA proteins during the late 1980s 
(Campbell et al. 1988; Reid and Day 1989). An imperfectly repeating motif of 
approximately 60 amino acid residues was noticed and termed the "short consensus 
repeat". This repeat is characterised (Figure 2.4) by the presence of a cysteine residue 
at either end (C ' and C n)  with two additional cysteines (Cys " and Cys ) 
distributed between them - it was later shown that these are disulfide linked in the 
pattern I - III and II -* IV. A tryptophan occurs - with two exceptions only among 
the RCA proteins (the 10th  and 20th  CCPs of fH, which have a Leu instead) - in the 
sequence between cysteines III and IV. Proline residues often occur at the third 
and/or fourth position after the first Cys (i.e. C' + 3/4) and the second position before 
the fourth Cys (C fv - 2). Additional Pro residues often occur adjacent, or next-door-
but-one, to these consensus prolines. A Gly residue is well conserved at (C 
H + 3) and 
three additional conserved glycines commonly occur at (C ' + 8/10), (C " - 7) and (C" 
+ 6/8). Within the ten residues prior to C H  there are four positions where 
hydrophobic residues are present in the sequences of the majority of CCP modules, 
and additional hydrophobic residues appear beyond C ". 	Thus the motif 
"hXhGXXhXhXC"XXG'I'hXhXG" (where '1' is the site of an insertion in the larger 
CCP modules) occurs commonly, but not in every CCP module. Insertions and 
53 
deletions occur most frequently after each of the four consensus glycines, apart from 
the (C 11 - 7) Gly; and before the consensus Trp. 
CR1 Fil CR2 C4BPa C4BPI1 MCP 1)AF 
(57) 1-2 (4) (60) 1-2(4) (60) 1-2 (8) (59) 1-2 (4) (54) 1-2 (4) (59) 	-2 (4) (59) 1-2 (3) 
(58) 2-3 (4) (57) 2-3 (4) (56) 2-3 (7) (58) 2-3 (4) (54) 2-3 (4) (59) 2-3(4) (61) 2-3 (4) 
(67) 3-4(5) (60)3-4(4) (57) 3-4(4) (60)3-4(4) (53)3 (62)3-4(4) (58) 3-4(4) 
(56) 4-5 (3) (53)4-5(4) (57) 4-5 (4) (56)4-5(4) (56)4 (59)4 
(57)5-6(4) (54)5-6(4) (67) 5-6(8) (62)5-6(4) 
(59)6-7(4) (61) 6-7 (3) (56)6-7 (3) (58)6-7 (3) 
(67) 7-8(5) (54) 7-8 (5) (57) 7-8 (4) (55) 7-8 (3) 
(57) 8-9 (4) (58)8-9(3) (52)8-9(4) (55) 8 
(58) 9-10 (4) (56) 9-10 (4) (67) 9-10 (8) 
(67) 10-11(5) (55) 10-11(6) (56) 10-11(4) 
(56) 11-12(3) (55) 11-12(6) (53) 11-12(4) 
(57) 12-13 (4) (54) 12-13 (8) (61) 12-13 (8) 
(59) 13-14(4) (51) 13-14(7) (56) 13-14(7) 
(67) 14-15(5) (54) 14-15 (5) (57) 14-15 (4) 
(57) 15-16(4) (57) 15-16(4) (57) 15 
(58) 16-17(4) (54) 16-17(4) 
(67) 17-18 (5) (55) 17-18(4) 
(56) 18-19(3) (55) 18-19(6) 
(57) 19-20(4) (55) 19-20(3) 
(59) 20-21 (4) (62)20 
(67) 21-22 (8) 
(57) 22-23 (4) 
(58) 23-24 (4) 
(67) 24-25 (5) 
(56) 25-26 (3) 
(57) 26-27 (4) 
(59) 27-28 (4) 
(67) 28-29 (7) 
(57) 29-30 (4) 
(57) 30 
(57)Mean(4.3) (56)Mean(4.6) (57.9)Mean(5.5) (57.9)Mean(3.7) (53.7)Mean(4) (59)Mean(4) (59.3)Mean(3.7) 
Table 2.1: Lengths, in residues, of CCP modules (and inter-CCP module linkers) in RCA 
proteins. The residue-length of a CCP module is defined as the number of residues between the N-
terminal cysteine and the C-terminal cysteine, both inclusive (shown in brackets on the left). Residue 
length of inter-CCP module linkers is defined as the number of residues between the C-terminal 
cysteine of the preceding CCP module and the N-terminal cysteine residue of the following CCP 
module (shown in brackets on the right). Mean values are shown below, corresponding to each protein. 
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Figure 2.5: Schematic to illustrate module and linker lengths. This figure is drawn on a distorted 
scale to emphasise the variation in length of CCP modules (51-67 residues) within RCA proteins and of 
the linkers (3-8 residues) between them. For convenience the first and last residues of a module are 
defined as C 1 and C IV  of the consensus sequence (see Figure 2.4), and linkers are defined as the 
sequences lying between C IV  of the N-terminal module and C 'of the C-terminal module. Modules are 
numbered. For abbreviations see text. The raw data for this figure were compiled from the Swissprot 
database (Boechann et al. 2003). 
Three-dimensional (31)) structure determination of CCP modules indicated 
that the residue before the first Cys, and the two residues beyond the last Cys 
commonly contribute to the three-dimensional structure of the module. Strictly 
speaking therefore, these residues could be considered to belong to the module rather 
than the connecting linking sequences. For the purposes of the alignment in Figure 
2.4, sequences starting at the residue before C 1 and finishing three residues after C IV 
(inclusive) were used. It is nonetheless convenient to regard the boundaries of each 
CCP module as C 1 and C ", and the "linker" residues as lying between the C " of the 
preceding module and the C' of the following module. According to that definition, 
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within the RCA proteins, the length of CCP module sequences in RCA proteins varies 
from 51 (factor H-13) to 67 (eight modules in CR1, two in CR2) (see Table 2.1; 
Figure 2.5). And the length of linker ranges from three to eight amino acid residues 
(Table 2.1). 
= CCP module 
= Structure solved (or inferred) 
1/1 etc. = Subgroup identifier, U = undefined* 
= fused exon - = split exon 
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Figure 2.6: Exon boundaries and assignment of the CCP modules of complement proteins into 
groups. The symbols used for module-types are the same as in figure 2.3. The modules for which 
experimentally solved (or inferred) 3D structures are available are shaded in blue. Most CCP modules 
are encoded by single exons; split and fused exons are highlighted in this figure - see key for symbols. 
The number above each module indicates assignment to sub-groups of CCPs according to a 
phylogenetic study by Krushkal et al. (2000) discussed in the text. The study divided the RCA proteins 
into two distinct groups (fH, the fH-related proteins and Factor XIIIb in one group - shown by the use 
of italics and numbering in red - and the remainder in the second group). Those modules that could 
not be classified are indicated by a "U". 
Many CCP module sequences are encoded by discrete exons and therefore 
they are class 1 domains. The exon boundaries appear to lie at random positions 
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within the linkers but nearly all exons in RCA genes have phase 1 introns (i.e. they 
interrupt the coding sequence after the first base-pair of a codon) at both ends, a 
typical feature of extracellular metazoan proteins and a signature of domain shuffling 
(Kaessmann et al. 2002). In CR2, however, the fourth, eighth and eleventh CCPs are 
class 2 domains since they are encoded by a split exon, while the following CCP pairs 
of CR2 are encoded by a fused exon: 1,2; 5,6; 9,10; and 12,13 (Fujisaku et al. 1989) 
(see Figure 2.6). The second CCPs of other RCAs - CR1, factor H, MCP and C4BPa 
(and the third modules of DAF and C4BP) are also class 2 domains with a splice site 
after the second position of the codon for the conserved Gly at position (Cys" + 3) 
(Hillarp et al. 1993). In the case of CR1, a similarly split exon encodes the second 
CCPs of LHRs B, C and D, and the sixth module of each LHR (Vik and Wong 1993). 
The third and fourth modules of each LHR in CR1 are encoded by fused exons (Vik 
and Wong 1993). 
2.4.2 "Evolution" of CCP modules 
The RCA gene cluster is thought to have evolved through a series of gene duplication 
events (Farries and Atkinson 1991), consistent with the symmetrical phases of most 
introns. Krushkal et al. (Krushkal et al. 2000) constructed a phylogenetic tree for 132 
individual module sequences of the RCA gene cluster including Factor XIII b subunit 
(and SBP1 from sand bass). Based on this they inferred a summary tree of 
relationships for the parent proteins. The tree identified two groups of proteins - 
factor H and the factor H-related proteins along with Factor XIIIb (and SBPI) formed 
one group, while MCP, DAF, C4BPct, CR2 and CR1 formed the other (and C4BPf3 
falls into neither). 	This division corresponds to two distinct sub-clusters on 
chromosome 1 separated by 7-22 centiMorgans. One possibility is that SBP1 is the 
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evolutionary precursor of both factor H and C4BPu, and that the two groups diverged 
in evolutionary history after the separation of the fish lineage. Within these groups, 
these authors identified "sub-types" of CCPs (illustrated in Figure 2.6). These maybe 
compared with the "clusters" described in Chapter 3, performed for a greater number 
of CCP module sequences. 
2.4.3 Comparison of sequences amongst CCP modules 
Levels of sequence identity amongst CCP modules in human RCA proteins range 
from virtually undetectable (except with reference to the four defining Cys residues 
and the highly conserved Trp) to 100%. Some of the sequences with low similarity in 
sequence are shown in Figure 2.7a. Even within a protein, CCP sequences may be 
very dissimilar e.g. C4BPa-1 versus C4BPa-6, or fl-i--13 versus fl-I20. In fact, the 
multiple sequence alignment (Figure 2.4) reveals that in addition to the Trp - Leu 
substitution in fl-I-.10 and ffl--20, there are several further oddities among the CCP-
module sequences of RCA proteins - e.g. the presence of an additional pair of Cys 
residues in C4BPa-6; the absence of any consensus Pro or Gly residues after C' in 
fH-43, fl-I--20, CR2-10 and CR2-11, and the presence of five Pro residues within 
positions C'+ 8 in fH-14. 
(A) 
C4BP8_O1 1 HPE-LPPVDNSI 1KG------YHLVG---KKTL1' NASK----KWD--NTTT1RLG 
CR2_08 1 AKATGQLL--------TKPQ---HQFV--RPDVNSS GKG------YKLSG---GVYQE QGTIP----WF--MEIRLXKI 
CR211 1 
--- FVAKV --- KGQI-LG - 	TYV 
QH-VRQSL-------QKLPA---GSRV--EL-VNTS QDG------YQLTG---HAYQM QDAENG--IWF--KKIPLKVI 
C4BPA_06 1 PE--pxLNwGEITQHRKsRrRwHCvyF-YGoiIsF1 RET----------S---RSAI QGDG----TWS--PRTP1GDI 
PH13 1 IKS-SNLIILRE---HLKNKK----ZPD-HNSNIRYR RGK---------EC---WIHTV Il-G----RWD---PEVNSMA 
FH20 1 VI-$REIME!4YN-- IALRWTAKQKLYSRTGESVRFV KRG------YRL0SRSHTLRTT WD-G----KLE----Y?TAKR 
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Figure 2.7: Differences and similarities between the primary sequences of CCP modules. (A) Six 
relatively dissimilar sequences were selected from the sequence alignment and juxtaposed. Levels of 
pair-wise identity are typically < 20%. Figure produced using BoxShade version 3.21 
(http://www.ch.embnet.org/software/BOX—fom-i.html). (B) Thick lines connect modules that share 
more than 90% pair-wise sequence identity; thin lines indicate 50-89% identity, with a label indicating 
the percentage identity (Altschul et al. 1990; Altschul et al. 1997). For clarity, not all (>90% identical) 
lines are drawn since the levels of identity can be deduced in some cases (e.g. between CR1-3 and 
CR1-17). 
CR1 on the other hand is exceptional in the extent of its internal sequence 
similarities - several of the CCP sequences within CR1 are exact, or nearly exact, 
duplicates or triplicates (see Figure 2.7b): modules 3-to-9 are almost identical to CR1 
modules lO-to-16; CCP modules 3 (and 10) and 4 (and 11) are nearly identical with 
modules 17 and 18, respectively; and modules 19-to-21 are ? 88% identical with 
modules 26-to-28. As mentioned previously, this occurrence of similar modules at 
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intervals of seven led to the division of the N-terminal 28 modules of CR1 into four 
LHRs, A, B, C and D. Modules in CR1 with divergent sequence lie at the N- and C-
terniini: modules 29 and 30 each have less than 50% identity with any other CR1 
module, while modules 1 and 2 are only 60-to-66% identical at best to other CCP 
modules. For completeness, it should be noted that modules 22-to-25 of CR1 are also 
rather divergent. No other complement control protein shows such a high level of 
internal sequence similarity, although CR2 modules 5 and 6 are 63% and 58% 
identical to CR2-9 and CR2-10, respectively (see Figure 2.7b). 
There is less similarity between modules located in different RCA proteins. 
The C-terminal modules of CR1 - numbers 29 and 30 - are 51% and 65% identical to 
the C-terminal two modules of CR2 (14 and 15) respectively. In fact, outside of the 
fH family, the 65% identity between C-terminal modules of CR1 and CR2 is matched 
only by CR2-9 versus CR1-7 (or 14). The set of other inter-protein identity-levels? 
50% are summarised in Figure 2.7b. 
We 
25 	The 3D structure of CCP module 
2.5.1 Early structural work on factor H 
The first structural data on CCP modules, derived from circular dichroisrn (CD) studies 
of fl-I, demonstrated an absence of a-helices (Sim and DiScipio 1982). A subsequent 
study combining Fourier transform-infrared spectroscopy (FT-IR) with secondary 
structure averaging methods predicted a 13-structure for each of the 20 CCP modules of 
factor H (Perkins et al. 1988). 
In order to obtain more detailed structural information (Barlow et al. 1991), a 
portion of factor H corresponding to what was predicted to be a single CCP module 
(residues 909-967 of the mature sequence, the 16th  CCP within the sequence, known as 
fH-16) was expressed in Saccharomyces cerevisiae as a recombinant entity in isolation 
from the remainder of the molecule. This sequence was not selected on the basis of its 
contributions to any known function of the parent protein, but because its sequence was 
regarded as typical of CCP module sequences in factor H. A pure (no salt or buffer) 1 
mM solution of this material (fH-16) at pH 4.0 and 37 °C was analysed by two-
dimensional (21)) 'H nuclear magnetic resonance spectroscopy (NMR). The spectra were 
consistent with those expected of a compactly folded globular protein, and demonstrated 
that such a sequence is able to fold independently. The NMR data confirmed the 
presence of 13-strands but, in comparison with the outcome of the FT-JR based-study, 
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Figure 2.8: Secondary and tertiary structure of a CCP module. (A) Moiscript (Kraulis 1991) 
representation of the first CCP module structure [the 16th  module of factor H, PDB ID: 1HCC (Norman 
et al. 1991)] to be revealed by NMR spectroscopy. The consensus "scaffold" of conserved residues, 
involving the cysteines (forming two disulfide bridges) and a buried tryptophan are drawn as ball-and-
stick. fl-strands are shown as arrows. (B) 3-strands drawn as arrows, disulfides indicated by the thick 
dotted lines, and the hypervariable loop drawn as a thick line between strands 2 and 3. The exact 
position and length of fl-strands, as formally defined according to the Kabsch and Sander criteria 
(Kabsch and Sander 1983), varies between modules. All structures solved to date, however, contain 
some or all of the eight strands at the approximate positions relative to the four consensus cysteines 
indicated here. In this Chapter we use the strand-numbering shown in this diagram even in modules 
where some of the strands are not formed. Thus the six strands of the 16th  CCP of fH are numbered 2, 
4, 5, 6, 7 and 8 (see Figure 2.8a and text). In the literature, pairs of strands such as 5 and 6 are 
sometimes considered to be segments of a common strand and thus often referred to as, for example, 
D' and D. 
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A more detailed analysis of the NMR data yielded the first 3D structure of a CCP 
module (Figure 2.8a) (Norman et al. 1991). The fold was described originally as 
approximating to a 3-sandwich or barrel, but it is smaller and less regular than classical 
examples of this fold such as found amongst the immunoglobulin (Bork et al. 1994) or 
fibronectin type III families (Potts and Campbell 1994; 1996). It does not in fact 
resemble closely any other known protein structure. One face consists of a twisted sheet 
of three antiparallel strands (numbers 2, 4 and 6 in Figure 2.8a). The other face was 
originally described as a two-stranded sheet. The longer of the two strands in this other 
face has two segments separated by a n-bulge - the more N-terminal segment extends the 
three-stranded sheet and thus participates in both faces, while the more C-terminal part 
(also corresponding to the C-terminus of the module) is exclusively part of the two-
stranded face. In the light of further examples of CCP module structures, these two 
segments can be regarded as two independent strands 7 and 8 (Figure 2.8) - and it is 
more convenient to consider f}f-46 as consisting of a twisted four-stranded sheet 
(containing J3-strands now numbered 2, 4, 6 and 7 - Figure 2.8a) forming a half-barrel 
while the separate two-stranded sheet (n-strands 5 and 8) closes off one end of the barrel. 
The open side of the half-barrel is covered by the N-terminal region of the module. Both 
sheets contribute hydrophobic side-chains to a compact core and there is a disulfide bond 
between C I and C 111, and another disulfide between C 11 and C ", as expected. These two 
disulfide bridges staple the N-terminus and the C-terminus to opposite ends of the four-
stranded sheet, and are far apart from one another, forming the upper and lower 
boundaries of the hydrophobic core. The module has, overall, an elongated shape with J3-
strands 2, 4, 6 and 7 aligned very approximately with the long axis while the N- and C-
termini are found at opposing ends of the long axis. This is consistent with the extended, 
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head-to-tail arrangement of CCP modules within RCA proteins suggested by other 
experimental methods. 
Alignments of CCP module sequences analysed in the light of the structure showed 
that many structurally important residues, such as the tryptophan that lies between C " 
and C Iv in the sequence and is buried in the structure, are conserved or conservatively 
replaced (Figure 2.4); therefore it appeared likely that other CCP modules would share a 
similar structure. To illustrate this point, the fH16 structure was used as a template for 
modelling of putative CCP modules from the selectin family, which have an extra pair of 
cysteines. The homology modelling (Norman et al. 1991) was consistent with the 




Figure 2.9: Overlay of the 3D solution structures of the 5th  and 16th  CCP modules of M. A tube 
representation of the backbones of the first two CCP module structures to be solved, which illustrates 
that although sequence identity between these two is low, they share a similar 3D structure. 
The fifth module of factor H (fl-I-5) has only 33% sequence identity with fl-I-16. It 
was therefore selected for 3D structure determination by NMR as a second, divergent, 
example of a CCP module (Barlow et al. 1992). The two modules may be seen (Figure 
2.9) to share the elongated scaffold-like 13-structure discussed above. There are, however, 
eight short 13-strands (numbered 1-8 - see Figure 2.8b) in fH-5. Strands I and 3 are 
apparently not present in module 16 (in other words the equivalent residues of fl-I--16 
while strand-like, did not adopt 1 and 'P dihedral angles within the ranges expected of a 
13-strand). These two additional strands form a small 13-sheet that closes off the other (N-
terminal) end of the half-barrel with respect to that occupied by the 5/8 13-sheet. To 
summarise the topology of the CCP module (Figure 2.8b): strand 1, when present, 
includes the N-terminus and C '; strand 2 follows the Gly at position (C' + 8/10); strands 
3 (when present), 4 and 5 occur (underlined) within the 
"hXhGXXhXhXC"XXG'T'hhXG" motif; strand 6 precedes (and may include) C "j 
strand 7 includes the (almost) invariant Trp; and strand 8 includes C IV  and the C-
terminus of the module. 
The 3D structures of fl-I-5 and fH--16 may be overlaid on the a and 13 carbons of 
the equivalent consensus Cys and Trp residues with a root mean square deviation (rmsd) 
of 1.45 A; but loops, bulges and turns diverge. The rmsd over the equivalent Ca atoms of 
49 residues after superposition using the program Combinatorial Extension (CE) 
(Shindyalov and Bourne 1998) is 2.6 A. One region in particular - corresponding to 
residues 17-22 of fH16 - was not well defined by the experimental data in either 
module, is highly variable in sequence amongst CCP modules generally, and corresponds 
to a prominent loop (Figure 2.8) that projects laterally from the elongated body of the 
module - this was named the "hypervariable" loop or region. 
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2.5.2 Further examples of CCP module structures 
Module(s) PDB code(s) References 
CCP-containing protein 
solved 
Complement Receptor 1 1GKN*II(,, 1GKG 1617, 1PPQ'1 , (Smith etal. 2002: 
15, 16, 17 O'Leary etal. 2004) 
 
Complement Receptor 2 1GHQ 1 2, 1LY2 12 (Szakonyi etal. 
1,2 2001; Prota etal. 
 2002) 
1H03 34, 1H04 34, 1H2P 34, (Uhrinova et al. 
I H2Q, I UOT 3,4, 1 OJV4, 
2003; Williams et al. 
 
2003; Lukacik et al. Decay Accelerating 
1, 2, 3, 4 1OJW -4,  1OJY 	1OK1 1.4, 2004) 
Factor (DAF) 
10K2 	10K3 ., 1OK91.4, 
1 NWV*23 





1HFH'1516, 1HF115, IHCC*16, (Norman et al. 1991; 
factor H () 2BZM'19 ,20 
Barlow etal. 1992; 
19,20 Barlow etal. 1993; 
Herbert et al. 2006c) 
C4b-Binding Protein a 2A55 1 ,2  (Jenkins et al. 2006) 
1,2 
(C4BPa) 
1G40 1 .4, 1G441.4, IVVC*34, (Wiles et al. 1997; 
Vaccinia Complement I VVD*34,  I VVE, 1 E5G*23, 
Henderson et al.  
2001; Murthy et al. 
Protein (VCP) 
1,2,3,4 
1RID 4, 1Y8E 14 2001; Ganesh et al. 
2004; Ganesh et al. 
2005) 
lGPZ 1 ,2, 1MD7 2, 1MD8 2 (Budayova-Spano et 
Cir 1,2 al. 2002a; 
Budayova-Spano et 
al. 2002b) 
CIS 2 1ELV7 (Gaboriaud etal. 
2000) 
MASP-2 1 3 2 1Q3X 2, 1ZJK 1 ,2 (Harmat et al. 2004; 
Gal _et_  al. _2005) 
0-2-glycoprotein I / 1ClZ 4, 1QUB 14 (Bouma et al. 1999; 




GABA3-R1 a (rat) 2 1 SS2*2 (cis-J.) 	1 SRZ, (/r,s-fo,z) (B!ein et al. 2004) 
1Z92 1 ,2, 21351 1,2,  2ERJ 1 ,2 (Rickert et al. 2005; 
IL-2Ra 1,2 Wang etal. 2005; 
Stauber_et_  al. _2006) 
IL- l5Ra 1 2ERS 1 (Lorenzen etal. 
2006) 
Table 2.2: Experimentally solved CCP-modules. Table of all experimentally determined CCP 
modules from human and non-human proteins at 3   April 2006. Only those structures determined by 
X-ray diffraction and NMR are listed. Symbols used in table: * CCP-modules solved by NMR, ^ CCP- 
MM 
modules solved by X-ray diffraction. It should be noted that although, factor H module 5 co-ordinates 
have not been deposited into the PDB, they are available for download from: 
http://www.bru.ed.ac.uk/—dinesh/ccp-db.html. Module number or ranges are indicated as subscript 
alongside their PDB codes. Abbreviations used in table: GABAB-Ria = Gamma-aminobutyric acid 
type B receptor, subunit 1 a ; IL-2Ra / IL-15Ra = Interleukin-2/-15 receptor a chain; MASP-2 = 
mannan-binding lectin-associated serine protease-2. 
In the decade and a half since the initial structural work that focussed on these two 
isolated CCP modules from factor H, a wealth of structural data on CCP module 3D 
structures has been amassed (Table 2.2). To date 35 such structures have been solved 
- normally in the context of longer fragments of the parent protein. Of these, four 
derive from the complete structure of 132GP1 (Bouma et al. 1999; Schwarzenbacher et 
al. 1999) - which also contains a fifth very divergent version of a CCP module that is 
involved in phospholipid binding (Steinkasserer et al. 1992), two from IL2Rct (Rickert 
et al. 2005; Wang et al. 2005; Stauber et al. 2006) and one each from IL15Rct 
(Lorenzen et al. 2006) and GABABR1a (Blein et al. 2004). The remainder are 
examples found in complement proteins - two from MASP 2 (Harmat et al. 2004; Gal 
et al. 2005), one module from Cis (Gaboriaud et al. 2000) and two from Cir 
(Budayova-Spano et al. 2002a; Budayova-Spano et al. 2002b), two from the N-
terminus of CR2 (Szakonyi et al. 2001; Prota et al. 2002), and the remainder from the 
complement regulators: fH (i.e. fH--15 (Barlow et al. 1993) and fl-1--19,20 (Herbert et 
al. 2006c), in addition to fl-I-5 and fH16), C4BP (two) (Jenkins et al. 2006), MCP 
(two) (Casasnovas et al. 1999), DAF (all four modules) (Uhrinova et al. 2003; 
Williams et al. 2003; Lukacik et al. 2004), CR1 (three) (Smith et al. 2002; O'Leary et 
al. 2004) and the viral mimic, VCP (all four modules representing the only complete 
protein structure) (Wiles et al. 1997; Henderson et al. 2001; Murthy et al. 2001; 
Ganesh et al. 2004; Ganesh et al. 2005). 
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Of the 35 CCP modules for which structures have been solved, 24 were 
determined by X-ray crystallography, 16 by NMR and five by both techniques. 
Several CCP module structures have been solved in different contexts - e.g. alone, or 
with neighbouring modules attached. 
VCP2-X VCP3-X VCP4-X DAF2-X DAF3-X 













Table 2.3: Comparison of individual CCP module structures solved by both X-ray diffraction 
and NMR. CE comparison of structures solved by X-ray diffraction (-X) against those solved by 
NMR (-N), PDB codes provided. All values are in Angstroms (A); Alignment length is indicated in 
brackets below. 
Where both NMR and X-ray diffraction were used to solve the structure (Table 2.3), 
agreement varied from good (e.g. 1.14 A for VCP-3) (Wiles et al. 1997; Murthy et 
al. 2001) to poor (3.31 A for VCP2) (Henderson et al. 2001; Murthy et al. 2001). It 
is rare for solution and crystallographic structures of proteins to differ significantly 
(Billeter 1992; Garbuzynskiy et al. 2005). In the case of VCP2 the presence or 
absence of neighbouring modules could possibly explain some of the discrepancies - 
e.g. the solution structure of VCP-2 was solved in the context of the 2,3 pair, while 
the crystal structure derives from a structure of intact protein. On the other hand, the 
solution structure of CCP module 16 of CR1 was essentially the same when solved as 
an isolated module (O'Leary et al. 2004) or in the context of the CR1-'15,16 and 
CRll6,17 pairs (Smith et al. 2002). 
BC.PI BGPI BC.)') BC)'! Cl, CIr Cl. COP C48P CR1 CR1 CR1 CR2 CR2 OAF OAF OAF OAF GAB, GAB) FH FR FR FR FR 11.15R54SF2 MSP2 MCP MC)' SC)' VCP VC)' 
-1 	-2 	-3 	-4 	-I 	-2 	-2 	-I 	-2 	-15 	-16 	-17 	-I 	-2 	-I 	-2 	-3 	-4 	-2 	-2 	-5 	-IS 	-16 	-IS 	-20 	-I 	-I 	-2 	-1 	-2 	-I 	-2 	-3 
BC)'! 2.59 
-2 (57) 
RG)'1 7.)) .79 
-3 (59) (57) 
1(G)'! 2.5) 1.40 1.48 
-4 (59) (57) (65) 
CI, 1.74 1.85 1.70 1.80 
(61) (58) (59) (59) 
CIr 2.3 1.77 3.37 2.00 8.45 
-2 (38) (36) (42) (3.5) (52) 
Ch 2.04 1.83 1.59 1.64 1.83 1.61 
-2 (50) (571 (58) (49) (50) (37) 
C4BP 3.10 3.40 2.76 2.59 3.14 3.00 2.71 
-1 (60) (57) (62) (60) (55) (30) (SI) 
C4 BP 236 1.79 1.95 1.93 1.98 1.66 1.87 3.39 
2 (59) (58) (08) (98) (09) (32) (58) (57) 
C  2.32 3.12 2.20 2.54 2.63 2.70 2.19 2.18 2.59 
-IS (51) (57) (54) (04) (59) (39) (48) (60) (51) 
C  2,51 1.61 1.83 1.87 1.93 1.57 1.54 3.20 1.56 2.99 
-16 (57) (58) (58) (58) (99) (33) (97) (55) (62) (50) 
CR1 2.18 3.08 1.85 2.27 2.29 1.69 2.17 2.92 2.10 2.61 2.22 
-17 (55) (69) (95) (09) (98) (40) (08) (59) (60) (55) (80) 
CR2 2.01 1.72 1.49 1.43 1.64 1.84 3.81 3.00 1.61 2.63 1.77 2.02 
-1 (60)   (59) (60) (38) (74) (59) (62) (58) (62) (62) 
CR2 2.23 1.46 1.19 1.68 1.74 2.21 1.90 2.69 1.98 2.52 1.79 1.66 1.57 
-2 (59) (97) (98) (58) (99) (35) (59) (58) (58) (58) (97) (57) (59) 
OAF 2.07 2.72 2.41 2,59 1.60 2.13 2.34 2.77 2.30 2.40 2.51 2.12 2.00 2.15 
-1 (61) (57) (00) (50) (62) (39) (91) (61) (99) (09) (99) (99) (65) (98) 
OAF 2.31 2.58 2.29 2.65 2.85 2.85 2.29 2.48 2.55 1.99 2.88 2.21 2,52 2.23 1.70 
-2 (57) (59) (07) (96) (62) (34) (51) (63) (59) (50) (58) (59) (60) (99) (63) 
OAF 2,49 1.21 1.69 1.51 1.69 1.53 1.40 3.92 1.73 3.02 1.26 2.31 1.75 1.89 2.98 2.86 
-3 (59) (9%) (98) (99) (99) (37) (97) (66) (62) (98) (62) (60) (62) (58) (09) (99) 
OAF 1.83 1.06 1.46 2.0) 1.96 .93 1.70 2,90 1.99 2.47 1.88 1.83 1.20 1.38 1.74 2.05 2.09 
4 (59) (57) (58) (59) (59) (38) (58) (99) (61) (53) (61) (61) (62) (98) (99) (59) (61) 
CAB, 2,65 1.92 2.47 2.45 2.7) 2.96 1.93 3,44 1.86 3.19 1.72 2.47 1.88 2.17 2.09 3.32 1.59 2.3) 
-2 (59) (57) (07) (60) (50) (32) (04) (50) (94) (56) (54) (97) (99) (54) (50) (61) (54) (04) 
CAB) 2.91 1.97 2.56 2.37 3.19 2,93 1.94 3.72 1.87 3.40 1.78 2.90 1.60 1.98 2.66 3.24 .49 2.11 .26 
2 (50) (57) (97) (56) (60) (36) (53) (59) (54) (59) (98) (97) (93) (94) (98) (59) (52) (54) )6I) 
FR 2,73 2.30 2.47 2.45 2.37 3.06 2,053.02 2.66 2.84 2.41 2.06 2.42 1.18 2.96 2.9)) 2,92 1.32 3.61 3.66 
-0 (57) (51) (56) (56) (57) (34) (49) (94) (95) (SI) (54) (96) (56) (06) (57) (57) (54) (90) (51) (57) 
FR 2,5) 3.02 2.20 2.79 2.70 2.95 2.65 2.67 2.74 2.43 3.00 2.36 2.69 0.44 1.83 2.09 3.00 2.13 3.19 3.26 2.72 
-IS (56) (52) (59) (99) (57) (33) (49) (60) (91) (58) (07) (58) (58) (57) (59) (61) (57) (57) (59) (07) (56) 
FR 2.562.77 1.93 2.65 2.57 2.50 2.49 2.69 2.77 2.22 3.09 2.28 2.39 2.19 2.32 2.01 3.02 2.32 2.99 2.99 2.60 2.09 
-16 (5)) (90) (54) (50) (52) (34) (49) (56) (59) (50) (55) (46) (40) (50) (53) (06) (05) (47) (51) (511 (49) (56) 
Fit 2.95 3.02 2.45 2.97 2.03 3.60 2,02 3.37 2.69 2.96 2.99 2.11 2.47 2.39 2.31 2.39 3.11 1.89 2.57 2.90 2.90 1.89 2.99 
-IS (58) (03) (09) (57) 59) (33) (57) (59) (57) (97) (97) (57) (98) (01) (59) (90) (57) (07) (52) (03) (50) (98) (53) 
FR 3.00 2,94 3.35 3.45 3.39 5.42 3.02 4.06 3.224.91 2.75 3.66 3.17 3.40 3.58 3.58 3.59 2,91 3.38 3.44 3.09 3.38 3.61 2,77 
-20 (98) (6)) (72) (56) (69) (46) (77) (53) (6)) (50) (65) (74) (73) (99) (05) (09) (59) (60) (56) (97) (07) (00) (65) (57) 
ILIOR 2.41 3.23 7.92 2,943.)02,3)2,523.9% 2,75 2,96 2.60 2.36 1,70 2.76 1.85 2,203.03 2.48 2.65 2.89 3.20 2.46 2.83 2.20 3.39 
1 (57) (07) (56) (56) (59) (60) (0))) (05) (61) (55) (01) (60) (6))) (96) (59) (50) (60) (60) (53) (03) (55) (99) (04) (06) (72) 
MS)'2 1.78 1.66 1.76 1,66 0.84 8.30 1.78 3.19 1.91 2.67 1.90 2.34 1.59 1.80 2.60 2.90 1.69 1.99 2.17 2,31 2.34 2,65 2.05 2.68 3.32 3.)) 
-1 (61) (98) (59) (99) (66) (52)  (00) (99) (09) (99) (08)  (59) (62) (62) (59) (99) (59) (99) (57) (55) (52) (08) (70) (60) 
MSF2 2.26 1,59 1.62 1.49 1.91 0.91 1.10 3.19 (.75 2.71 2.00 1.91 1.80 1.80 2.62 3.02 1.34 1.73 2.29 1.82 2.07 2.89 2_93 3.30 4.48 2.97 1.87 
-2 (60) (98) (09) (59) (61) (II) (69) (56) (59) (61) (59) (60) (00) (59) (62) (90) (59) (59) (61) (98) (97) (60) (40) (66) (74) (69) (611 
MC)' 2.10 2,77 2.29 2,74 2.63 2.96 2.33 2.6)) 2,5) 2.50 2.82 2.48 2.14 2.11 1.11 1.56 2,74 1.74 3.69 2.61 3.15 2.16 2.25 2.10 3,56 2.21 2,6)) 1.96 
-1 (57) (56) (57) (50) (6)) (93) (58) (56) (50) (59)  (88)  (58) (02) (62) (59) (58) (64) (54) (57) (08) (52) (55) (60) (58) (61) (62) 
MC)' 2.71 1.62 2.12 1.88 2.19 1.60 1.78 3.60 2.00 3.26 1.30 2.72 2.27 2.3) 2.94 3.36 1.58 2.36 2.10 1.90 3.02 3.39 3.42 3.20 3.30 2.97 2.27 1.64 3.16 
-2 (08) (58) (5%) (97) (60) (33) (07) (57) (62) (58) (62) (01) (03) (59) (50) (60) (62) (62) (59) (98) (56) (08) (96) (56) (71) (61) (60) (60) (50) 
VC1' 3.17 2.98 2.7) 2.11 2.70 2.56 3.10 3.02 3.59 2.97 2.49 2,79 2.01 2.46 3.14 3.05 2.79 2.03 3,28 3,19 2.54 3,15 3,01 3,17 3,803,12 2.74 2,50 3.05 3.3! 
-1 (59) (56) (60) (59) (61) (30) (06) (62) (62) (04) (57) (55) (98) (07) (61) (63) (57) (08) (00) (99) (97) (61) (96) (58) (65) (98) (00) (59) (57) (00) 
'C)' 2,64 2,20 2.16 2.07 2.32 2,04 2.27 3.45 2.9) 2,93 2,64 3.35 2.60 2.32 2.68 2.8) 2.77 2.87 2.15 2,17 2,36 2.02 2.69 2.04 3,38 3.54 2.16 212 2.96 2.65 3,73 
_2 (59) (59) (56) (57) (50) (36) (08) (08) (60) (07) (00) (60) (62) (07) (57) (57) (0)) (60) (51) (07) (54) (06) (5)) (50) (66) (60) (58) (58) (58) (0)) (66) 
VC],  2.8)) 2.24 2,00 2.34 2,6)) 2,05 2.32 2,92 0.24 2.56 2,24 2,27 2.52 2,06 2,41 2.45 2.39 2.54 2,66 2,65 2.74 2,08 2.34 2,1,5 3.31 2.65 2.65 217 2.56 2.78 2.42 	2.26 
-3 (57) (52) (97) (08) (58) (34) (50) (57) (51)   (57) (57) (93) (58) (57) (57) (97) (93) (53) (06) (50) (54) (50) (57) (54) (58) (58) (59) (59) (58) (95) 
VC P 2.56 1.81 1.67 1.03 2.03 2.54 2.33 3,09 2.32 2.30 2.67 1,91 1.85 1.51 2,62 2.48 2.11 1.88 3,14 2.45 2,05 264 2.45 2.64 3.08 2.93 1.97 2.34 2.69 2.60 2.)) 	7,22 	2.17 
(57) (49) (57) (51) (57) (33) (56) (58) (56) (911 (55) (07) (57) (57) (07) (57) (56) (97) (50) (56) (56) (56) (46) (55) (50) (54) (07) (90) 51) (57) (57) (53) (55) 
Table 2.4: Pairwise comparison of individual CCP module structures based on Ca rrnsds using CE. All values are in Angstroms (A); values in brackets indicate "Alignment length". Colour scheme used: 2.00 A (blue); > 2.00 A and 
2.50 A (green); > 2.50 A and <3.00 A (magenta); 3.00 A (black); Alignment length < 40 amino acids (red). Abbreviations as in text except for BGPI = 02GP1; C41311 = C4BPn; GABc/GABt cis-/trans-GABA5RI a; IL15R= ILl 5Ra; MSP2 
= MASP2. 
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Using CE, all 34 solved CCP module structures were compared with one 
another (Table 2.4). 	The more recently solved module structures may be 
superimposed by CE on the original mean structure of fl-I--i 6 using the Ca atoms of 
between -46 and 65 residues (out of -60). The resulting rmsd values lie between 
approximately 1.9 and 3.6 A (see Table 2.4). The most similar to fl-1--46 is 132GPI-3 
(rmsd = 1.93 A over 54 residues), DAF--2 (rmsd = 2.01 A over 56 residues) and 
C4BPci-1 (rmsd = 2.05 A over 56 residues). The neighbouring module - fH-15 - also 
overlays relatively well (rmsd = 2.09 A over 56 residues). Note that the CCP module 
of known structure with most sequence similarity (42% identity) to fH-16 is VCP--3 
(rmsd = 2.34 A over 54 residues). This is considerably less structural similarity than 
is generally observed for proteins of such high sequence similarity - e.g. 50% 
sequence identity typically corresponds on average to an rmsd < 1 A over equivalent 
backbone atoms (Chothia and Lesk 1986). The most dissimilar modules in structure 
to fH-16 are IL15Ra-1, MCP-.2 and CRl16 (see Table 2.4). Fewer CCP module 
structures superimpose well on the structure of fl-15 than on fl-I---46 - the most similar 
is VCP-4 (rmsd = 2.09 A) and the most different are the two forms of GABABR1a 
(rmsd = 3.86 A (trans) and 3.61 A (cis)). The second CCP module of Cir was 
excluded from this analysis since the relevant coordinate files are missing residues in 
its module making its structural alignment length too short. 
Globally, DAF-4, MASP2-2, i32GPI-2 and -3 appear to be the most 
conventional out of the set of solved 3D structures - their rmsds (according to CE) are 
< 2 A for each of sixteen other modules. DAF-4 can be considered the most 
"typical" with none of the 33 modules compared> 3 A, and its rmsd as low as 1.2 A 
when compared to CR2-1 (it only deviates by more than 2.5 A in the case of four 
modules). The two most similar modules structurally are the first modules of Cir and 
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MASP2, whose rmsd = 0.84 A over all residues. These two modules share 42% 
sequence identity. The most divergent among all CCP modules are fH-..20, C4BPctl, 
and VCP-4, with rmsds> 3 A for each of 29, 19, and 16 other modules, respectively. 
The two most dissimilar modules structurally are fl-I--20 and CR1—i5 (rmsd = 4.91 A 
over 56 residues); fl-1-20 also deviates by > 4 A versus MASP2-2 and C4BPu-1. 













Figure 2.10: Overlay of all 34 CCP structures. A consensus 3D structure emerges from an overlay 
of all 34 CCP structures solved to date (3rd April 2006). Left-hand side: two views (related by a 1800 
rotation about the vertical axis) of a superposition (using Multiprot, see text) of all 34 accessible CCP 
module 3D structures. The structures of the two atypical modules in IL2Rct were excluded from this 
analysis. To help interpret the overlay, a Molscript representation showing the same views of fH-5 is 
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drawn on the right-hand side, with strands numbered 1-8 as in Figure 2.8. It is not intended that the 
viewer try to trace individual structures within the superposition but this figure summarises structural 
divergence and provides a good representation of the consensus structure; the hypervariable loop is 
indicated. 
Figure 2.10 shows a global overlay of all 34 CCP module structures for which 
coordinates are currently available. From this superposition, a "consensus module 
structure" emerges that can be considered in conjunction with the multiple sequence 
alignment in Figure 2.4 and schematic in Figure 2.8. The best conserved part of the 
structure corresponds to the four stranded antiparallel J3-sheet comprised of strands 2, 
4, 6 and 7, with the inner J3-strands 4 and 6 being particularly highly conserved. 
Residues corresponding to J3-strands 3 and 5 converge less well and the first and last 
strands (1 and 8) are the least well-conserved. The sequence connecting f3-strands 3 
and 4 is never the site of an insertion and is the most highly conserved turn. The 4-5 
loop is also structurally conserved - insertions in the 4-5 loop as exemplified in this 
set of structures by CR117, occur only in CR1-7/14/21/28; CR1-3/10/17/24; CR.2-5 
and 9 (six residue insertions); and MCP-3 (five residue insertion). The 6-7 loop is 
more variable in size - with CR1-17 illustrating the maximum length it attains 
amongst the RCA proteins, and IL15Rci-'l having highest deviation among the set. 
The stretches of residues between strands 1 and 2, are poorly conserved but have the 
same general appearance in the overlaid structures - an extended region running 
towards the C-terminus followed by a change of direction so that strand 2 heads 
towards the N-terminus. The 1-2 region is a site for insertions in only a few modules 
(e.g. C4BPa6) for which there are no structures as yet. The three regions in the 
current structure set displaying the highest variability lie between strands 2 and 3 
(hypervariable loop), strands 5 and 6, and strands 7 and 8. All these regions lie to the 
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"sides" of the modules, away from the termini and the junctions with neighbouring 
modules. Both the 5-6 and the 7-8 regions of the great majority of the solved 
structures do, nonetheless, converge towards a consensus that is perceptible in the 
overlay. The 5-6 region is notable for its bulge-like appearance as the main chain 
leaves strand 5 at the (C " + 8) Gly and makes two sharp bends to direct itself first 
back into the body of the module and then "down" (in Figure 2.10) to form strand 6 
that is aligned with strand 4. Obvious outliers are the Clr, Cls and MASP2 modules 
that are unusual in having large insertions in both these regions, which form 
prominent features protruding laterally from the bodies of the module (in the case of 
Clr2 and C1s-2 the 7-8 insertions were not visible in the electron density, 
presumably due to their flexibility). It is only in the 2-3 region that no consensus 
appears in the overlay - this is the "hypervariable" region referred to previously, and 
is a site of sequence and length-diversity across the CCP module family (Kirkitadze 
and Barlow 2001); it is also the site of the cis/trans isomerisation in GABABR1a2 
(Blein et al. 2004). 
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2.6 	Intermodular junctions - structure and mobility 
2.6.1 Introduction to junctions 
Each intermodular junction may be regarded as being made up from proximal loops and 
strands of the respective neighbours, plus the "linker". As already discussed, the linker is 
defined, for convenience, as the sequence of residues between C 'j" of the preceding 
module and C 'of the next module. The forces that influence the structure and flexibility 
of such a junction thus consist of: covalent linkages and non-covalent interactions within 
the linker; interactions between the proximal loops/strands of the neighbouring modules; 
and interactions between loops/strands of the respective modules and the linker. 
Approximately 14% of linkers between modules of the RCA proteins have only three 
residues. This appears to be a minimum with regard to the possibility of both modules 
being able to fold successfully, consistent with the fact that one or two residues after C 's', 
and before C 1, commonly form part of strands 8 and 1 respectively. The most common 
linker length (see Figure 2.5) is four residues ('-58% of linkers), while linkers of five, six, 
seven and eight residues also occur (Table 2.1). Four of a total of six eight-residue 
linkers and two out of a total of four seven-residue linkers are found in CR2, which has 
on average the longest linkers (5.5 residues) of any of the RCA proteins (cf. factor H - 
4.6; CR1 - 4.3). The orientation of one module relative to its neighbour can be 
characterised by the three angles: tilt, twist and skew (Figure 2.12) described in the 
Materials and Methods section. Figure 2.12 is a summary of tilt, twist and skew angles 
(Table 2.6) for all of the CCP junctions that are available in the Protein Data Bank. The 
surface area (SA) buried in each junction (Table 2.5) is also indicated in Figure 2.12. 
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2.6.2 Examples of intermodular junction structures - discussion 
The initial structural investigation of a pair of CCP modules was performed on the 
15  I 
and 16th  modules from factor H expressed as a recombinant protein in S. cerevisiae. 
These studies were carried out using two-dimensional 'H-NMR on a pure (no salt or 
buffer) 2 mM sample of protein at pH 4.7 and 27 °C (Barlow et al. 1993). The basis of 
an NMR-derived structure is a list of pairs of atoms that are < 5 A apart in the folded 
protein - each entry in such a list is referred to as a distance-restraint. While many 
intramodular distance-restraints were inferred from the spectra, intermodular distance 
restraints (i.e. between two residues, each residing in a different module) were almost 
absent. Only one such restraint could be detected. The ensuing structure calculations, 
based on all distance-restraints, indicated an extended, head-to-tail arrangement of the 
two neighbouring CCP modules with a very limited intermodular interface (buried 
surface area = 573 A2). The lack of significant contacts between the modules was 
consistent with the observation that the NMR frequencies of module 16 hydrogen nuclei 
(protons) were independent of whether module 16 was studied in isolation or in the 
context of the pair. A preferred intermodular orientation was evident amongst the 
ensemble of calculated structures, presumably due to distance-restraints between residues 
of the linker and residues of near-by loops from the two modules. A subsequent structure 
calculation, however, using a different computational algorithm (Wiles et al. 1997), 
indicated a somewhat different intermodular conformation. It is highly probable that 
significant flexibility exists between modules 15 and 16 of factor H. On the other hand, 
the shortness of the linker (four residues) and the steric bulk of the two modules must 
limit the freedom of intermodular movement to some extent - disallowing for example a 
conformation in which the two modules are organised in a side-by-side arrangement. 
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3X Module I 
N- 
C 
MCP hexamer in unit cell 	 Module I  
Module 2 
Figure 2.11: The 3D crystal structure of the N-terminal two CCP modules of MCP. The left-hand 
panel shows the arrangement of the six molecules in the unit cell, with each molecule drawn in a 
different colour. The right-hand panel shows a cartoon of one molecule. Some residues that were 
proposed to represent a key interaction site for measles virus binding are drawn as ball-and —stick. 
Subsequently the structure of a second module-pair was determined using X-ray 
crystallography (Casasnovas et al. 1999). The N-terminal two CCP modules of MCP 
(MCP-1,2) were expressed in Chinese hamster ovary cells as a high-mannose glycoform, 
and their structure was solved at a resolution of 3.1 A. Crystals were grown at 20 °C, pH 
6.5 [in 16% 8 kDa polyethylene glycol (PEG)] and, notably, 40 mM CaCl2. The 
asymmetric unit of the crystal contained six molecules of MCP-1,2. Two sets of three 
molecules each formed a "three-legged table" in which each leg consists of module 2 
(Figure 2.11). One table is inverted and it stacks on top of the other creating the 
hexamer. Extensive contacts between molecules were observed, and these were 
particularly evident within each trimer. The N-terminal end of the first module contacts 
residues within the small interface between the two CCP modules in the neighbouring 
molecule. A Ca 2+  ion appeared to be ligated by aspartate residues of CCP module 1 lying 
close to the interface and this ion participates in solvent-mediated contacts with module 
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2. Bearing in mind the extent of intermolecular interactions compared to the more 
limited intramolecular intermodular contacts, it seems likely that the N-terminal two 
domains of a monomeric version of MCP would be less constrained relative to one 
another than they are in the crystallographic hexamer. Some evidence for flexibility 
derives from the range of conformations within the unit cell (see Figure 2.12). The tilt 
angle between the two CCP modules differs between members of the hexamer over the 
range 61 to 75 ° (mean 68.3 + sd 5.7 0  n = 6), and the twist and skew angles are -158+7 
and —20+2 0  respectively. While Ca 2+  was needed for crystallisation, the physiological 
relevance of the Ca 2+  ion, and its role in stabilising the junction within the crystal are not 
entirely clear. The crystal structure of MCP-1,2 thus leaves unresolved the issue of the 
flexibility of the intermodular junction under physiological conditions. It remains 
possible that in its physiological state it is just as flexible as the factor H 15-16 module 
pair. An additional interesting aspect of the MCP-1,2 structure is the presence of a 
glycan moiety on each module (N-linked to N49 and N80). These occupy the concave 
surface created by the tilt angle between modules, and project towards one another. The 
N-glycan on N80 (in module 2) could have a stabilising influence on the structure of that 
module since it has hydrophobic contacts with hydrophobic side-chains that might 
otherwise be solvent-exposed. This could explain the requirement of N-glycosylation at 
N80 for virus binding (Figure 2.11) (Maisner et al. 1996). 
CCP-containing protein PDB code(s) Module 1 Module 2 Bimodule Buried 
C4BPa 2A55 1 2 434074 4365.78 8194.07 512.45 
factor  1HFH 1516 4161.13 3843.43 7431.17 573.39 
2BZM*1920 3920.47 4388.50 7576.76 732.21 
DAF 1H03 3,4 4072.09 4303.13 7864.32 510.90 
1NWV 2,3  4684.01 4044.11 8275.20 452.92 
1OK3 1 , 4314.42 4306.75 8141.22 479.95 
1OK3 2,3  4403.66 3992.75 7793.96 602.45 
1OK3 3,4 4033.63 4350.62 7848.45 535.80 
MCP 1CKL7 4576.91 4220.77 8340.89 456.79 
CR1 1GKN 116  4489.55 3976.54 7971.51 494.58 
1GKG 617 4068.81 4809.27 8380.24 497,84 
CR2 1LY2 1 ,2 4700.86 4180.76 7897.61 984,01 
VCP 1G40 1 ,2 5341.84 4201.85 8653.74 889.95 
1G40 2,3  4103.66 3979.33 7492.39 590.60 
1G40 3,4 3988.90 4083.96 7261,93 810.93 
1VVC 34 3686.33 3785.37 7080.40 391.30 
1E5G 2,3  3961.39 3454.97 7146.18 270.18 
CIr 1GPZ 1 ,2 4672.76 4759,40 8954.35 477.81 
P2-GPI 1QUB 1 ,2 4173.13 3942.93 7619.73 496.33 
1QUB 2,3  3928.82 4134.70 7700.87 362.65 
1QUB 3,4 4186.09 3874,36 7491.51 568.94 
MASP-2 1ZJK 1 ,2 4178.72 4244.20 7987.84 435.08 
Table 2.5: Calculated buried surface area among CCP bimodules. All units are in A2. 











VCP-13-X 1G40 1 4.4 -9.9 66.5 1.6 8.6 8.1 
DAF-34-X 10K3 2 7.6 113.7 59.1 1.5 9.8 3.9 
B2GPI-12-X 1QUB 3 10.9 133.8 -139.9 na na na 
FH-1920-N 2BZM 4 11.1 15.5 149.7 6.4 8.4 neT 
DAF-34-X 1H03 5 12 112.6 39 6 5.6 39.5 
MASP2-12-X 1ZJK 6 12.5 79.1 119.4 na na na 
CRI-1617-N 1GKG 7 16.3 110.8 -6.6 9 18.5 41.5 
Clr-12-X 1GPZ 8 22.2 97.6 124.9 na na na 
DAF-24-X 10K3 9 24.9 -55.8 -54.1 4.8 13.4 1 
VCP-23-N 1 E5 10 31.2 144.1 77.6 10.4 11.9 24.7 
CR1-1516-N 1GKN 11 31.2 161 -44.9 7.3 13.7 21.5 
DAF-23-X 10K3 12 31.5 -168.5 -63.5 5.3 4.4 2 
B2GPI-23-X 1QUB 13 32.9 89.1 60.1 na na na 
VCP-24-X 1G40 14 35.2 -12.7 -91.5 1.3 3.5 3.6 
DAF-134 10K3 15 37 114.7 139.1 2.1 8.2 3.4 
CRI-1517-N 1GOP 16 37.6 -81.7 -19.9 na na na 
C413Pa-12-N 2A55 17 38.4 3.7 -110.2 4.4 5.7 17.9 
DAF-144 10K3 18 39.3 -134.1 152.5 0.4 17.7 0.5 
DAF-124 10K3 19 41.1 -87 107.4 0.1 2.8 10.4 
B2GPI-134 1QUB 20 41.9 -139.2 -143.7 na na na 
DAF-23-N 1NWV 21 45.4 128.7 -127.5 20.9 15.3 24.2 
B2GPI-24-X 1QUB 22 48.4 144.1 103.3 na na na 
FH-1516-N 1HFH 23 50 -130 155 13 17 23 
B2GPI-34-X 1QUB 24 53.2 40.2 100.2 na na na 
B2GPI-14-X 1QUB 25 56.3 -78.5 -121.4 na na na 
VCP-12-X 1G40 26 62.8 -18.5 69.1 4 9.2 8.5 
VCP-23-X 1G40 27 64.6 7.4 -91 1.7 2.6 3.6 
VCP--34-N 1VVC 28 67.2 7.2 81.3 6.3 9.2 11 
MCP-12-X 1CKL 29 68.3 -158.3 -20.3 5.7 7 2.2 
VCP-34-X 1G40 30 97.9 -31.5 66.5 4.1 10 8.2 
VCP-14.X 1G40 31 99.7 -19.4 75.4 1.3 2 1.2 
CR2-12-X 1LY2 32 142.2 -4.2 43.6 2.6 20.1 2.9 
Table 2.6: Intermodular angles for all CCP module pairs and larger fragments. Tilt, twist and 
skew angles plotted for all experimentally determined structures of multiple CCP-module fragments. 
The values for pairs of modules and for non-consecutive modules (red), in order of increasing tilt angle 
Modules solved by X-ray diffraction marked with an "-X", while structures solved by NMR 
marked with an "-N" and corresponding PDB codes shown. Error values represent the standard 
deviation of angles observed, calculated for structures where several molecules are present in the unit 
cell of a crystal or where an ensemble exists for structures solved by NMR (na = not applicable; net = 
not entered; value seems to be an overestimation of intermodular flexibility, and could be due to local 
flexibility). 
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Figure 2.12: Graphical representation of intermodular angles and buried surface area. Skew 
(transparent dots), tilt (solid dots) and twist (squares) angles plotted (left-hand scale, see key for 
symbols) for all experimentally determined structures of multiple CCP-module fragments. Values for 
pairs of modules are plotted in order of increasing tilt angle; the identity of the protein and the two 
modules involved is marked on the graph; N = solved by NMR; X = solved by X-ray diffraction. Red 
symbols are used to emphasise that some of the pairs analysed are non-adjacent. Where more than one 
structure is available - i.e. where there is an ensemble of NMR-derived structures or where several 
molecules are present in the unit cell of a crystal - the data points plotted are average values and error 
bars represent the standard deviation of angles observed. Buried surface areas for each junction are 
plotted as yellow bars (right-hand scale). Details of the calculation are given in the text. The raw data 
is in the tables on previous two pages. 
Two papers (Bouma et al. 1999; Schwarzenbacher et al. 1999) subsequently 
described the crystal structure of human [3-2-glycoprotein I (32GPI) purified from 
plasma. While this protein is not directly involved in the complement system, this work 
was of interest since it revealed three new inter-CCP module junctions; the fifth CCP 
module is aberrant and so the 4-5 junction is excluded from the overall analysis. Crystals 
were grown at high salt [1.5 M (NH4)2SO4 or (NH4)2HPO4] and either pH 5.6 or 7.5. 














with excellent conservation of the intermodular angles. As in previous examples, the 
modules are arranged end-to-end with relatively few intermodular contacts. In particular 
the 2-3 inter -nodular junction buries little surface area (362 A2) and there is a relatively 
small tilt between these modules (tilt = 33 0;  twist = 89 0;  skew = 60 0)  (see Figure 2.12). 
The 1,2 junction in both 32GPI structures, although burying a larger SA (496 A2) than the 
2,3 junction exhibits an even shallower tilt - just 10.9 0  on average (twist = 134 0  and 
skew = -140 0) - thus making it one of the most elongated module pair observed to date. 
The J32GP1 3,4 junction is more markedly tilted (tilt = 53 twist = 40 0;  skew = 100 0)  
In the light of previous comments on intermodular orientations of MCP within the crystal 
lattice, it is of interest that a subsequent solution study of the structure of J32GP1 (Hammel 
et al. 2002), based on small-angle X-ray scattering (SAXS), suggested that the "J-shaped" 
conformation observed in both crystal structures does not predominate - an alternative 
"S-shaped" solution conformation of the protein was proposed that is more consistent 
with the SAXS data. In this conformation the 2-3 junction has a 60 0  tilt rather than the 
33 0  tilt observed in the crystal structure. Various explanations for the inconsistency 
between the crystal structures and the scattering data are possible, including a dynamic 
interchange of still other conformations. Thus, like the structure of MCP-1,2, the crystal 
structures of J32GP1 may reveal only a very limited set of the possible conformations at 
the 2-3 junction that occur under physiological conditions. One consideration, advanced 
by the authors of the SAXS study (Hammel et al. 2002) is that the high ionic strength of 
conditions used for crystallisation was such that hydrophobic interactions between 
modules could be artificially strong. 
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Figure 2.13: The 3D crystal structure of intact VCP. A Moiscript representation of both molecules 
(A and B) of VCP in the unit cell, with each CCP module drawn in a different colour. The relatively 
open junction between the central modules is evident, as the more extensive junction between modules 
1 and 2. 
Another example of differences between the conformations of solution and crystal 
structures came to light with the determination of the first complete complement protein 
structure - that of VCP (Murthy et al. 2001) (Figure 2.13). Crystals of VCP were 
obtained at pH 7.5, 20 °C and in -10% PEG 6000 or 8000. The three protein molecules 
in the unit cell of one crystal form of intact VCP, and two molecules in another, exhibited 
essentially the same tilt, twist and skew angles at the three respective intermodular 
junctions, suggesting a structure (Murthy et al. 2001) that is rigid throughout its length. 
Within each molecule, the three tilt angles (ranging from 63-100 0)  are larger than the tilt 
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angles observed in 132GP1, but the 2-3 junction buries the least SA (591 A2). 
Interestingly, the solution structure of the 2,3 CCP module pair of VCP determined by 
1H,'5N-NMR (Henderson et al. 2001), together with measurements of NMR relaxation 
and a series of other biophysical studies (Kirkitadze et al. 1999b), strongly indicated 
flexibility at this junction. The solution structure of a VCP 3,4 module-pair had also been 
solved using 'H,15N-NMR (Wiles et al. 1997). Unlike in the cases of VCP-2,3 and 
fl-F--45,16, for VCP-3,4 a useful number of distance-restraints involving hydrogen nuclei 
on different modules were obtained. In contrast to the VCP-2,3 situation, these allowed 
the intermodular orientation to be calculated with some confidence, although there were 
insufficient distance-restraints to define it fully (tilt = 67±6 0;  twist = 7±9 0;  skew = 
81±11 0)  The subsequent crystal structure of intact VCP (Murthy et al. 200 1) yielded a 
more tilted but roughly similar 3,4 intermodular orientation (see Figure 2.12, tilt = 100±1 
0; twist = -19±2 0;  skew = 75±1 0)  with a junction involving the same residues. Thus in 
the case of VCP-3,4, the differences between crystal and NMR structures was less 
significant - and both methods were consistent with a relatively inflexible junction. 
A third example where crystal and solution structures have been interpreted in a 
complementary fashion is provided by studies of the N-terminal modules of CR2. An 
unusual side-by-side orientation of these two modules (reflected in a very large tilt angle 
of 142 0  and buried SA of 984 A2), made possible by the eight-residue linker, was 
observed by crystallography for both free and complexed (with C3d) forms (Szakonyi et 
al. 2001; Prota et al. 2002). On the other hand, biophysical solution studies and 
sedimentation modelling were consistent with a more extended arrangement (Guthridge 
et al. 2001). 	Additionally, another solution study using X-ray scattering and 
sedimentation modelling (Gilbert et al. 2005) revealed a high degree of flexibility in the 
FIM 
linker between the two modules, that was able to adopt a wide range of different 
conformations. 
A fourth example, the central modules of decay accelerating factor (DAF-2,3), 
were solved both in solution as a module-pair (Uhrinova et al. 2003), and in its intact four 
module form, by crystallography (DAF--4-4) (Lukacik et al. 2004). While there is 
reasonable agreement between NMR and X-ray at the level of the structures of the 
individual CCP 2 and 3 modules (Table 2.3), the crystal structure solved under conditions 
used to encourage crystal growth (4°C, 20% polyethylene glycol, pH 4.6) indicated a 
more closed and rigid CCP2-CCP3 interface (burying the alkyl components of Arg and 
Lys side chains previously inferred to have direct binding roles) (buried surface = 602.45 
A2; tilt = 31.5±5.3 0;  twist = -168.5±4.4 0;  skew = -63.5±2 0)  than the solution one, which 
under physiological conditions, suggested an open and semi-flexible junction (buried 
surface = 452.92 A2; tilt = 45.4±20.9 0;  twist = 128.7±15.3 0;  skew = -127.5±24.2 0)  
exposing positively charged side chains. As a result, the two papers (Uhrinova et al. 
2003; Lukacik et al. 2004) suggest different interpretations with respect to functional 
versus structural roles of residues in and near the junctions between CCP modules, and 
the "true" nature of the junction arrangement is still a matter of debate and investigation 
(Brook et al. 2004). 
These examples demonstrate that junctions that are flexible in solution under 
approximately physiological conditions may be rigidified either by the conditions used 
for growing crystals, or by the process of forming the crystal. In the latter case, the 
observed conformation might reflect one of several, or even many, possibilities that is 
energetically favoured in solution. Clearly, caution should be exercised when inferring 
from these structures the proximity of residues that are functionally important within the 
same binding site, but are on different modules. It is known, however, that some 
MR 
junctions between CCP modules are relatively rigid, even in solution. The interface 
between modules 15 and 16 of CR1 (Smith et al. 2002) is another example of a more 
defined junction, as indicated by NMR and a range of other biophysical data (Kirkitadze 
et al. 1999a; Kirkitadze et al. 1999c); a number of NOE-derived distance restraints 
between the two modules, as well as between the linker and the modules were observed. 
Crystal structures for the pairs of CCP modules in classical and lectin pathway 
complement proteins, Clr (Budayova-Spano et al. 2002b) and MASP2 (Gal et al. 2005), 
that both possess identical overall domain architecture, revealed highly analogous 
individual CCP module structures [when compared with each others corresponding 
modules (rmsd < 1 A, Table 2.4)], and also revealed comparable intermodular small tilts 
(Table 2.6). A noticeable feature for these pairs of modules was the linker region of four 
residues (372-375 in Cir and 362-365 in MASP2) between the two CCPs, which formed 
part of one continuous n-strand in both Cir and MASP2. These regions in Cir and 
MASP2 formed backbone-backbone hydrogen bonds and van der Waals contacts with 
residues from both CCPs. Even though the amino acid sequence of the linker region 
possessed only 50% similarity in MASP2 and Cir, the segments that contacted this linker 
(e.g. in MASP2 residues 330-335, 414-416, and 387-388) when compared with 
equivalent segments in Cl r, revealed a high degree of similarity (-67%) (Gal et al. 2005), 
forming a basis of explanation for similar relative orientations observed in the MASP2 
and Cl r structures. 
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Figure 2.14: Location of hypervariable loops in C413Pa.-1,2 and DAF-2,3. The hypervariable 
loops in consecutive C4BPa modules 1 and 2, lie on the same side of the y-axis (Jenkins et al. 2006), 
whereas in DAF--2,3 they lie on opposite sides (Lukacik et al. 2004). Thus the respective intermodular 
orientations greatly complicate interpretation of mutagenesis data on the basis of sequence alignments 
alone; apart from other evidence of flexibility and rigidity among regulators, and the fact that more 
than one module is involved in a combinatorial fashion for complement regulation (See Table 2.6 for 
inter-modular angles). Figures adapted from (Lukacik et al. 2004; Jenkins et al. 2006). 
The latest two structures to be solved were solution structures of the two N-
terminal modules in C4BPa (Jenkins et al. 2006), and the C-terminal two modules in 
factor H (Herbert et al. 2006c). Like CRI-15,16, both these module pairs (C4BPa-4,2 
and fl-1'--49,20) appeared to show limited flexibility, consistent with sets of module-to-
module and module-to-linker distance restraints that dictate a well defined mutual 
orientation of the CCP-module pairs. The module pair in C4BP exhibits small twist 
angles, and a unique arrangement, where both hypervariable loop regions of adjacent 
modules occur on the same side (Figure 2.14). 
In Figure 2.12 intermodular angles of all the available NMR and crystal structures 
of CCP module-pairs, are plotted in order of increasing tilt angles. This figure also 
contains data for the orientations of non-neighbouring modules. The uncertainties 
(reflecting experimental limitations, flexibility or both) are greatest for the NMR-derived 
structures. Average tilt angles for the neighbouring pairs range from 8 to 142 with over 
half the structures displaying tilts between 31 and 64 • There is no correlation between 
tilt angles and twist or skew angles - the latter two angles cover almost the full 0 to +1-
180 O  range. There is a trend for higher buried SA with higher tilt-angles to the extent 
that outliers can be commented upon. The VCP-1,2 junction buries a large SA for its tilt 
angle but this can be explained by the specific nature of the intermodular interface (see 
Figure 2.13). On the other hand, MCP-1,2 buries a small SA relative to the interrnodular 
tilt - but as mentioned previously there are complications here due to glycosylation, 
crystal contacts and the Ca2 -ion present at the intermodular interface. 
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2.6.3 Some emerging themes 
With the exception of the CR2-1,2, DAF-1,2 and fH-19,20 pairs, all linkers within the 
3D structures solved so far consist of four residues. Inspection of the various 
intermodular interfaces within this set of structure reveals the following. (i) The 
backbone of the linker participates in H-bonds with residues in the body of the module - 
the N-terminal half of the linker frequently forms part of f3-strand 8 (which has H-bonds 
to strand 5 and a disulfide bond to strand 4, see Figure 2.8b) and the C-terminal half is 
sometimes a part of 13-strand 1 (H-bonded to strand 3, disulfide linked to strand 6). (ii) 
The consequence of these linker residues being involved in 13-strand formation is that few 
covalent bonds within the linker are freely rotatable. Combined with the steric bulk of 
the modules this limits flexibility at the junction even in the absence of favourable 
interactions between the bodies of the modules. (iii) Because of the lack of potential 
flexibility and the fact that the bodies of the modules are tethered by a short linker, there 
is inevitably the potential for van der Waals contacts between modules to provide 
energetically favoured conformations. Due to the generally small size of the interface 
and possible lack of specificity such conformations may not occupy deep potential 
energy wells, and may not be unique - but some conformations may be sufficiently 
favoured to be "frozen out" by crystallisation, especially where crystals are grown in the 
cold, or under far from physiological conditions (e.g. high salt, high PEG). (iv) Where 
alkyl and aromatic side-chains (or long polar or charged side-chains with alkyl segments) 
are present, there is the potential for more specific interactions created by both close 
packing (van der Waals) and exclusion of water (hydrophobic effect). The linker - 
which frequently contains residues with large side-chains - and both modules can 
contribute to such a junction which consequently has the potential to be relatively rigid. 
An example of such a junction is that of VCP-3-4. (v) Equivalent residues within 
modules participate in most junctions - these are located in: the regions just prior to 
strand 2, and strand 5 itself (at the N-terminus); and strand 3 and the 3-4 loop, and the 6-
7 loop (at the C-terminus). Inspection of these residues in sequence alignments could 
provide clues as to the sort of junction that might be formed. (vi) The 1-2, 3-4, 4-5 and 
6-7 loops are frequently the sites of insertions and these may create unique junctions. 
For example in VCP1,2, the side-chain of Arg40 in the 4-5 loop of module 1 is 
extended and largely buried; it runs parallel with the linker, making many contacts with 
linker residues, and its guanido- group participates in an unusual intermodular H-bond 
with the carboxyl group of Asp84. On the other hand, such insertions do not necessarily 
participate in the junction - an example is CR116's 1006-1010 (or C4BPa2's 108-
112) insertion between strands 6 and 7. 
In conclusion, a very wide range of intermodular orientations has now been 
observed and the various junctions between CCP modules may have varying degrees 
of flexibility. Under the circumstances it is hardly surprising that it has proved 
impossible to predict, on the basis of the residues likely to be involved, either the 
structure or the flexibility of the junction. Therefore, for the time being, the 
exploitation of homology for reliably predicting RCA protein structures is limited to 
individual modules (Chapter 3). Still more experimental evidence is required before 
junction structures and intermodular orientations can be predicted by homology. 
There is clearly a strong case for future extensive mutagenesis and structural studies 
of intermodular junctions, as well as structural work on further new examples of 
junctions with native sequences. 
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2.7 Concluding remarks 
The past decade and a half has delivered a wealth of detail for the CCP modules that 
are the structural and functional building-blocks of the regulators of complement 
activation. The sequence and structure comparisons undertaken in this chapter 
provide a basis for further sub-family specific classification of CCP-modules that can 
be exploited using homology modelling to fill gaps in structural knowledge for other 
modules (see Chapter 3). There is a need for more high-resolution studies of protein 
fragments; by NMR, which can deliver information on structure and flexibility under 
approximately physiological conditions and in solution, and crystallography, which 
give access to larger fragments or intact proteins, and produce more accurate 
structures at the level of individual modules. Mutagenesis of junction residues 
combined with high-resolution structural work will shed much-needed light on the 
relationship between primary structure and intermodular orientation. Biophysical 
studies, such as FRET, are needed to obtain data on very long fragments, too large for 
NMR and too flexible for crystallography. There is a particularly pressing need for 
more studies of the RCA proteins in complex with their binding partners. The "holy 
grail" would be a structure of an intact RCA with C3b or C4b (and perhaps with 
factor I). But more realistic targets such as mapping RCA residues involved in ligand 
binding using NMR, the use of biophysical techniques to monitor changes in overall 
conformation upon ligand-binding, or high-resolution structural work on complexes 
of RCA fragments with smaller ligands (fragments of C3b/C4b, or pathogenic 
proteins) would also be immensely valuable. 
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Large-scale modelling as a route to multiple surface 
comparisons of the CCP module family 
3.1 Motivation for modelling CCP modules 
A sizable fraction of the vertebrate proteome consists of proteins that are composed 
from a limited repertoire of domain- or module-types (Bork et al. 1996). In the cases 
of the most commonly occurring types of modules there are now numerous 
experimentally-derived three-dimensional (31)) structures (Copley et al. 2002). These 
provide the opportunity to predict structures for the remaining examples of a 
particular module-type through comparative modelling. The resolution attained with 
this widely used technique (also known as homology modelling) is high enough to 
advocate the use of such models as approximations of the true 3D structures (Baker 
and Sali 2001; Peitsch 2002). In turn, a well-populated database of 3D structures 
allows, within a class of modules, comparisons based upon structural features rather 
than sequences. Such an approach should provide a richer source of information for 
the design and rationalisation of mutagenesis experiments; it might also shed light on 
phenotypes associated with specific polymorphisms. Ultimately structure-based 
comparisons could be a useful tool in the prediction of function, identification of 
functional sites (Nicholls et al. 1991; Blomberg et al. 1999; Pawlowski and Godzik 
2001), and design of therapeutic proteins in appropriate cases. The most obvious 
features to use in a comparison of module structures of the same type are their 
surfaces. 









Figure 3.1: The CCP module fold and arrangement. (a) Moiscript (Kraulis 1991) representation of 
the 313-structure of the first CCP module [the 16th  module of factor H, PDB ID: 1 HCC (Norman et al. 
199 1)] revealed by NMR spectroscopy. The consensus "scaffold" of conserved residues, involving the 
cysteines (forming two disulfide bridges) and a buried tryptophan are drawn as ball-and-stick. 3-
strands are shown as arrows. (b) Rasmol (Sayle and Milner-White 1995) Ca-trace representation of the 
3D-crystal structure of the intact four CCP modules of DAF [PDB ID: 1 0K3 (Lukacik et al. 2004)]. 
The four modules are arranged in a head-to-tail fashion connected by their short linkers. 
The 3D structures of a wide range of CCP modules - 25 in total, including 14 
CCP modules from human RCA proteins - have been determined experimentally over 
the last decade [count up to May 2005 (Soares et al. 2005); update provided in Section 
3.5] (See Figure 3.4, CCP-module structures solved shown in blue). Each 
approximately 60-residue CCP module is characterised by a compact hydrophobic 
core wrapped in a 13-sheet framework, held together by two strictly conserved 
disulfide bridges (Kirkitadze and Barlow 200 1) (Figure 3. 1, Chapter 2). Because it is 
time-consuming to solve 3D structures by NMR or X-ray crystallography, many 
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attempts to model CCP-module structures have been reported (Norman et al. 1991; 
Kuttner-Kondo et al. 1996; Chou and Heinrikson 1997; Villoutreix et al. 1998; 
Liszewski et al. 2000; Ranganathan et al. 2000; Aslam and Perkins 2001; Hellwage et 
al. 2002; Perkins and Goodship 2002; Weyer et al. 2004; Saunders et al. 2006). In 
most cases, however, the CCP module structures within these models were based on a 
smaller set of structural templates than are now available, non-optimal templates, or in 
the case of Chou and Henrikson (1997) - erroneously created, when the module 
structure was already published. Consequently, there is currently scope for improving 
the quality of modelled CCP structures. 
Module deletion and site-directed mutagenesis approaches have revealed the 
identity of numerous functional CCP modules (Medof et al. 1982; Krych et al. 1991; 
Brodbeck et al. 1996; Hardig et al. 1997; Krych-Goldberg et al. 1999; Jokiranta et al. 
2000; Liszewski et al. 2000; Blom et al. 2001a; Kuttner-Kondo et al. 2001). This, 
however, is restricted mainly to the RCAs, and is not exhaustive even for this set of 
proteins. Moreover, at the level of individual side-chains, functional-site mapping 
through experiment is still incomplete in most cases. 
While computational, sequence-based methods exist that screen for residues 
important for function on the basis of sub-family specific conservation (Lichtarge et 
al. 1996; Glaser et al. 2003), such analyses are hampered if the location of functional 
patches on different modules is not equivalent (with reference to the common 
structural scaffold). For CCP-modules, such non-equivalence is strongly suggested 
by the observation that in most cases several neighbouring modules are implicated in 
interactions with a single asymmetric partner protein. Because protein-protein and 
protein-ligand interactions are a surface phenomenon, one approach to suggesting the 
location of functional sites in this case is to examine the properties of CCP-module 
surfaces. The concept of surface-to-surface comparison holds considerable promise 
in analysing models based upon sequence homology (Blomberg et al. 1999). Surface 
electrostatics play a key role in protein-ligand binding and protein-protein 
interactions. 	Electrostatic properties determine the relative orientation during 
molecular recognition, whereas charge-charge and hydrogen bonding interactions 
contribute to binding specificity and affinity [see (Honig and Nicholls 1995) for a 
review]. It has been demonstrated that where similar electrostatic properties are 
shared by a set of proteins, this may indicate similar behaviour and function (Ullmann 
et al. 1997; Botti et al. 1998; Wade et al. 1998; Blomberg et al. 1999). There is plenty 
of evidence for the involvement of electrostatic interactions in the recognition by 
RCA proteins of C3b and C4b, and glycosaminoglycans (Pangbum et al. 1991; 
Blackmore et al. 1996; Blackmore et al. 1998b; Krych et al. 1998; Prodinger et al. 
1998; Blom et al. 1999; Blom et al. 2000b; Brodbeck et al. 2000; Liszewski et al. 
2000; Blom et at. 2001a; Kuttner-Kondo et al. 2001). 
In this chapter, a large-scale modelling strategy targeted at individual modules 
is presented, with the aim of providing surface information for a large number of 
modules with the highest possible precision. The strategy makes optimal use of the 
current set of available experimentally-derived CCP module structures. The database 
of models was subsequently used in a multiple surface comparison of 28 CCP 
modules from complement receptor-type 1 (CR1, CD35) (Klickstein et al. 1987). 
Functionally critical surface residues are likely to be under different evolutionary 
pressures compared to non-critical residues. Despite highly conserved sequences, the 
two functional sites in CR1 display radically different surface features. This 
observation is entirely consistent with previous studies of CR1 that show distinct 
functional profiles for the two sites (Krych et al. 1991; Krych et al. 1994; Krych et al. 
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1998). Further analysis demonstrated that in this example, surface comparison readily 
highlighted functionally important sites. 
W. 
3.2 Introduction to comparative modelling 
Of all protein structure prediction methods, i.e. comparative modelling, fold 
recognition/threading and ab-initio modelling - comparative or homology-based 
modelling results in the most accurate models of protein structures (Sanchez and Sali 
1998; Peitsch 2002). It is based on the principle that if a protein sequence shows 
significant sequence similarity to another protein of known three-dimensional 
structure due to homology, then an approximate 3D model of that protein can be 
obtained. 
The steps involved in comparative protein structure modelling (Figure 3.2) are 
Build model for target 
using information from template structures 
(Modeller I SwissModel) 
described in brief, and include: 
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Figure 3.2: Flowchart depicting the various steps involved in comparative modelling. 
STi 
Identification of known structures (templates) related to the target 
sequence 
Alignment of the templates with the target sequence 
Building of a model based on the alignment 
Evaluation of the model 
3.2.1 Template search and selection 
A similarity search such as BLAST (Altschul et al. 1990) or FASTA (Pearson and 
Lipman 1988) is carried out against the Protein Data Bank (PDB) (Berman et al. 
2000) to find a homologue of the query sequence (target) with at least one 
experimental structure (template). If more than one (different) homologous structure 
exists, it is not necessary to select only one template for modelling. In fact, the use of 
several templates approximately equidistant from the target sequence generally 
increases model accuracy (Srinivasan and Blundell 1993; Sanchez and Sall 1997). 
However, if more than one crystal structure exists for the same protein sequence; the 
highest resolution structure should be selected as template. Often a large family of 
proteins that includes target and templates can be organised into sub-families. In 
these cases construction of a multiple sequence alignment, the use of a clustering 
procedure, or creation of a phylogenetic tree can help in selecting the template from 
the sub-family that is closest to the target sequence (Corpet 1988; Relief 2000). 
3.2.2 Target-template alignment 
This is an important step in comparative modelling. Once the most suitable template 
is selected following the template search, maximal effort to obtain the most accurate 
alignment possible is needed because no comparative modelling method can recover 
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from an incorrect alignment (Marti-Renom et al. 2002). Various pair-wise alignment 
algorithms are used to calculate a similarity score on the basis of which to infer 
sequence homology between two sequences (e.g. target and template sequence). 
Examples include BLAST (based upon the Smith-Waterman algorithm) (Altschul et 
al. 1990), which searches for both full and partial sequence matches, i.e. local and 
global similarity; and FASTA (based upon the Needleman-Wunsch algorithm) 
(Pearson and Lipman 1988), which calculates a global similarity score between two 
sequences in the library. For aligning three or more sequences (multiple sequence 
alignments), ClustalW (Thompson et al. 1994) or ClustalX (Thompson et al. 1997) 
are the most widely used programs (Wallace et al. 2005). They are based on a 
heuristic referred to as 'progressive alignment' (Feng and Doolittle 1987). 
Progressive alignment allows large alignments of distantly related sequences to be 
constructed quickly and simply. It is based on building up a full alignment 
progressively, using branching order of a quick approximate tree (called the guide 
tree) to guide the alignments. This principle is also used as an optimiser for other 
programs, such as T-Coffee (Notredame et al. 2000) and ProbCons (Do et al. 2005), 
which are more accurate (Wallace et al. 2005) and gaining popularity. 
All of these programs attempt to align sequences according to their 
evolutionary relatedness. For closely related protein sequences with sequence identity 
higher than 40%, the alignment is almost always correct. Regions of low local 
sequence similarity become common when the overall sequence identity is below 
40% (Saqi et al. 1998). The alignment becomes difficult in the "twilight zone" of 
between 20-30% sequence identity (Rost 1999). As the sequence similarity 
decreases, alignments contain an increasingly large number of gaps, and alignment 
errors occur more frequently, especially when prepared automatically. In such cases, 
101 
careful manual editing of the alignment (i.e. human intervention) is required, to 
incorporate sequence-specific details such as local secondary and tertiary structure 
information, to place gaps more appropriately, and render the alignment more 
accurate. 
3.2.3 Model building 
Given an optimal target-template alignment, a variety of methods can be used to 
create a 3D model of a protein. The original and still widely used method is 
modelling by rigid-body assembly (Blundell et al. 1987; Greer 1990; Schwede et al. 
2003), which assembles a model from a small number of rigid bodies obtained from 
aligned protein template structure. The assembly involves fitting the rigid bodies onto 
the framework (i.e. the core of the aligned regions) and rebuilding the non-conserved 
parts, i.e. loops and side-chains. Another method, modelling by segment matching, 
relies on the approximate positions of conserved atoms in templates (Claessens et al. 
1989; Levitt 1992). It uses a subset of atomic positions, derived from the alignment 
as a guide to find matching segments in a representative database of all known protein 
structures. The database contains short segments of protein structures that are 
selected using energy or geometry rules, or a combination of these criteria. A third 
method involves modelling by satisfaction of spatial restraints (spatial restraints 
involve distances, angles, dihedral angles, and pairs of dihedral angles defined by 
atoms or pseudo atoms) obtained from the template, and its application to the target 
sequence in the alignment (Sall and Blundell 1993; Aszodi and Taylor 1996; Kolinski 
et al. 2001). Spatial restraints are derived from the alignment, and the model is 
obtained by minimising the violations to these restraints. Accuracies of the various 
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model building methods are comparable when used optimally (Marti-Renom et al. 
2002). 
Several programs and servers based on the above methods exist for model 
building (Wallner and Elofsson 2005). 	For example, SWISS-MODEL 
(http://swissmodel.expasy.org//SWISS-MODEL.html) (Guex and Peitsch 1997; 
Schwede et al. 2003) is a fully automated web server where a user can choose from 
two modelling modes: (1) A First Approach mode, where the user simply inputs a 
sequence and the server performs all the necessary steps automatically and returns a 
model via email; and (2) An Optimise mode, where the user can edit alignments under 
the Swiss-PdbViewer (Guex and Peitsch 1997) interface before sending out a 
modelling request to the server. Other modelling programs include Composer 
(Sutcliffe et al. 1987a; Sutcliffe et al. 1987b) available as part of the SYBYL (Tripos 
Associates, St. Louis, MO, USA) modelling environment; and Homology (Greer 
1990) under the Insight II (Accelrys Inc., San Diego, CA, USA) modelling 
environment. Another widely used program called Modeller (Sali and Blundell 1993) 
constructs comparative models given a target-template alignment by satisfaction of 
spatial restraints. It is available as a stand-alone command line program, although a 
graphical interface to it does exist as part of the QUANTA (Accelrys Inc., San Diego, 
CA, USA) suite of programs. 
3.2.4 Model evaluation 
It is essential for assessing the value of 3D protein models to estimate their overall 
accuracy. In general, mistakes in comparative modelling include side-chain packing 
errors, distortions and rigid body shifts in correctly aligned regions, errors in inserted 
regions (loops), incorrect alignments, and inappropriate templates (Marti-Renom et al. 
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2000). Another form of inaccuracy could result from the deviation from ideal 
stereochemical values for bond lengths and angles. The sources of these problems are 
primarily based on alignment errors, and excessive molecular dynamics attempting to 
remedy these errors. Such inaccuracies can easily be detected with programs such as 
Procheck (Laskowski et al. 1993) and WHATCHECK (Hooft et al. 1996), which, like 
Procheck, runs a series of tests to evaluate model stereochemistry that detect 
deviations from normal bond lengths, dihedrals, etc. 
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Figure 3.3: Example Ramachandran plot. The phi-psi torsion angles for all residues in the structure 
(except those at the chain termini) are shown as square dots. Glycine residues are separately identified 
by triangles as these are not restricted to the regions of the plot that are applicable to the other sidechain 
types. The colouring/shading on the plot represents the different regions described in (Morris et al. 
1992): the darkest areas (here shown in red) correspond to the "core" regions representing the "most 
favoured" combinations of phi-psi values; the darker yellow region correspond to the "additionally 
allowed regions", while the lighter yellow region correspond to the "generously allowed regions". The 
disallowed regions lie outside these regions (white). Symbols within the plot as described in Morris et 
al. 1992: A - Core a; a - Allowed a; —a - Generous a; B - Core f3; b - Allowed I; —b - Generous I; L - 
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Core left-handed a; I - Allowed left-handed a; -1 - Generous left-handed a; p - Allowed e; -p - 
Generous E. 
A Rarnachandran plot produced as part of a PROCHECK evaluation depicts 
the phi-psi torsion angles (in a polypeptide, the main chain N-Ca and Ca-C bonds are 
relatively free to rotate; these rotations are represented by the torsion angles phi and 
psi, respectively) for all residues in a structure (except those at the chain termini) 
(Figure 3.3), and thus detects inaccuracies that could arise from the deviation from 
ideal stereochemical values of bond lengths and bond angles. The different regions, 
i.e. most favoured, additional allowed, generously allowed and disallowed regions on 
the Ramachandran plot are described in Morris et al. (Morris et al. 1992). Ideally, one 
would hope to find greater than 90% of the residues for a particular model within the 
"most favoured or core regions" of the plot, and it serves as one of the better guides to 
the stereochemical quality of a protein structure (Laskowski et al. 1993). 
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3.3 Materials and Methods 
3.3.1 Sequence-based clustering of CCP modules 
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Figure 3.4: Cluster assignment of CCP modules. Cartoon displaying the molecular architectures of 
a representative set of human CCP-module containing proteins derived from the database SMART 
(http://smart.embl-heidelberg.de/). The 243 putative CCP-modules are depicted by yellow (blue when 
the module is of known structure, orange when it is known to be a CCP-module, but not detected by 
SMART) oval symbols. The letters within the CCP-module symbols denote the cluster to which the 
sequence was assigned. The colour of the text indicates the level of confidence in the assignment, 
decreasing from black (initial core assignment) to red (strong) to green (weak), as described in the 
"Materials and Methods" section. Refer to key for explanation of symbols. Ambiguously assigned 
modules are marked by red asterisks (A/E: CSMD1-4 and CSMD1-10; A/F: Factor B-3 and C2-3; 
B/D: Factor H--3; B/F: l32GPI-4). Abbreviations used in the figure: Sim. = similar; EGF = epidermal 
growth factor; CUB = first found in Cir, Cis, uEGF and bone morphogenic protein; LDL = low 
density lipoprotein; MAC = membrane attack complex; PAPP A = pregnancy-associated plasma 
protein-A; SEZ-6 like = Seizure 6-like; 32GP1 = 3-2-glycoprotein I (also called Apolipoprotein H or 
ApoH); CSMD1 = CUB and sushi domain-containing protein 1; IL2Ra = Interleukin-2 receptor a 
chain; ILI5R = Interleukin-15 receptor a chain; GABA-BRIa = Gamma-aminobutyric acid type B 
receptor subunit 1 a. All other abbreviations explained in text. 
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Previous work (Kirkitadze and Barlow 2001) revealed that the residue before the first 
cysteine and two or three residues after the fourth and last cysteine of the consensus 
sequence commonly contribute to the 3D structure of a CCP module. Consequently, 
in the current study, one residue prior to the first consensus cysteine and three 
residues following the fourth consensus cysteine were included in the sequence 
selected to represent each CCP module. 
Using this approach, sequences representing 243 CCP modules from 48 
proteins [47 human proteins plus one from vaccinia virus (VCP)] were extracted from 
the SMART database (http://smart.ernbl-heidelberg.de/) (Schultz et al. 1998; Letunic 
et al. 2004). The vaccinia virus protein, VCP, with four CCP modules, was included 
along with the human sequences in this process because its structure has been 
experimentally determined (Wiles et al. 1997; Henderson et al. 2001; Murthy et al. 
2001; Ganesh et al. 2004). It therefore provides valuable additional templates for 
modelling purposes. As a route to optimal template selection, the sequences were 
then classified by means of a clustering procedure. Initial cluster assignments were 
produced according to the "unweighted paired-group method with arithmetic mean" 
(UPGMA) using a program that implements Corpet's MULTALIN algorithm (Corpet 
1988), concomitantly with rounds of multiple sequence alignment and subsequent 
manual removal of individual sequences that impeded convergence. Nine stable 
groups or clusters, (labelled A through I) were identified in this manner. 
A hidden Markov model (HMM) was then built for each of these nine clusters 
using the software package HMMer version 2.0 (http://hmmer.wustl.edu/). HMMs 
are sensitive at detecting remote relationships among sequences and are hence widely 
used [see (Durbin 1998) for information on HMM-methodology]. All sequences 
(including the initial set) were scanned with the HMMs, and module sequences were 
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assigned to clusters using cut-off expectancy values (E-values) of 1010  for strong, and 
10 for weak assignments. Sequences that failed to be matched to an HMM were 
labelled as unassigned. Weak HMM-assignments were further investigated by 
pairwise similarity comparisons of the respective module sequences with the stably 
assigned set using MPSrch (Collins and Coulson 1990). They were accepted only if 
corroborated by predominance of the HMM-assignment in the MPSrch list of the five 
most similar module sequences. If sequences were matched to more than one HMM 
with E-value < 10, then they were either: labelled as ambiguous if the E-value of 
the second match was within one order of magnitude; or assigned to the cluster with 
the higher score. Of 243 module sequences, 169 were strongly assigned by HMM, 30 
were weakly assigned and six were ambiguously assigned, while 38 could not be 
assigned to a cluster at all (Figure 3.4). 
Each cluster was subsequently aligned separately using ClustalX version 1.81 
(Thompson et al. 1997). The automated alignments were edited manually placing 
strong emphasis on conserving the "Cys-Cys-Cys-Trp-Cys" signature pattern 
(Kirkitadze and Barlow 2001) and positioning alignment gaps plausibly considering 
the experimentally solved 3D structures within the cluster. 
3.3.2 Selecting the most suitable program for CCP module modelling 
A test comparison of the various model building programs mentioned earlier resulted 
in Modeller (Sall and Blundell 1993) being selected as the most appropriate for 
automated large-scale modelling of complement control protein modules. Modeller is 
freely available to academic users at: http://salilab.org/modeller/. It is fully command 
line driven and hence provides more flexibility than both, Composer (Sutcliffe et al. 
1987a; Sutcliffe et al. 1987b) under the SYBYL environment (Tripos Associates, St. 
W. 
Louis, MO, USA), and Homology under the Insight II modelling environment 
(Accelrys Inc., San Diego, CA, USA), which require visualisation graphical 
interfaces. A web-server such as SWISS-MODEL (Guex and Peitsch 1997; Schwede 
et al. 2003) is unsuitable for handling a large volume of requests since this could 
overload the server. Another major advantage of Modeller was that it allows for 
direct submission of target-template alignments for model building. Finally, it is ideal 
for CCP modelling because it automatically restrains disulfide bridges during model 
construction. 
Model building using Modeller was performed by extracting distance and 
dihedral angle restraints on the target sequence from its alignment with the target 
structure. These template-derived restraints were combined with most of the 
CHARMM energy terms (Brooks et al. 1983) to obtain a full objective function. 
Finally, this function was optimised by conjugate gradients and molecular dynamics 
with simulated annealing to construct a model that satisfies all the spatial restraints as 
well as possible. Ten models were thus derived for each target sequence. The 
representative model for each sequence was that which had the lowest value of the 
objective function score. 
3.3.3 Automated comparative modelling of each cluster 
A sequence of programs to carry out the step-wise modelling task as described below 
were called from a PERL script as summarised in Figure 3.5. Eighty-three sequences 
out of the original set of 243 were not modelled because either they were not assigned 
to a cluster, or they belong to clusters D, E, I for which no templates are yet available. 
A detailed work-flow of the automation is provided below. 
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Figure 3.5: Work flow of automated method for each cluster. Flow-chart summarising the tasks 
implemented by a PERL script, which automatically calls the appropriate programs when presented 
with a multiple sequence alignment for a given cluster. 
3.3.3.1 Identifying modelling templates within each cluster alignment 
All sequence names were substituted by their unique Accession Numbers to ease the 
programming task. The control PERL script first employs an option within ClustaiW 
version 1.83 (Thompson et al. 1994) to convert an entire cluster multiple sequence 
alignment from FASTA to PIR format, as required for Modeller version 6v2 (Sall and 
Blundell 1993). All target sequences are indicated by keyword "sequence" and 
template structures are flagged by keyword "structure" (Figure 3.6). 
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>P1; P02749 04 F+ 
structure: P02749 04 F+ ................ 
KCPFPSRPDNGFVNYPAKPTLYYKDKATFGCHDGYSLDGPEE IECTKLGNWSA-MPSCKAS * 
>P1; P17927 04 F 
sequence:P17927 04  
KCTPP-NVENGI LVSDNRSLFSLNEVVEFRCQPGFVMKGPRRVKCQALNKWEPELPSCSRV* 
>P1; P17927_i iF 
sequence:P17927 11 F:.:.:. ....... 
KCTPP-NVENGI LVS DNRSLFSLNEVVEFRCQPGFVMKGPRRVKCQALNKWEPELPSCSRV* 
>P1;P17927 18_F 
sequence:P17927 18 F ............... 
KCTPP-NVENGI LVSDNRSLFSLNEVVEFRCQPGFVMKGPRRVKCQALNKWEPELPSCSRV* 
>P1; P179272 5_F 
sequence:P17927 25 F:.:.:. .......... 
KCTAP-EVENAIRVPGNRSFFSLTEI IRFRCQPGFVMVGSHTVQCQTNGRWGPKLPHCSRV* 
Figure 3.6: Example of a section of cluster F alignment in Modeller-PIR file format. For each 
sequence in a cluster alignment file, the first line is composed of a unique code containing the 
SwissProt/TrEMBL (Boeckrnann et al. 2003) accession number followed by the module number and 
then the cluster, in the format sequence ">P1;code" (e.g. >P;P17927_25F). The second line with ten 
fields separated by colons generally contains information about the sequence or structure file. Only the 
first two fields are mandatory indicating whether the file contains a "sequence" or "structure" and 
providing Modeller with their unique codes. The remaining fields are left blank indicated by a series of 
".". The third line contains the respective sequence, with "*" marking its end. All gaps in the 
alignment are depicted by "-" 
3.3.3.2 Extracting target-template alignment 
For each Modeller-PIR format cluster alignment, each sequence is considered 
individually, and the cluster screened for sequences corresponding to modules of 
known structures, to serve as templates for modelling. If no template is found, no 
model is created. On the other hand, if one or more template sequences do exist 
(flagged by keyword "structure"), the script extracts the target sequence along with 
the template sequence(s) directly from the alignment (Figure 3.7). 
P17927 25 F. au 




>P1; P17927 25 F 
sequence:P1792725F 
KCTAP-EVENAIRVPGNRSFFSLTEI IRFRCQPGFVMVGSHTVQCQTNGRWGPKLPHCSRV* 
Figure 3.7: Example intermediary output for each sequence extracted depicting a typical target-
template alignment. The example above displays the alignment for the target sequence P1 7927_25_F 
with its template structure P0274904F+, saved in a unique file name P17927_25_F.ali 
3.3.3.3 Preparing input files for Modeller, model building and 
evaluation 
The script then prepares a standard input format file called a 'top' file for input to 
Modeller (Figure 3.8). Once a target-template alignment is provided, Modeller 
calculates a 3D model of the target automatically. The "P17927_25_F.top" routine 
below generates ten models of target sequence "P17927_25_F" based on the 
"P02749_04_F+" template structure and the alignment in the file "P17927_25_F.ali". 
P17927 25 F.top 
# Homology modelling by the Modeller6v2 TOP routine 'model' 
INCLUDE 	 # Include the predefined TOP routines 
SET OUTPUT CONTROL 	1 1 1 1 1 	# uncomment to produce a large log file 
SET ALNFILE = 'P17927 25 F.ali' # Alignment file 
SET KNOWNS = 'P02749 04 F+' 	 # Template structure 
SET SEQUENCE = 'P17927 25 F' # Target sequence 
SET ATOM—FILES—DIRECTORY = '/CCP- structures/ ' # Template P03 file location 
SET STARTING MODEL = 1 	 # index of the first model 
SET ENDING—MODEL = 10 # index of the last model (create 10 
models) 
CALL ROUTINE = 'model' 	 # build homology model 
Figure 3.8: Example of a Modeller TOP routine (P17927_25_F.top). The first line includes 
Modeller variable and routine definitions. The following lines set parameter values for the "model" 
routine. ALNFILE names the file that contains the target-template alignment in Modeller-PIR format. 
KNOWNS define the known template structure(s) in the alignment file. SEQUENCE defines the name 
of the target sequence in ALNFILE. STARTING—MODEL and ENDING—MODEL define the number 
of models that are calculated (their indices run from 1 to 10). The last line in the file calls the "model" 
ROUTINE that actually calculates the model. (# - Prefixed comments explaining each step follow the 
commands). 
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Once the ten models for each sequence were generated, the model with the 
lowest value of the Modeller "objective function" (which is reported in the second line 
of the PDB file) is selected. The general form of the objective function and the 
structure of optimisation are similar to molecular dynamics programs, such as 
CHARMM (Brooks et al. 1983; Sali and Blundell 1993). 
The model with the lowest value of the Modeller "objective function" is then 
subjected to stereochemical evaluation using the program Procheck version 3.5.4 
(Laskowski et al. 1993). For the RCA CCP-modules, out of the 63 modelled 
structures, 61 had more than 90% of residues in combined 'core" and "allowed" 
regions of the Ramachandran plot, and the other two had more than 85% of residues 
in these regions. 
It should be noted that the PERL script has been implemented to prompt the 
user to select between the option of directly modelling all sequences in a given cluster 
alignment, or to model protein sequences individually based on their unique accession 
number. 
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3.3.4 Surface electrostatic analysis 
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Figure 3.9: Scheme for comparing electrostatics of CR1. (a) CR1 superposition obtained using 
Multiprot (Shatsky et al. 2002; 2004) shown as dashed Ca trace. (b) The dissimilarity matrix produced 
by PIPSA is submitted to NMRC1ust for clustering, or alternatively can be viewed using program Mage 
(Richardson and Richardson 1992), to see each protein in 3D-electrostatic surface space. 
The CCP modules of CR1 were selected to illustrate the utility of a surface-
comparison approach because they have been the subject of extensive functional and 
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mutagenesis studies in the past (Krych et al. 1991; Krych et al. 1994; Krych et al. 
1998; Krych-Goldberg et al. 1999). The set of experimentally determined and 
modelled 3D structures representing the N-terminal 28 CR1 CCP modules (out of 30 
in total) was pulled from the database, and subjected to a comparative analysis of 
electrostatic properties using a combination of the programs; PIPSA version 1.0 
(Blomberg et al. 1999), NMRC1ust version 1.2 (Kelley et al. 1996) and GRASP 
(Nicholls et al. 1991). 
A structural alignment was obtained using Multiprot (Shatsky et al. 2002; 
2004) to ensure that all module orientations are preserved such that surfaces at 
equivalent locations could be compared (Figure 3.9a). The aligned structures were 
then analysed using PIPSA, to find similarities within this set of CCP modules based 
on their surface electrostatic properties. PIPSA computes the molecular potentials of 
the model surfaces analytically as a multipole expansion that permits comparison of 
large datasets (Blomberg et al. 1999). The modules were then clustered by submitting 
the dissimilarity matrix generated by PIPSA to NMRClust. Surface electrostatic 
property-based cluster diagrams were derived manually by successive joining of 
closest neighbours based on similarity threshold values provided to NMRCIust 
(Figure 3.9b). To help assess the validity of the clusters derived in this way, 
electrostatic surface images were also generated by GRASP, and inspected and 
grouped manually. 
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3.4 Results and Discussion 
3.4.1 Clustering helps to optimise the choice of templates for modelling 
A reliable procedure for cluster assignment enhances the value of the large-scale 
modelling procedure used in this study because it ensures that the most appropriate set 
of templates will be employed in each case. Using an implementation of the 
hierarchical cluster assignment method of Corpet (Corpet 1988), which was extended 
through subsequent sequence comparisons using hidden Markov models and 
exhaustive similarity comparisons, a total of 205 out of the original set of 243 CCP 
module sequences were each assigned to one of nine clusters (labelled A through 1). 
Standard phylogenetic methods have drawbacks when applied to this family as 
alternative approaches to clustering. This is often observed with shorter protein 
sequences (Rokas et al. 2003). The main problem is that estimates of evolutionary 
distances are at lower levels of precision than with longer sequences. This "low 
signal-to-noise ratio problem" is addressed more satisfactorily by a protocol such as 
the one we applied here to produce the initial set of clusters, since only stable 
assignments are reported. The additional HMM-based assignments (shown in Figure 
3.4) are more tentative, but all of them are corroborated independently by sequence 
comparisons. 
The clusters to which the modules of the RCA proteins are assigned are shown 
in Figure 3.4. In such a representation, the four heptad or "long homologous repeats" 
(LHRs) - HCAFACA - that comprise the N-terminal 28 modules of CR1 are readily 
apparent. The LHRs of CR1 were recognised previously (Klickstein et al. 1987; 
Hourcade et al. 1988; Klickstein et al. 1988) and are thought to have an evolutionary 
origin involving exon duplication and shuffling (Hourcade et al. 1990). The triad 
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CAF additionally appears twice in CR2 and once each in C4BP and MCP for a total of 
eight occurrences. Also apparent in Figure 3.4 are imperfect tetrad repeats in CR2: 
from the N-terminus - AFAC, AFAX, AF'I"C, and AFAF [X = unassigned, '1' is the 
site of an inserted module in the 16-module splice variants (Moore et al. 1987; Barel 
et al. 1998), which in independent sequence comparisons using MPSrch, displays 
strong similarity with other A-cluster members]. With the exception of factor H and 
factor H related proteins, CCP modules from just a few clusters - A, F, C and H - 
account for all but one of the assigned modules of the RCA family (MCP has a G-
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Figure 3.10: Comparison of assignment of the CCP modules of complement proteins into clusters 
or groups. The symbols used for module-types are the same as in figure 3.4 for a set of human 
complement proteins. The modules for which experimentally solved 3D structures are available are 
shaded more strongly (see key). The number above each module indicates assignment to sub-groups of 
CCPs according to a phylogenetic study by Krushkal et al. (Krushkal et al. 2000) (as in the chapter 2) 
and Soares et al. (Scares et al. 2005) clusters are indicated by letters within the CCP symbols. Those 
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modules that could not be classified by these methods are indicated by a "U" (Krushkal et al.) or by an 
absence of a letter (Soares et al.). 
Interestingly, the majority of N-terminal CCP modules from amongst the RCA 
proteins either remained unassigned (fH, VCP and C413PJ3), or were only weakly 
assigned (MCP and C4BPct) to a cluster. This might imply varying rates of evolution 
and, intriguingly coincides with a requirement of these modules for functional 
viability of the respective proteins. Moreover, in the first, second and third LHRs of 
CR1, and in DAF, C4BPct and MCP, a triad of modules comprise a binding site for 
components within the convertase enzymes of complement, and facilitates the 
dissociation or destruction of these proteolytic complexes (Medof et al. 1982; Krych 
et al. 1991; Brodbeck et al. 1996; Hardig et al. 1997; Liszewski et al. 2000; Blom et 
al. 2001a; Kuttner-Kondo et al. 2001). The cluster assignments for these functional 
units all seem to follow a motif XCA (where X = A, G, H or unassigned). 
The unit XCA is not, however, seen in fl-I even though this protein regulates 
the convertases in a similar way to the other RCAs, and its N-terminal three CCP 
modules are critical for this function (Jokiranta et al. 2000). Factor H contains six 
modules not assigned to clusters, consecutive runs of six B-cluster members and three 
modules of cluster I. Members of these clusters are unique to fl-I and the ff1-related 
proteins amongst the RCA proteins, but blood-clotting factor XIIIb also contains B-
and 1-cluster members. These proteins are closely linked and located within 650 kb-
2.2 Mb in chromosome 1 (Rey-Campos et al. 1990; Skerka et al. 1995). This 
observation of a clear distinction between fH and the other RCAs is consistent with 
one made by Krushkal et al. who constructed a phylogenetic tree for 132 individual 
module sequences of the RCA gene cluster (Figure 3.10). Factor H is thought to have 
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diverged from CR1, CR2, MCP and DAF at an early point in evolutionary history 
(Krushkal et al. 2000) (Chapter 2). 
3.4.2 Modelling 
Three-dimensional (3D) structure modelling was accomplished for 135 individual 
human CCP module sequences, in each case based on the most similar homologues or 
set of homologues for which experimentally determined structures were available. At 
the start of this procedure (outlined schematically in Figure 3.5), each of the nine 
sequence clusters was aligned separately. The multiple alignments were subsequently 
used to guide the automated modelling of individual CCP modules of unknown 
structure using the program Modeller (Sali and Blundell 1993). When the large-scale 
modelling process was first run, a total of 16 experimentally solved 3D CCP module 
structures were available as templates. The experimentally determined 3D structures 
of the four DAF CCP modules were unavailable at the time, and therefore not 
included. Subsequently, these served as a very useful means of validating the 
structural models (see Section 3.4.3). A further five experimentally determined 
module structures - ff1-5, 32GPI-1, 132GPI-3, C1s-2 and VCP-4 - were not assigned 
to any of the nine clusters and therefore not used as templates. 
The total of 135 modelled structures resulting from the first run included those 
of 63 RCA CCP modules (27 from CR1, nine from factor H, four from DAF, two 
from MCP, nine from C4BPa and l, 12 from CR2). All models are available at the 
CCP-module model database http://www.bru.ed.ac.uk/-dinesh/ccp-db.html (snapshot 
shown below, Figure 3.11). This database is updated as necessary, to reflect the 
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growing number of available CCP module sequences, and as more template structures 
are deposited. 
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Figure 3.11: Snapshot of the CCP-module model database website. The database is accessible at 
http://www.bru.ed.ac.uk/.-dineshlccp-db.html. Models are downloadable (in PDB format) at the click 
of a mouse-button. The website also serves as a comprehensive CCP module information resource. 
Since its inception, the website has received a total of 4,291hits, including 2,460 unique hits (different 
IP-addresses) worldwide. 	The website statistics are provided by the CQ-counter 
(http://www.cqcounter.coml) as of May, 2006. 
Fifty sequences, assigned to clusters D, E and I, were not modelled since no template 
structures were available at the time. While models for these modules could be 
obtained by modelling based on sequence similarity with the closest template 
identified using programs such as BLAST (Altschul et al. 1997) or MPSrch, they 
would be expected to be less reliable. It was decided to refrain from such attempts in 
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this automated exercise because I-cluster sequences are noticeably different, for 
example, compared with B- and A-cluster sequences (Figure 3.12), which are hard to 
distinguish by visual inspection, in that they appear to lack the conserved or 
conservatively replaced hydrophobic residues in predicted f3-strands 2 and 3 (Figure 
3.12). Similarly, cluster E members are characterised by short hypervariable loops 
and a lack of insertions between J3-strands 5 and 6, or 7 and 8- using the Wiles et al., 
convention for numbering the strands (Wiles et al. 1997) and D-cluster members have 
an extra pair of cysteines, allowing an additional putative disulfide bond [modelled in 
(Norman et al. 1991; Weyer et al. 2004), and in Chapter 4]. 
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Figure 3.12: Signature topology diagram of clusters. The topology schematic depicts extent of 
consensus secondary structure and conserved or conservatively replaced residues for each cluster 
alignment (A through to I). Full cluster alignments are provided in Appendix. 3-strands are depicted 
by arrows, and other consensus residues out-with the strands shown within cylinder representations on 
the basis of the structure of factor H module 5. Consensus residues are labelled by their single-letter 
amino acid codes, and h = hydrophobic residue. Disulfide bonds are indicated by dotted lines between 
cysteine residues. The lengths of loops are indicated numerically. 
The models generated in the current work may be compared with those 
reported previously from the other RCAs - namely, C4BPa (Villoutreix et al. 1998), 
MCP (Liszewski et al. 2000), and fH (Aslam and Perkins 2001; Perkins and Goodship 
2002) - for which no experimental structures were available at the time. In the case of 
C4BPa, the r.m.s.d. values over Ca atoms range from 2.6 A (C4BPa-5) to 3.2 A 
(C4BPa'=4); for MCP-3 and MCP-4 the values are 2.2 A and 2.7 A, respectively; for 
fl-I they range from 1.6 A (fH12) to 3.4 A (fH2). The new models are thus 
significantly different from previously published models. But how do they compare 
to experimentally determined structures? 
3.4.3 Validation of models against known structures - Part I 
The coordinates for the experimentally determined structures (Uhrinova et al. 2003; 
Williams et al. 2003; Lukacik et al. 2004) of the DAF CCP modules became available 
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after the first run of the modelling procedure described above had been completed. 
This allowed a comparison of modelled and experimental structures. A high level of 
structural similarity - r.m.s.d.s (Ca) of 1.7 A, 2 A, 1.2 A and 1.9 A for DAF modules 
1 to 4, respectively - was observed, supporting the modelling strategy used in this 
work (Figure 3.13a). Previously reported models of DAF, built when only fll-15 and 
fl-I--i 6 were available as templates (Kuttner-Kondo et al. 1996), exhibit a lower level 
of similarity with the crystal structure - r.m.s.d.s (C) of 2.1 A, 2.6 A, 3.3 A and 2.5 
A for DAF modules 1 to 4, respectively. Models of DAF-2 and DAF-3 that were 
built (Kuttner-Kondo et al. 2001) after MCP-1 and MCP-2 also became available as 
templates, display r.m.s.d.s (Ca) of 2 A and 1.6 A compared to the equivalent 
modules of the crystal structure, i.e. were no more accurate than those obtained using 
the automated cluster-based modelling procedure described here. These data suggest 
that the current set of modelled structures are generally likely to be in the same range 
of accuracy, or more accurate, than previous ones (also see Section 3.5.1.2). In 
addition, the advantages of an automated modelling procedure for straightforward 
updating of the database are evident. The utility of the database has already been put 
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DAF-3: r.m.s.d. 1.2A 	DAF-4: r.m.s.d. 1.9A 	 .) 
DAF-3 structure 	DAF-3 model 
Figure 3.13: DAF-1,2,3,4 test comparison. (a): Ribbon trace of the modelled module structures of 
DAF-1-4 (blue) created by the automated modelling procedure, compared with corresponding modules 
from the highest resolved crystal structures (red) (PDB ID: 10K3 for modules 1 and 2; PDB ID: 1H03 
for modules 3 and 4). R.m.s.d. values (Ca atoms) are indicated in each case. (b): Comparison of the 
modelled (on the right) versus the experimental structure of DAF-3 showing (i) electrostatic surfaces 
(negative charge coloured red, positive charge coloured blue, ranging from -5 kT to +5 kT) generated 
with GRASP (Nicholls et al. 1991) and (ii) lipophilic surfaces (ranging from hydrophilic coloured blue, 
to lipophilic or hydrophobic coloured brown) generated using MOLCAD (Heiden et al. 1993). 
The feasibility of using the new models in surface comparisons was examined 
by a comparison of electrostatic and lipophilic surfaces of modelled versus empirical 
CCP module structures. The two structures of DAF3, for example, share very 
similar surface properties (Figure 3.13b). [The DAF3 model was built using three 
templates - VCP--2 (Murthy et al. 2001), CRl-46 (Smith et al. 2002) and MCP-2 
(Casasnovas et al. 1999) - with pairwise sequence identity percentages of 45%, 38% 
and 34%, respectively.] The surface representation of our model is also visibly in 
better agreement with the experimentally determined structure than a previously 
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published model of DAF--3 that was based on a template from a different cluster 
(Kuttner-Kondo et al. 1996). Thus this example illustrates that careful template-
choice could benefit subsequent application of the models involving surface-
comparison. While one cannot be certain that all models generated by this procedure 
will be as accurate as this verifiable example, the strategy to select the best template, 
and to update the CCP model database when new templates become available, aims to 
ensure that the best possible surface representation is available to the user at any given 
time. 
3.4.4 Surface electrostatic analysis of CR1 
The program PIPSA (Blomberg et al. 1999) was employed to compare electrostatic 
properties of the N-terminal 28 CR1 modules (25 modelled structures plus three 
experimentally determined ones). The PIPSA-generated cluster diagram (Figure 
3.14) was compared to the manually grouped GRASP-generated electrostatic surface-
images of the CR1 modules. Reassuringly, most module associations made by PIPSA 
showed good agreement with the groups of GRASP images. This implies that PIPSA 
could, in future work, be applied to a larger set of CCP modules and used to compare 
module surfaces between proteins. 
The majority of relationships in the PIPSA-generated cluster diagram based on 
electrostatic surfaces (Figure 3.14) match up both with a sequence-based tree (Figure 
3.15), and the cluster-assignments (Figure 3.4); e.g. CCP modules 4, 11, 18 and 25 
(all in cluster F) are in the same surface-cluster. However, PIPSA also suggested 
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Figure 3.14: Electrostatic surface clustering of CR1 modules 1-28. Surface cluster-diagram 
depicting electrostatic similarities amongst the N-terminal 28 modules of CR1 according to PIPSA and 
NMRCIust. Labels are coloured according to sequence cluster. GRASP-derived images of 
electrostatic surfaces for selected modules are also shown (box) to validate the clustering. In each case, 






Figure 3.15: Sequence-based CR1 phylogenetic tree. The tree confirms the validity of the 
clustering, by placing all cluster members in their respective groups/clusters (A, C, F, M. 
3.4.5 Surface comparisons can identify modules important for function 
According to the sequence-based clustering, CR1-2 is most similar to CR19, 
CRl16 and CR1-23; with all four modules belonging to cluster C. For example, 
CR12 has approximately 67% pairwise sequence identity with both CR19 and 
CR1-16 (Figure 3.16a). In the cluster diagram based on electrostatic surface-
properties, however, CR1--'2 is instead grouped with CR1-3, CRl10 and CRl17, 
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which were all assigned to sequence cluster A (Figure 3.14). Note that no significant 
sequence similarity was found through a pairwise BLAST comparison of CR1-2 and 
CRl-'3. From inspection of Figure 3.14, it is evident that the electrostatic surface of 
CR1-2 does indeed resemble more closely that of CRl--3 than it does those of CR1-9 
or CR1-16 (see below). Thus a comparison of relationships based on surfaces versus 
those based on sequences readily identified a case where two modules (CR1-2 and 
CR1-9) had clearly diverged significantly in terms of their surface properties, but not 
in overall sequence. Given the close evolutionary relatedness of these modules as 
judged by their equivalent positions within the four LHRs in CR1 (Hourcade et al. 
1990) (Figure 3.4, Figure 3.16), this observation implies that some surface-exposed 
residues have been the subject of adaptive mutation while the remainder of the 
sequence has undergone predominantly neutral variation. Therefore the modules 
affected are candidates for being functionally important ones, with their non-
conserved residues representing possible sites of interaction with binding partners. 
This notion is borne out by previously reported (Klickstein et al. 1988; Krych 
et al. 1991; Krych et al. 1994) functional studies showing that CR1-2 and CR1-9 
(and the nearly identical CR1-16) contribute to two different multimodular binding 
sites - called functional sites 1 and 2 respectively (Figure 3.16b). These sites have 
different, although related functional profiles (Klickstein et al. 1988; Krych et al. 
1991; Krych et al. 1994). Site 1 was shown to be composed of CCP modules 1-3; it 
primarily binds C4b, while C3b is only weakly bound, and is the primary locus of 
convertase decay accelerating activity in CR1. Site 2— of which there are two copies, 
one formed by CCP modules 8-10 and the other by CCP modules 15-17 - binds both 









14 	 21 	 28 
 
(b) 	CR1 OSS 	Q ioLH GGQ flJtDIXyl 
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Figure 3.16: CR1 inter-module sequence relationships. (a) This figure was extracted from Chapter 
2 (Figure 2.7). The thick lines connect modules that share more than 90% pairwise sequence identity; 
thin lines indicate 50% to 89% identity, with a label indicating the percentage identity. For clarity, not 
all lines are drawn (more than 90% identical) since the level of identity can be deduced in some cases 
(e.g. CR1.-3 and CR1.-17). Pairwise sequence identities calculated using BLAST (Altschul et al. 
1990). (b) Modular representation of CR1 showing the functional sites: Site 1, and two copies of Site 
2, and their corresponding functional profiles below. The four heptad long homologous repeats 
(LHRs) are also labelled. 
34.6 Surface comparisons pinpoint functional sites 
While CR12 and CR1-9/CR116 do not cluster together on the basis of their 
electrostatic surfaces, the differences between them lie primarily on one face - that 
presented in the right-hand frame of Figure 3.17. This face of CR1-16 is dominated 
by electropositive side-chains while the equivalent face of CR1-2 displays 
significantly less positive charge and a substantial amount of negative charge. The 
remainder of the module surfaces, on the other hand, appear similar; those charged 
residues present are conserved or conservatively replaced (R64 is conservatively 
replaced with K964, D is conserved at positions 68 and 968, and R is conserved at 
122 and 1022). Thus further inspection of a pair of modules that have diverged in 
130  
terms of surface properties, but not in sequence, immediately suggests a putative 
binding face that could be explored using mutagenesis. 
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Figure 3.17: A more detailed comparison of surface electrostatics of CR1-2 and CR1-16. Three 
views, rotated by 120° about they-axis, are shown for each module. The faces of CRl-2 and CR116 
displayed in the left-hand frame exhibit similarities to one another. In contrast, the faces displayed in 
the right-hand frame, exhibit clear differences between modules. Those amino acid residues discussed 
in the text are highlighted. 
In fact, residues lying on the divergent faces of these two modules have, in 
previous work (Krych et al. 1994; Krych et al. 1998), already been substituted for one 
another. In CR116, two such individual substitutions - N1009D and K1016E 
(Figure 3.17) - brought about, in functional site 2, the loss of iC3 binding [iC3 is a 
form of C3 that, as a result of hydrolysis of the thioester bond, has a conformation and 
reactivity similar to that of C3b (Isenman et al. 1981)] and C4b binding, as well as a 
loss of cofactor activity directed towards both these ligands. Strikingly, the reciprocal 
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mutation D109N increased C3b-binding, while mutation E116K also conferred C3b-
binding on site 1 and increased its cofactor activity with respect to C3b and C4b. 
These experimental results thus fully support the notion that the divergence in surface 
charge between these modules has occurred amongst functionally critical residues and 
has arisen through the need for the different sites to perform different functions. 
Therefore, at least in this example, the approach of multiple surface-comparisons is 
remarkable in its ability to quickly pin-point important regions. The extent to which 
such comparisons identify functional sites more generally thus warrants further 
investigation. 
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3.5 	Further discussion and validation of models in light of 
new experimentally determined CCP modules 
Ten experimentally determined CCP-structure modules (Blein et al. 2004; Harmat et 
al. 2004; Gal et al. 2005; Rickert et al. 2005; Wang et al. 2005; Herbert et al. 2006c; 
Jenkins et al. 2006; Lorenzen et al. 2006; Stauber et al. 2006) have been deposited 
into the PDB since publication of the abovementioned work (Soares et al. 2005) 
(Figure 3.18; see Chapter 2, Table 2.2 for up-to-date list). 
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Figure 3.18: Structural status of experimentally determined CCP modules. Revisited cartoon 
displaying the molecular architectures of a representative set of human CCP-module containing 
proteins derived from the database SMART (http://smart.embl-heidelberg.de/) as in Figure 3.4. Refer 
to figure 3.4 and key for explanation of symbols. All previously solved CCP modules at time of 
submission for publication (Scares et al. 2005) shown in blue. New experimentally determined CCP 
modules are underlined in bold. These include CCP modules from: Interleukin-2 receptor a chain (IL-
2Ra) - the two CCP modules; Interleukin-15 receptor a chain (IL-15R) - the N-terminal module, 
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Gamma-aminobutyric acid type B receptor, subunit I a (GABA-B-Rla) solved for rat - two forms of 
the second CCP-module in cis- and trans- conformations (it should be noted that there exists only two 
conservative substitutions between rat and human for this module); mannan-binding lectin-associated 
serine protease-2 (MASP-2) - the two CCP-modules; factor H - the C-terminal modules (19 and 20); 
and C4b-binding protein a (C4BP(x) the N-terminal two CCP-modules. 
The newly solved structures (Figure 3.18) include five modules not assigned 
to any cluster (IL-15Ra'--1, IL-2Rct--2, fH-20, MASP2-1,2), two from cluster C 
(C4BPa2 and GABABRlct-'2), and one each from clusters A (C4BPa-1), B (fl-l9) 
and H (IL2Ra-4). These new structures allow further scrutiny of the accuracy of the 
3D-models produced by the automated procedures. 	Recent experimentally 
determined module structures that do not fall into any sequence cluster will not be 






3.5.1 Model versus structure comparisons - Part II 
3.5.1.1 The novelty of experimentally determined CCP module 
structures in IL2Ra and GABAB-Ria 
Perhaps the most interesting of the new structures to be determined, is that of the pair 










Figure 3.19: Domain swapping in IL-Ma. (a) The IL-2Ra structure (Rickert et al. 2005) is 
separated into its CCP1 (blue) and CCP2 (green) modules to show the swapped A and B (CCP1), and F 
and G (CCP2) 3-strand locations, respectively. Cysteine residues (six in CCP1 and four in CCP2) are 
shown in purple as stick representations and labelled. Semitransparent ovals in two diagrams of the 
separated modules highlight the corresponding strands, which are involved in the strand swap. A 
surface representation of IL-2Ra in the centre shows the intact pair of modules. The figure is adapted 
from Rickert et al. (Rickert et al. 2005). (b) A representative structure of a CCP module [factor H 
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module 16 (Norman et al. 1991)]. The analogous strand/loop region to those involved in the strand 
swap between IL-2Rct CCP1 and CCP2 domain are highlighted by a semitransparent oval in M-1 6. 
According to the sequence clustering, module 1 of IL-2Ra belongs to cluster 
H, while module 2 is not assigned (Figure 3.18). The crystal structure of this module-
pair was recently solved (Rickert et al. 2005; Wang et at. 2005; Stauber et al. 2006). 
It revealed an unusual and unique arrangement for the module-pair, where portions of 
each module were involved in a structural "swap" with each other. Strands A and B 
of CCP1 exchange with strands F and G of CCP2, to give the folding topology strand 
F-on strands-G-C-D-E for CCP1 and strand A-on strands-B-H-I-J for CCP2 (Figure 
3.19). The intermodular disulfide bonds between Cys3 and Cys46 of CCP1, and 
Cys 147 and Cys 104 of CCP2 enforce the strand exchange by "pinning" strand A of 
CCP 1 to strand I of CCP2 and strand G of CCP2 to strand D in CCP 1 to maintain the 
CCP-module-like fold in both modules. 
This unexpected structural aberrance resulted in the model for IL-Ma--1 being 
different from other CCP-like module structures, especially for the swapped strand 
portion of the module. The sequence clustering conducted in this work did not pick 
out this unique arrangement. This begs the question - should this module, IL-Ma—1, 
have been placed in cluster-D, which are characterised by six cysteine-containing 
motif sequences (Figure 3.12)? None of the other modules in cluster-H contain six 
cysteines. Furthermore, is there a possibility that consecutive neighbouring pairs of 
modules in members of cluster-D adopt a similar arrangement to IL-2Ra? Both 
scenarios are unlikely for the following reasons. Even though the sequences of 
cluster-D members contain six cysteine residues per module, these are unlikely to 
undergo a strand swap, given that the additional pair of cysteines are present at 
different locations to the ones seen in the sequence of IL-Mot (Figure 3.20) and 
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additionally, the extra pair of cysteine residues among cluster-D members (example 
modelled in Chapter 4) are close in space within the folded CCP module - to readily 
form three stable intramodular disulfides, unlike 1L-Ma—l. 
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Figure 3.20: Alignment of cluster-D and IL-2Ra-4 sequence. ClustaiX alignment of a selection of 
cluster-D sequence members with cluster-H member, IL-Ma--1 (P01589 01 H), to bring out their 
variation in sequence. The alignment reveals that the extra pair of cysteines in IL-Ma--1 (circled) is 
located at different positions in comparison with other cluster-D members. The sixth cysteine in IL-
2Ra-1 is located in the linker region of its sequence. The disulfide pattern for cluster-D is indicated 
above. Region involved in strand swap in IL-2Ru--1 shown with a dashed line below its sequence. 
It should be pointed out that in the functionally similar IL-15Rcx, which 
contains a single CCP module, the experimentally determined CCP-module forms a 
regular CCP-module structure with the expected disulfide pattern formation (Cys I - 
Cys III, Cys II - Cys IV) (Lorenzen et al. 2006). 
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Figure 3.21: . 1: Solution structure of rat GABAB-Rla CCP2. (a) Moiscript (Kraulis 1991) 
representation of the closest-to-mean structure of the trans-form. Assignment of fl-strands was based 
on a consensus among members of the ensemble (Procheck-NMR (Laskowski et al. 1996)) and 
annotated according to Henderson et al. (Henderson et al. 2001). Cysteine and tryptophan are shown in 
ball-and-stick representation. The helical segment is seen in red. (b) Multiprot (Shatsky et al. 2002; 
2004) Ca trace superposition of experimentally solved CCP module structures (trans-CCP2 and cis-
CCP2 in red, others in cyan). The figure is taken from Blein et al., 2004 (Blein et al. 2004). 
From the solution structure of the CCP module pair in the heterodimeric G-
protein-coupled receptor GABAB-Rla of rat, it was seen that only one of the two 
modules was compactly folded - module 2 (Blein et al. 2004). Module 1 was 
experimentally confirmed as containing large regions of disorder. The structure of 
module 2 in human GABAB-R1a--2 (cluster C) displayed two forms - a major form 
with a trans-configuration at the Leul 18-Pro 119 peptide bond, and a minor form with 
a cis-configuration at the same location; cis-trans isomerisation is unique among all 
solved CCP-modules to date (Figure 3.21). These two forms have a backbone r.m.s.d. 
value of 1.26 A between them over all 61 residues (Blein et al. 2004). Although its 
CCP module has an overall 3D-structure that resembles other CCP modules (Soares 
and Barlow 2005), an additional unusual feature of its sequence is a lack of proline 
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residues in the stretch following the first consensus cysteine, which corresponds to a 
short helical segment seen in the closest-to-mean structure (Figure 3.21a), and 37.5% 
of structures in the ensemble. This is unusual among CCP modules, and the average 
number of proline residues within this region is two (Figure 3.22). 
PCG--LPPT--- 	3D EL--PEN 	S I cNL 	 EVE---------.CTSNE'E Gr 	P ----- IPOCIIP 
- 	;E--PCH CNHG-------P IGEHS ---------- CTVNNt -G p-----PPECPGK 
- P 	P ANGP -- EDF TDGP 	SGN2G -------S IGNEG------ -- - 	CEG-------GE 	P - 	ppccIv 
TCP--Y -t----PL /Pt - -GT - E 	ICNEO------- P IGEEX ------------ HOS-VAI Y. ----- PPACHHV 
VCP_02 	
1PPWEGWYP 
--s 	---t 	- L[1--G- 	S P 	 AGES----------- CELGET 1 	PS--- --$PAcEv 
CEl_iS -TPPL--- P' N- /N I--Th- EP /CTPG-------AGNES --------
Ic 
	
ECILEGN- H H ----- PPtOSI 
CRA_O2 	-NPPL- - - P - N-/H i--KG-- 	sç 	SCTKG-------IGESS --------TCIIEGt- i NE-- •-- picrpx 
CRO1 	 --SPPP 	P P S--PP TL PCPGT - -- - IGEKS-----ATKDKVSG 	HP----- PKCEPF 
PH_iS -QPP-- E}LGT SSPSSQES- 	PH 5 TCEGG-PEENE-------CYM-----VS PP---------CEGL 
FH_16 -EPPE--- 5HG 	HIS---L5 j GE P CFEG------- - 	PAI ------- 
	
LG-----  ES 	P------PSCTKT 
DAP 03 	 -NPGH--- 	G S ScNPG-------HGSTS --------SFCLISGS-fS. P------PECPEI 
B2GPI_02 -Fi--- EG/ Y P------H PAl S SCNTG-------GADS --------IHCTEEG----K 	E------PVAPI 
GABA02 	 -KSYL-- EGK 	DLP 	DGAP 	crpr------ 	SEP 	------SIC-3G---- PP -------- pHcçVN 
CR202 -EPIV ---PGGYK Q-STP?P-- - OS P CKTN-- --- GNKC -------------SOiANN---- 	Pf - 	PTCV
VCPO4 	 -HPTI---SNGYLP 	PS?S-- - SN 	:Ci-:yG-------50555 --------STCSPGN----T .P-E---- PKCP- 
520P1_03 -PPSL---PTFAT ' PEAGEAN L E) ECLP--------P0NDT---------TCTTHG----N --------PECKS
B2GPI04 	 -FPSP---PL)SF A- PAFP-- 	OH 	CHIG-------rGPEE---------ECTKLG----N----P/SEAS 
CR115 -APDH--- FAK :T-çTNASD- PS ECPPE-------GPP-F5----------TCLDN----L 	P-----KEVCKIK 
EAAFO2 	 --VPTP--- SAP Z0P'!IT'N?- 	5 E ECPPG 	--PEPPLSP ------- TSLQN----LK 1---------EPCKKK 
Clr02 -QPPN--- 	S 1TTlGV- P \P 	CHEP------ 	TPAGLG' TCTAQG----I HESHGSK PICLPV
C1_02 	 -APES--- H DPESP 	L S\ TCHEP------V ENGOG------GE HcJGNG----5 NE\iGP PHCVPV 
PH_OS -NPYi----P A' 	lENS- - i' 	.0- rAG------P TEGAAT---------CTST0-----I ------PESTlE 
VCP_01 	 -IPSPP-- PGFK P ETEANAN A S LCLPG-------KSKSAGP----------CTGTG-----------N';'CIKP 
B2GPI_0I --EVEr' ---- PEST /? T 	- 	EPGE P -ZCKPG 	--PPGGTIP -- ---- -----ICPLTG----L IN-- -- 	CTPR 
Cis_Ol 	 --QPKT 	DEFTI 'N p- C'S I TCKSJG ------ 	IEGNt' - YLUFT /CQDE'G---- 	P - ---- PI'CSIK 
MCP01 --EPP --EAMEL EPKP----? 	EP'CY-NG ------ --IPPLEI ------ H ICE'PNH---- S----E'E'ACVPE 
GABA_Ol 	 -4pPSAEGGt-'?P 	PL'.VYAiN .5 5 'CPGE ------ N 	GPK\ ------ ----EKCLNG----/ - 
Figure 3.22: Multiple sequence alignment of a number of solved CCP module structures. The 
hyper-variable loop is marked within the red box. Also included in the alignment are the GABA_01 
and GABA_02 sequences (arrow). The lack of proline residues in GABAB-Rla---2 is apparent. 
The two conformers were compared with the models produced using the 
automated procedure, and appear to be rather divergent structurally, with backbone 
r.m.s.d. values of 2.55 A for the cis-form and 2.92 A for the trans-form. The major 
sources of deviation occur in the region of the hypervariable loop - the location of 
peptide bond Leu-Pro isomerisation. It should however be noted, that there exists two 
conservative substitutions (Va114311e and Glul27Asp) between the rat structure, and 
human model. 
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3.5.1.2 Comparison of models with new CCP module structures of 
C4BPa and factor H 
The N-terminal module pair of C4BPu was recently solved by NMR (Jenkins et al. 
2006). A structural superposition of individual models of modules and the closest-to-
mean NMR structure by Combinatorial Extension (CE) (Shindyalov and Bourne 
1998) revealed a Ca r.m.s.d. value of 2.64 A over 61 residues for C4BPct1 (a 
member of cluster A), and an r.m.s.d. value of 1.7 A over 62 residues for C4BPa2 
(belonging to cluster Q. These values compare favourably with other previously 
published models by Villoutreix et al., 1998 (Villoutreix et al. 1998) (Table 3.1, 
Figure 3.23). 
C4BPa-1 NMR structure C4BPa2 NMR structure 
C4BPct-4 mode] 264 
(61) 
C4BPa2 model 1.7 
(62) 





Table 3.1: Comparison of C411 Pa-1 and C4BFz-2 with previously published models. = Model 
created by the automated procedure (Soares et al. 2005); = Previously published model by Villoutreix 
et al., 1998 (Villoutreix et al. 1998). All r.m.s.d. values are in Angstroms (A). The alignment length is 
provided below in parenthesis. 
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Figure 3.23: Overlay of the experimentally determined C413Pu'-.2 with models. NMR structure of 
C4131?a-2 [PDB code: 2A55, (Jenkins et al. 2006)] shown in green; model created by automated 
procedure (Soares et al. 2005) shown in blue, previously published model by Villoutreix el al., 1998 
(Villoutreix et al. 1998) shown in red. 
The two C-terminal CCP-modules of factor H (modules 19 and 20) were also 
solved recently by NMR (Herbert et at. 2006c). CCP-module 19 was assigned to 
cluster B, whereas module 20 was unassigned, consistent with its divergent sequence, 
lacking the tryptophan residue between cysteines 3 and 4 (Soares and Barlow 2005). 
While module 20 is structurally divergent to any CCP solved to date, module 19 
appears to share features characteristic of B-cluster members. A comparison of model 
versus structure using CE, reveal a backbone r.m.s.d. value of 1.9 A over all residues. 
This can be compared with the previously published models by (1) Aslam and 
Perkins, 2001 (Aslam and Perkins 200 1) (model PDB code: 1HAQ, chain A), which 
has an r.m.s.d. value of 3.46 A over all 59 residues against the experimental structure; 
(2) the model published by Hellwage et al., 2002 (Hellwage et al. 2002) (model PDB 
code: 1FHC), which reveal an r.m.s.d. value of 3.5 A over 58 residues against the 
experimental structure, and (3) the model available at the factor H-associated HUS 
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mutation database (http://www.fh-hus.org/) (Saunders et al. 2006), which has an 
r.m.s.d. value of 2.8 A over 55 residues against the experimental structure. 
As was the case in the DAF modules, the models created for the two C4BPa 
modules and factor H module 19, using the automated procedure, are more accurate 
than the other published ones. 
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Chapter 4 
Disease-causing sequence variations in CCP-module-
containing proteins: applications of models to 
medicine 
4.1 Introduction 
A failure to properly control complement underlies the debilitating symptoms of a 
long list of autoimmune, degenerative and iatrogenic disorders (Chapter 1). 
Membrane-associated regulators of complement activation (RCA) are present on all 
host cells, where they have a protective function. Soluble regulators augment the 
membrane-bound ones and, additionally, act to modulate complement activation on 
self-surfaces not enclosed by a cell membrane and on apoptotic and necrotic cells. 
Because there is functional degeneracy amongst the RCA proteins, individuals with 
variant forms may escape consequences for most of their lives, but they may be 
predisposed to medical conditions that arise from inappropriate or misdirected 
complement activation. For example, several mutations in factor H (fl-I), and a few in 
membrane cofactor protein (MCP), predispose to atypical haemolytic uraemic 
syndrome (aHUS) (Warwicker et al. 1998; Richards et al. 2003; Goodship 2004; 
Goodship et al. 2004), a rare, often fatal kidney disease. A different amino-acid 
substitution in fl-I increases the risk of contracting the eye condition, age-related 
macular degeneration (AMD), a common cause of irreversible sight-loss in people 
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over 60 (Edwards et al. 2005; Hageman et al. 2005; Haines et al. 2005; Klein et al. 
2005). Variations in complement receptor type 1 (CR1) are known to occur with 
increased frequency in certain malaria-exposed populations in Africa (Moulds et al. 
2000), which confer resistance to some pathological symptoms. 
Based on the models described in Chapter 3, and new ones described in this 
chapter, we can predict structural and functional consequences of disease-linked 
amino acid substitutions. The results of such an exercise are described and discussed 
below. Disease-causing and human-specific evolutionary mutations that occur in the 
CCP module of a protein that is probably not a complement participant - sushi-repeat-
containing protein, X-linked 2 (SRPX2) are also described (Roll et al. 2006). The 
sequence data and the 31)-structural models used are all available online at 
http://www.bru.ed.ac.uk/—dinesh/ccp-db.html. To place this work in context, some 
background information on diseases caused by sequence variations in the above 
mentioned proteins is presented first. 
4.1.1 Atypical Haemolytic Uraemic Syndrome 
Haemolytic uraemic syndrome (HUS) causes the majority of kidney failures in 
children and is typically associated with bacterial infections. It is characterised by 
thrombocytopenia, microangiopathic haemolytic anaemia, and acute renal failure 
(Taylor 2001; Blackall and Marques 2004). 	A related disorder of the 
microvasculature is thrombotic thrombocytopenic purpura (TTP). TTP occurs mainly 
in adults, and is normally accompanied by neurological deficits; but TTP and HUS are 
regarded by many clinicians as a different manifestation of the same 
pathophysio logical process. 
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The rare atypical HUS (5-10% of cases of HUS) is not linked to infection, but 
is sporadic or familial. While full recovery from typical HUS is the norm, the long-
term diagnosis for sufferers of aHUS is unfavourable. A growing list of genetic 
mutations and SNPs (Table 4.2 and 4.3) within the RCA gene cluster has been 
associated with aHUS (Warwicker et al. 1998; BuddIes et al. 2000; Richards et al. 
2001; Caprioli et al. 2003; Dragon-Durey et al. 2004; Sanchez-Corral et al. 2004). 
These include both missense mutations yielding normal plasma levels of factor H and 
MCP, and mutations leading to fH and MCP deficiency. Factor H deficiency has also 
been linked to membranoproliferative glomerulonephritis type II (MPGN II), and (in 
one case) to type III collagen glomerulopathy (Ault 2000). Additionally, some aHUS 
patients carry mutations in the protein encoded by the factor I gene (Fremeaux-Bacchi 
et al. 2004) - a complement, non-CCP-containing protein, which will not be discussed 
further. 
Numerous missense mutations associated with aHUS cluster in fH CCPs 19 
and 20 (Perez-Caballero et al. 2001; Esparza-Gordillo et al. 2005), and a haplotype 
block involving alleles spread across the RCA gene cluster (Esparza-Gordillo et al. 
2005) is strongly linked to disease. A reasonable biological model would involve a 
deficit in fH-mediated complement-regulation on the basement membrane exposed by 
the large fenestrations of the capillary endothelium within the glomerulus. If 
accompanied by a deficit of one or more cell-surface complement regulators, the 
defensive capacity of near-by cells might be overwhelmed. Alternatively, inadequate 
protection of endothelial cells against complement activation, might lead to 
compromise of the endothelial cell layer and exposure of the underlying basement 
membrane that is not protected by a fully functional fH. Environmental triggers, such 
as immunosuppressive drugs, cancer therapies, and oral contraceptives, are also 
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involved. Thus the disease is probably multifactorial with fH dysfunction playing a 
central role. Intriguingly, a factor H mutation was identified in a TTP patient who 
developed renal failure - the mutation was absent in a sibling who also had TTP but 
presented with exclusively neurological symptoms (Noris et al. 2005). Overall, the 
correlation of mutations/SNPs with disease penetrance, disease severity, prognosis, 
and choice of treatments, remains obscure in the case of aHUS. 
4.1.2 Age-related Macular Degeneration 
As a disease of the macula, a region of densely packed photoreceptors towards the 
centre of the retina, AMD affects central-field vision leading to significant loss in 
quality of life for up to 50 million sufferers worldwide. AMD is a complex disease, 
probably involving a combination of genetic factors and environmental triggers, such 
as diet and (especially) smoking. The characteristic feature of early AMD is the 
presence of large fatty yellow deposits - drusen - between the retinal pigment 
epithelium (RPE) that underlies and nourish the photoreceptors, and the layer of 
extracellular matrix known as Bruch's membrane (BM) that separates the RPE from 
its blood supply in the choroid (Figure 4.1). The drusen intrude into the RPE and 
contain cell debris in addition to copious quantities of immune-associated molecules. 
In particular, they contain both complement regulators and the C5b-C9, membrane 
attack complex (Johnson et al. 2001). Hageman et al. cleverly noticed a connection 
between AMD and MPGN type II, a rare kidney disease (Mullins et al. 2001). Some 
MPGN II patients develop ocular drusen that closely resemble those of AMD. 
Glomerulonephritis had been connected to fH dysfunction or deficiency, leading 
Hageman et al. to perform an SNP analysis of FH1 in two large cohorts of AMD 
patients and matched control sets (Hageman et al. 2005). This led to the identification 
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of both at-risk and protective haplotypes clustered in the N-terminal half of factor H 
(Table 4.2). The most common at-risk haplotype - present at a frequency of 50% in 
AMD cases and 29% in controls - included the SNP Y402H. Simultaneously, three 
other groups had independently identified Y402H of fl-I as a susceptibility-SNP in 




Figure 4.1: Age-related macular degeneration. (a) The retinas of AMD eyes (top left) develop 
abnormal deposits called drusen (yellow spots); as shown by the red staining (right), drusen contain 
complement proteins. (b) AMD robs it victims of central vision (as illustrated by the simulated picture 
on the bottom right), and can leave them legally blind even though a rim of peripheral vision may 
remain. Figure taken from (Marx 2006). 
A plausible disease model would involve an instigating, localised, release of 
debris from necrotic RPE cells that is deposited in the space between the RPE and 
BM. The deposits would include potent stimulators of the alternative pathway. In the 
absence of fully functional fH, they could trigger a self-perpetuating cycle of 
inflammatory events involving bystander cell-damage, further release of cell debris, 
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and accumulation of immune molecules. This process would lead over time to 
formation and then expansion of drusen to the point where they compromise the RPE 
and incite phenomena associated with the later stages of AMD - geographic atrophy 
and choroidal neovascularisation. Other genes have also been linked to AMD, and it 
may well be that disease instigation and progression depends upon additional proteins 
malfunctioning, as well as environmental factors. A SNP in the coding region of the 
L0C387715 gene (Rivera et al. 2005), accounts for 40% of AMD cases. Variation in 
the complement factor B gene (Gold et al. 2006) have also been linked to AMD. 
Studies conducted in Chinese, Finnish, French, Italian, and Russian populations 
confirmed the existence of the Y402H variant of fH among AN/ID patients (Souied et 
al. 2005; Fisher et al. 2006; Lau et al. 2006; Seitsonen et al. 2006; Simonelli et al. 
2006). Surprisingly, another study among patients of AMD in a Japanese population, 
did not make any statistically significant link between factor H variants and AMD 
(Okamoto et al. 2006). 
4.1.3 Role of CR1 in malaria 
 
::;Rosette 	Vascular obstruction 
 
- 
Figure 4.2: Rosette formation. The left panel (image source: Texas Medical Center website) shows 
an infected RBC (centre) binding healthy RBCs causing clumping or agglutination called "rosetting". 
The right panel depicts formation of a rosette in the microvasculature. Rosetting is probably a strategy 
used by the parasite to remain sequestered in the microvasculature to avoid destruction in the spleen 
and liver. Erythrocyte rosetting causes obstruction of the blood flow in microcapillaries. Formation of 
rosettes correlates with severity of malaria (Rowe et al. 1995). 
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Malaria is an infection caused by the parasite genus Plasmodium, and is spread from 
person to person by mosquitoes. Each year, malaria kills over a million people, 
primarily in Sub-Saharan Africa (source: World Health Organization, 2006), where 
infection is caused by the Plasmodiuni falciparum strain - the most severe, and life-
threatening form of the disease. 
Like other complement regulators, CR1 has been hijacked by pathogens, to 
facilitate entry into host cells or down-regulate complement activation (Chapter 1). In 
this regard, CR! has been reported to act as a receptor on the surface of uninfected red 
blood cells (RBCs) for a protein encoded by the Plasmodium falciparum genome - 
i.e. P. falciparum erythrocyte membrane protein 1 (PfEMP 1), that is expressed on the 
surface of infected RBCs (Rowe et al. 1997; Krych-Goldberg et al. 2002). This 
interaction contributes to agglutination and rosetting - events that are important in 
malaria pathogenesis (Figure 4.2) (Rowe et al. 1995; Rowe et al. 1997; Rowe et al. 
2000). 
Phenotype Frequency (%) Amino Correlation with 
Caucasians 	African-Americans 	Africans Acid malaria 
McC(a+) 98 99 82-95 Lys 1590 Unknown 
McC(b+) 1 44 44-56 Glu 1590 Unknown 
Sl:1 99 65 37 Arg 1601 
S1:2 1 39 68-72 Gly 1601 Reduced rosetting of 




Table 4.1: Knops blood group polymorphisms. A  McC = McCoy; SI = Swain-Langley. McCa and 
McCb are one allelic antigen pair. Sil and S12 are another pair. The corresponding phenotypes for the 
first pair are McC(a+) and McC(b+), and for the second pair are SI: I and S1:2. Table adapted from 
(Krych-Goldberg et al. 2002). 
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CR1 in humans exhibit various genetic polymorphisms, including those 
represented by the Knops blood-group system (Table 4.1) (Moulds et al. 1991; Rao et 
al. 1991; Moulds 2002; Moulds etal. 2002), which is of interest in this chapter. In the 
most common allotype of CR! (the 30 CCP module size-variant, containing four 
LHRs), two of the Knops blood-group antigens were traced to point mutations that 
produce a single amino acid residue change in CCP 25 (Moulds etal. 2001; Moulds et 
al. 2002). An A to G mutation, at nucleotide 4795, causes a Lys l59OGlu change, and 
defines the McCa/McCb polymorphism. An SNP at nucleotide 4828 causes an 
Argl60lGly change, and defines the S!:l/S!:2 polymorphism. The frequency of 
McC(b+) and Sl:2 phenotypes or polymorphisms are greatly increased in malaria-
exposed African populations as compared to Caucasians (Table 4.1) (Moulds et al. 
2000). This suggests a selective pressure for McC(b+) and Sl:2 in malaria-exposed 
populations. 
The pathological event proposed to be transformed by these epitopes is 
rosetting. Rosetting of RBCs carrying the Sl:2 variant is lower compared to RBCs 
carrying the Sl:1 variant (Rowe et al. 1997). Reduced rosette formation would 
decrease the microcapillary occlusion that impairs blood flow in malaria (Figure 4.2). 
Further, the number of the parasites sequestered in the bloodstream would be less if 
rosetting was inefficient (Miller et al. 1994). 
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4.1.4 Disease-causing and evolutionary mutations in SRPX 2 
Sushi-repeat protein, X-linked 2 (SRPX2) is a secreted protein expressed in neurons 
of the adult human brain. It is made up from four major domains; three putative CCP 
modules, with one hyalin repeat domain (HYR) inserted between CCP modules 2 and 
3 (Figure 4.3a). It shares 35% sequence identity with cluster-D member SRPX 
(Figure 4.3b) and displays sequence characteristics of other cluster-D members 
(Chapter 3), including conservation of the six-cysteine residue motif 
N (1) - 	CCP cU 	CC? 	 C (465) 
 
SRPX2-CCP1 1TLNI 	eEA •YS 	t 	HS 	EL D •F I sPRSV LPS 	"GTA * 
SRPX-CCP1 1 LLçSDRV 
consensus 1 
Figure 4.3: Modular architecture and sequence of SRPX2. (a) Modular architecture of SRPX2. 
The 465-residue SRPX2 protein is made up of a 23 amino acid signal sequence (shown in red), 
followed by a 34-residue stretch preceding the three CCP modules and Hyalin repeat domain (HYR), 
which is inserted between CCPs 2 and 3. Figure is taken from SMART (http://smart.embl-
heidelberg.de/). (b) Pairwise sequence alignment between CCP1 of SRPX and SRPX2. BOXSHADE 
(http://www.ch.embnet.org/software/BOXform.html) output for pairwise comparison between CCPI 
of SRPX and SRPX2. Identities = 21/59 (35%) marked by '*', Positives (identities and conservative 
substitutions) = 3 6/59 (61 %) marked by '.', Gaps (insertions or deletions) = 0/59 (0%). 
The SRPX2 gene was recently identified as being responsible for two related 
disorders of the rolandic/sylvian speech areas (Roll et al. 2006). The rolandic and 
sylvian fissures divide the cortex hemispheres of primate brains into their main 
anatomical structures. In humans, these areas participate in speech production under 
the control of the Broca's area. 
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Figure 4.4: Main anatomical structures of the brain involved in linguistic activity. Image taken 
from "The Brain: A Neuroscience Primer, 3 d  edition"; Worth Publishers, New York, 2000, pp.  442 by 
Richard F. Thompson. 
Two mutations; (i) N327S, which results in gain-of-glycosylation in an as yet 
unidentified region, and (ii) Y72S located in the first CCP module, were implicated in 
rolandic seizures associated with oral and speech dyspraxia and mental retardation 
(Roll et al. 2006). Since it is linked to defects in the functioning and the development 
of such brain regions, SRPX2 may be one of the specific genes whose evolution may 
have participated in the recent emergence of higher-order human-specific cognitive 
functions. 
In a study conducted by Royer et al., 2006 (unpublished), the molecular 
evolution of the SRPX2 gene was examined (see attached preprint in appendix). 
While population genetics did not detect a selective sweep, adaptive evolution in the 
human lineage was suggested by a synonymous/non-synonymous analysis (a 
stochastic effect was not ruled out). One single, fixed amino acid change (R75K) 
occurred in the first CCP module of SRPX2 after the human-chimpanzee split. The 
three-dimensional modelling work, discussed in this chapter, examined the effects of 
both this evolutionary mutation (R75K) and the previously identified disease-causing 
mutation (Y72S). 
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4.2 Materials and Methods 
Homology-derived models for eight modules in factor H - numbers 2, 3, 4, 11, 12, 14, 
17, and 18; and the remaining two and 27 modules in MCP and CR1 respectively - are 
downloadable 	from 	the 	CCP-module 	model 	database 
(http://www.bru.ed.ac.uk/—dinesh/ccp-db.html). These were created using the large-
scale modelling procedure described in Chapter 3 (Soares et al. 2005). Two other 
modules in factor H - numbers 1 and 7 - were homology-modelled individually for the 
purposes of this exercise, and are likewise available online. 
4.2.1 Modelling method for factor H CCP modules 1 and 7 
Modelling of each of these two CCP modules was based upon the structure with the 
most similar sequence as identified in the PDB (Berman et al. 2000) 
(http://www.rcsb.org/pdb) with a BLAST search (Altschul et al. 1990), and employed 
the program Modeller release 8 version 1 (Sali and Blundell 1993). Modules I and 7 
were based upon templates DAF-2 (PDB ID: 10K3) and VCP-4 (PDB ID: 1G40) 
respectively. The sequence alignments between target and template sequences 
(Figure 4.5) were created based on initial multiple sequence alignments, which were 
further manually edited to ensure the most plausible alignment of conserved amino 
acid residues and secondary structure elements between the templates and those 
strongly predicted by PsiPred version 2.4 (McGuffin et al. 2000) in the target 
sequences. Disulfide bridges were automatically restrained during model building. 
Twenty models were generated in each case, and the one with the lowest objective 
function score was selected as the representative model. 
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consensus 1 
 Figure  4.5: Optimal target-template alignment used for modelling fH CCPs I and 7. 
BOXSHADE (http://www.ch.embnet.org/soflwarelBOX_form.html) output of the optimal sequence 
alignment between target fT-J-CCP 1 and template DAF-CCP2 (above) and fT-1-CCP7 and VCP-CCP4 
9below). Identical residues are marked by '*' and conservative substitutions shown by '.' in the 
consensus line. 
For each representative model, non-identical side-chains between template and 
target were optimised using the side-chain replacement program, SCWRL version 3 
(Bower et al. 1997). The models were then protonated, and subjected to energy 
minimisation carried out in SYBYL version 6.9 (Tripos Associates, St. Louis, MO, 
USA) using the Tripos forcefield (30 steps steepest descent followed by 30 steps 
conjugate gradient). The models were finally checked for valid stereochemistry using 
PROCHECK version 3.5.4 (Laskowski et al. 1993). 
The accuracy of these two models may be inferior relative to those created 
previously by the large-scale modelling strategy because of lower sequence similarity 
between targets and templates. They represent, however, the product of the best 
available modelling techniques and are available for download at the CCP-module 
model database (http://www.bru.ed.ac.uk/—dinesh/ccp-db.html). 
4.2.2 Modelling method of the first CCP module of human SRPX2 
Modelling of the first CCP module of human SRPX2 was undertaken based on its 
closest homologue in the Protein Data Bank (PDB) (http://www.rcsb.org/pdb)  
(Berman et al. 2000) - the first CCP module of complement receptor type 2 (CR2) 
(Prota et al. 2002) (PDB ID: 1LY2), identified with a BLAST search (Altschul et al. 
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1990; Altschul et al. 1997). The target and template share 29% sequence identity 
from N- to C-terminal cysteines. The program Modeller release 8 version 1 (Sali and 
Blundell 1993) was used. 
The alignment between the target and template sequences (Figure 4.6) was 
based on an initial multiple sequence alignment of several individual human CCP-
module sequences assigned to cluster-D (with the addition of template sequence CR2-
CCP1) using the program PROBCONS (Do et al. 2005). Cluster-D members are 
characterised by the presence of a six-cysteine residue motif, forming three putative 
disulfide bridges (Chapter 3). The target-template sequence alignment was subjected 
to further minor manual editing, guided by positioning of secondary structure 
elements more appropriately between the target and template sequences. Secondary 
structure elements were defined by the server PsiPred version 2.4 (McGuffin et al. 
2000) for the target sequence, and DSSP (Kabsch and Sander 1983) for the template 
structure. 
C59 	 C71 	 C87 C91 	 C105 	 C117 
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Figure 4.6: Optimal target-template alignment used for modelling SRPX2-CCP1. BOXSHADE 
(http://www.ch.embnet.org/sofiware/BOXform.html) output of the optimal sequence alignment 
between target CCPI of SRPX2 (SRPX2-sushi 1), and template CR2 CCP1 (CR2-sushi1). Cysteine 
residues involved in disulfide bridge formation are connected by lines and labelled above the SRPX2-
CCP1 sequence (the additional disulfide in SRPX2 is shown in red). Identical residues are marked by 
'' and conservative substitutions shown by '.' in the consensus line. 
It was noticed from a preliminary modelling run, that Cys 71 and Cys 87 lie 
close in space within the folded structural model. Subsequently, this additional 
putative disulfide bridge present in the target, absent in its corresponding template, 
was restrained during model building. Twenty-five models were generated, and the 
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one with the lowest objective function score (Sall and Blundell 1993) selected as the 
representative model. The loop 'KGGNY' in the hypervariable loop region of SRPX2, 
for which CR2-template-derived restraints were largely absent, was subsequently 
remodelled under SYBYL version 6.9 (Tripos Associates, St. Louis, MO, USA) after 
conducting a loop search for that region against a high-resolution subset of the PDB, 
to select the best root-mean square fitted, matching loop conformation for that region. 
Non-identical side-chain residues of the representative model were optimised 
using the side-chain replacement program SCWRL version 3 (Bower et al. 1997). 
The model was then protonated and subjected to energy minimisation using the Tripos 
forcefield (Clark et al. 1989) (20 steps steepest descent followed by 20 steps 
conjugate gradient) under SYBYL to remove clashes and bad geometries. The model 
structure was finally checked for valid stereochemistry using PROCHECK version 
3.5.4 (Laskowski et al. 1993). 
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4.3 Results and Discussion 
4.3.1 Predicted structural consequences of amino acid substitutions in 
factor H 
Structural predictions (summarised in Table 4.2 below) can be combined with 
knowledge of phenotype and of the locations of binding sites on factor H (Chapter 1), 











Figure 4.7: 3D-model of factor H CCP module 7. Cartoon schematic PyMol (http://www.pymol.org) 
representation of module depicting a typical CCP-module fold. 13-strands numbered and disulfides and 
tryptophan are drawn as sticks. The AMD-associated SNIP, 402, and aHUS-implicated variant, 400, 
located in the hypervariable loop are shown as sticks. 
For example, the model of module 7 suggests that the SNP involving residue position 
402 - a His in the population at-risk of AMD, otherwise a Tyr - is not likely to 
disrupt the structure of module 7 since its side-chain is largely solvent-exposed 
(Figure 4.7). Nor is it likely to affect the orientation or flexibility of module 7 with 
respect to its neighbouring modules. A local effect on the structure or flexibility of 
the hypervariable loop cannot be ruled out. Module 7 is known to form part of a 
binding site for polyanions (one of three such sites in factor H), and also to contribute 
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to a binding site for C-reactive protein (Giannakis et al. 2003). It is therefore likely 
that its hypervariable loop is involved in direct contact with ligand, and that 
substitution with His perturbs one or other interaction so as to compromise affinity. 
Even a minor effect on binding could be critical since incomplete shut-down of the 
AP, over a time-course of years, could promote the gradual enlargement of ocular 
drusen. Many individuals with the at-risk allele do not have AMD, so the disease 
process may require some triggering event - for example compromise of cells in the 
RPE due to another disease or an environmental insult - or there might be additional 
gene products involved. The occurrence of another structurally-neutral (according to 
our predictions) mutation in an adjacent residue, Q400K (Figure 4.7), in an aHUS 
patient reinforces the hypothesis that there is a binding site in this hypervariable 
region of module 7. 
Table 4.2 summarises the predicted structural consequences for a selection of 
disease-linked mutations and SNPs of factor H. Many of these involve a consensus 
Cys; or (not shown) they involve the introduction of stop codons/deletions. Variants 
in either of these categories are likely to have serious consequences for expression, 
and structural integrity and stability - indeed many are known to be associated with 
factor H deficiencies. Another class of mutations are those that are predicted to 
disrupt the interface between two modules. In this case, it is not likely that expression 
will be adversely affected, although a more open interface could increase 
susceptibility to proteolysis. More likely, these mutations illustrate the functional 
importance of defined levels of flexibility between modules of the intact protein. Of 
the remaining variations (Figure 4.9), several involve buried hydrophobic residues 
(V835, W978, W1157, V1197, and F1199) likely to destabilise individual module 
structures. One of these (W978) affects the stability of module 16, not previously 
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shown to interact directly with other complement proteins, and therefore having a 
potential role in the overall protein architecture of M. On the other hand this CCP 
module, along with modules 1, 7 (see above), 14, 18, 19, and 20, harbour disease-
associated residues that are solvent-exposed suggesting the involvement of ligands, 
some of which may not have been identified so far. 
1 	 2 	3 	4 	5 	6 	7 8 
— +HV-Ioop ---p. p 	—p. p —p. p. 
FHO1 DCNfLPPRRNTE---I L1GSWS--L)QLYP-EGTQAIYKCRL'GYRSL---G----NVIMVCR-KGEWVALNPLRKCQKR 
FH02 PCGH-PGDTFG --- TFTLTGG --- NVFE--YGVKAVYTCNEGYQLL--G-E1NYRECDTDG-WT--NDI EICEVV 
FH03 cLp-vTz\pENc;KIvssnt4EpD --- REy1I-rc;QAvRFvcNsGyKIEG--DEEMf-:csDDGFws--KEKPKCV1I 
FH04 SCKS--PDVING ---- SPISQK --- IIYK-ENERFQYKCNMGYEYSERG ---- DAVCTESG-WR --- PLPSCEEK 
FH05 SCDN--PYI NG----DYSPLP.---IKHR-TGDEITYQCRNGFYPATRG---TAKCTSTG-WI---PAPRCTLK 
FHOG PCDY--PDIKHGG--LYHENMRRPYFPVA-VGKYYSYYCDEHFaTP-SGSYWDHICTQDG-'JS---PAVPCLRK 
FH07 KCYF--PYLENG ----NQNYG---RKFV-QGKSIDVACHPGYALNKA--QTTVTCMENG-WS --- PTPRCIRV 
FHO8 TCSKSSIDIENG ---- FISESQ --- YTYA-LKEKAKYQCKLGYVTA-DGETSGSIRCGKDG-WS---AQPTCIKS 
FH 09 scDI--PvFMNA ---- RTKNDF --- TwFK-LNDTLDYEcHDGyEsN-TGSTTGSIVcCYNG-ws --- DLPICYER 
F}i1O ECEL--PKIDVH --- LVPDRKK --- DQYK-VGEVLKFSCKPGFTIV--G--PNSVQCYHG-LS--t'DLdICKEQ 
Fall SCGP-PPELLNG --- NVKEKTK --- EEYG-HSEVVEYYCNPRFLMK--G--PNKIQCV-DGEWT --- TLPVCIVE 
FB12 TCGD-IPELEHG ---- WAQLSS --- PPYY-YGDSVEFNCSESFTMI--G--HRSITCI-HGVWT --- QLPOCVAT 
FH13 KCKSSNLI ILEE----HLKNKK----EFD-HNSNIRYRCR-G--KE--G--WIHTVCI-NGRWD---PEV1C5Mi\ 
FH14 LOPP-PPQIPN ---- HNMTTT --- LNYR-DGEKVSVLCQENYLIQ-E- --- EEITCK-DGRWQ---SIPLCVEK 
FH15 PCSQ-PPQIEHG ---- TINSSRSSQESYA-HGTKLSYTCEGGFRISEENETTcYMGKWSSPPQCEGL 
FH16 pcKs-PPEISHG ---- VVAHMS --- DSYQ-YGEEVTYKcFEGFGID--G--PAIAKCL-GEKWS --- HrPSCIKT 
FH17 DCLS-LPSFENA ---- IPMGEK--KDVYK-AGEQVTYTCETYYKMD--G--ASNVTCI-NSRWT --- GRLTCRDT 
FH18 SCVN- PFTVQN----YIVSRQ--MSKYP-SGERVRYQCRSPYEMF--G--DEEVMCL-NGNWT---EPPQCDS 
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Figure 4.8: Disease-associated variants mapped on the multiple sequence alignment of the 20 
factor H CCP modules. j3-strands (arrows) indicated above sequences along with hypervariable loop 
(H V-loop). Consensus residues for each position in the alignment (the greater the height of the residue, 
the greater the conservation) are shown below (Crooks et al. 2004) (http://weblogo.berke1ey.edu!). 
Variants (Table 4.2) highlighted as follows: bold letters indicate the variant is expressed at normal or 
high levels in plasma; underlined bold residues indicate the variant is expressed at low levels or is 
absent; italicised bold residues indicate variants where no information is available. 
Importantly, the majority of non-structural residues, however, lie in or close to 
the GAG-binding site. It is interesting that several such mutants are nonetheless 
pulled out on a heparin column (Lehtinen et al. 2006). On the other hand, heparin is 
not regarded as a physiological ligand for GAG-binding proteins. 
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Figure 4.9: Disease-associated factor H variants mapped onto models and NMR structures. 
SMART representation of factor H, with CCPs involved in disease labelled at the top. Models (CCPs 
1, 2, 11, 14, 17 and 18) and NMR structures (CCPs 15 and 16; 19 and 20 - boxed below) shown in 
cartoon representation, with disease-associated variant residue side-chains shown in stick 
representation coloured red and labelled. Factor H models for CCP 7 (see Figure 4.7) and CCP 9 are 
not shown. The collagen type-Ill glomerulopathy implicated variant in CCP9 (C536R) co-occurs with 
C959Y in CCP 16, and is highly likely to cause structural disruption. 
Variant/Reference CCP Predicted effect Pathology ff1 level 
162V (Hageman et al. I No effect on structure AMID High 
2005)  
R78G (Caprioli et al. 1 Structural disruption HUS n.r. 
2003)  
R127L (Dragon-Durey et 2 Protein more "sticky?" MPGNII Low 
al. 2004)  
Q400K (Dragon-Durey et 7 No effect on structure HUS n.r. 
al. 2004)  
Y402H (Hageman et al. 7 No effect on structure AMID High 
2005)  
C431 S (Dragon-Durey et 7 Structural disruption MPGNII Low 
al. 2004)  
C536R,C959Y (Ault et al. 9,16 Structural disruption CIIIG Absent 
1997; Ault 2000)  
C630W (Neumann et al. ii Structural disruption HUS Normal 
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2003)  
C673Y (Dragon-Durey et 11 Structural disruption HUS Low/Normal 
al. 2004)  
C673S (Dragon-Durey et 11 Structural disruption MPGNH Low 
al. 2004) 
V835L (Gilges et al. 14 Structural disruption HUS n.r. 
2000)  
E850K (Neumann et al. 14 No effect on structure HUS High 
2003)  
S8901 (Noris et al. 2005) 15 Protein more 	sticky? HUS Normal 
H893R (Dragon-Durey et 15 Disrupts junction HUS Low 
al. 2004)  
C915S (Dragon-Durey et 15 Structural disruption HUS Low 
al. 2004)  
E936D (Caprioli et al. 16 No effect on structure HUS Normal 
2003)  
Q950H (Caprioli et al. 16 No effect on structure HUS n.r. 
2003)  
Y951H (Caprioli et al. 16 Disrupts junction? HUS n.r. 
2003)  
T956M (Perez-Caballero 16 No effect on structure HUS Normal/High 
et al. 2001; Esparza- 
Gordillo et al. 2005)  
C973Y (Gilges et al. 16 Structural disruption HUS Low/Absent 
2000)  
W978C (Neumann et al. 16 Structural disruption HUS Normal 
2003)  
T987A (Gilges et al. 16/17 Disrupts junction HUS n.r. 
2000)  
VI007C (Gilges et al. 17 Protein cross-linked? HUS Normal 
2000)  
Y1O21F (Neumann et al. 17 Disrupts junction? HUS Normal 
2003)  
C1043R (Neumann et al. 17 Structural disruption I-[US Normal 
2003)  
Q1076E (Richards et al. 18 No effect on structure HUS Normal 
2001; Neumann et al. 
2003) _ ____________  
D I I 19G (Richards et al. 19 Disrupts GAG-binding sitet HUS Normal 
2001)  
V1134G (Neumann et al. 19 Structural disruption HUS High 
2003)  
Y1 142D (Neumann et al. 19 Disrupts junction HUS High 
2003)  
W1 157R (Neumann et al. 19 Structural disruption HUS High 
2003)  
Cii 63W (Caprioli et al. 19 Structural disruption HUS n.r. 
2003)  
RI 182S (Gilges et al. 20 Disrupts GAG-binding site HUS n.r. 
2000)  
Wi 183R (Remuzzi et al. 20 Disrupts GAG-binding site HUS Normal 
2002; Neumann et al. 
2003)  
WI 183L (Perez-Caballero 20 Disrupts GAG-binding site HUS Normal/High 
et al. 2001; Dragon-Durey 
et al. 2004; Esparza- 
Gordillo et al. 2005)  
Ti 184R (Richards et al. 20 Disrupts GAG-binding site HUS Normal 
2001)  
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Li 189F (Rodriguez de 20 C3b-binding? HUS Normal 
Cordoba et al. 2004; 
Esparza-Gordillo et al. 
2005)  
Li 189R (Perez-Caballero 20 C3b-binding? HUS Normal/High 
et al. 2001; Esparza- 
Gordillo 	al. _et_ _2005)  
1191IL (Richards et al. 20 Disrupts GAG-binding site HUS n.r. 
2001; Neumann etal. 
2003)  
1199iW (Rodriguez de 20 Disrupts GAG-binding site HUS Normal 
Cordoba et al. 2004; 
Esparza-Gordillo et al. 
2005)  
G  194D (Perkins and 20 Structural disruption HUS n.r. 
Goodship 2002; Caprioli 
et al. 2003)  
VI 197A (Caprioli etal. 20 Structural disruption HUS Low/Normal 
2001; Perez-Caballero et 
al. 2001; Richards et al. 
2001; Caprioli etal. 2003; 
Esparza-Gordillo et al. 
2005)  
El 198A (Caprioli et al. 20 Disrupts GAG-binding site H1JS n.r. 
2003)  
F1 199S (Dragon-Durey et 20 Structural disruption HUS Low 
al. 2004)  
Ri2iOC (Caprioli et al. 20 Protein cross-linked? HUS Normal/High 
2001; Perkins and 
Goodship 2002; Sanchez- 
Corral et al. 2002; 
Caprioli et al. 2003; 
Neumann et al. 2003; 
Esparza-Gordillo et al. 
2005)  
RI215G (Warwicker et al. 20 Disrupts GAG-binding site HUS Normal 
1998; Richards et al. 
2001)  
R1215Q (Caprioli et al. 20 Disrupts GAG-binding site HUS Normal 
2001)  
P1226S (Neumann et al. 20 Structural disruption HUS High 
2003)  
Table 4.2: Disease-associated factor H variants. tThe  GAG-binding site on fH-19,20 has been very 
recently delineated experimentally (Herbert et al. 2006b). Abbreviations used in Table4.2: CHIG = 
collagen type III glomerulopathy; n.r. = not reported/known; other abbreviations explained in text. 
The data in Table 4.2 provides a very clear indication that it is the inability of 
variant forms of factor H to distinguish, properly, self- from non-self surfaces via 
their carbohydrates that is the dominant disease-causing factor. 
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4.3.2 Predicted structural consequences of amino acid substitutions in 
MCP 
To date, only three missense disease-associated mutations have been observed in 
MCP that predispose individuals to aHUS (Table 4.3, Figure 4.10) - one each, 
occurring in modules 2, 3 and 4. 
Variant/Reference CCP Predicted effect Pathology MCP level 
R  03W (Esparza- 2 Affects C3b-binding? HUS Normal 
Gordillo_et_  al. _2005)  
P165S (Esparza-Gordillo 3 Disrupts structure HUS Low 
et al. 2005)  
S240P* (Richards et al. 4 Affects C3b-binding and HUS Normal 
2003)  cofactor activity toward C4b  
Table 4.3: Disease-associated MCP variants. OR103W was erroneously reported as R103T in 
(Esparza-Gordillo et al. 2005). A corrigendum was subsequently published in this regard. *S240P  was 
reported as S206P in (Richards et al. 2003) - this numbering excluded the signal peptide. For 
consistency, all numbering in the above table include the 34 amino acid signal peptide. 
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C256-C283 




Figure 4.10: Crystal structure (CCP 2) and 3D-models (CCP 3 and 4) of MCP. Cartoon schematic 
PyMol (http://wviw.pymol.org) representation of MCP CCP-modules 2, 3 and 4, with disulfides and 
tryptophan drawn as sticks and labelled. The location of aHUS-associated SNPs; R103 (CCP2), P165 
(CCP3) and S240 (CCP4) are shown in stick representation and labelled. 
Arg 103 in module 2 is highly surface exposed (Figure 4.10), away from the 
interface with neighbouring modules. Substitution of a positively charged Arg with a 
hydrophobic aromatic Trp residue at that position would have a drastic effect on the 
surface properties in that region and could thus have a functional effect. It is therefore 
likely that R103 is in direct contact with a ligand. Pro 165 located in module 3, on the 
other hand is completely buried (Figure 4.10). A proline residue at this position is 
commonly conserved, as part of the CCP module scaffold (Chapter 2, Section 2.4.1). 
A change from a conformationally important proline, to a polar serine amino acid 
could therefore, impact on local structure and disrupt it. Ser 240 is surface exposed 
and located at the start of the hypervariable loop in CCP4 (Figure 4.10). It has been 
shown to be important for complement regulation through mutagenesis experiments 
(Liszewski et al. 2000). A change to a proline residue at this position would thus have 
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both a structural and a functional effect. In fact, individuals with the S240P variant 
expressed normal quantities of protein, but demonstrated approximately 50% 
reduction in C3b-binding in heterozygotes, and a complete lack of C3b-binding in 
homozygotes (Richards et al. 2003). This suggests that it is the failure of the variant 
form to inactivate or regulate C3b that mediates development of disease (Richards et 
al. 2003; Esparza-Gordillo et al. 2005). 
4.3.3 Model of CR1 CCP 25 sheds light on haplotypic variants in 
malaria-exposed populations 
From the data provided in Table 4.1, epitopes in CR1-CCP 25 appear to protect 
against severe malaria. The availability of 3D-models provides a useful means of 
inferring how such SNPs influence the surfaces properties of the module concerned 
and how this could affect their functions. 
The model of wild-type CCP 25 was downloaded from the CCP module model 
database (http://www.bru.ed.ac.uk/'-dinesh1ccp-db.html) (Soares et al. 2005). The 
mutant version was modelled using the same alignment as used for the wild-type 
model from the large-scale procedure, but substituting the two implicated residues and 
subsequently remodelled using Modeller (Sali and Blundell 1993). 
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Figure 4.11: Interpreting CR1 SNPs in malaria-exposed populations. (a) The upper panel shows 
wild-type (WT) (red) and variant (green) models for CRl-25 as backbone ribbons, with disulfides, 
conserved tryptophan and SNP residues shown in ball-and-stick representation. Figure created using 
SYBYL (Tripos Associates, St. Louis, MO, USA) (b) The lower panel depicts the electrostatic 
GRASP surfaces (Nicholls et al. 1991) of wild-type and haplotypic variants in CR1-25. The region of 
corresponding surface-charge change is shown by the blue line. 
 
The modelled structure reveals that the side-chains of R1601 and K1590 are 
surface-exposed and proximal to one another (Figure 4.11 a). R1601 is located at the 
start of the hypervariable loop, which commonly provides a large, exposed surface 
area for protein-protein interactions (Jenkins et al. 2006) (Section 4.6.4). K1590 is 
located at the N-terminus of the module, one residue before the first Cys (C1591) 
residue in CCP 25. Substitution with Gly and Glu (respectively) will result in drastic 
change in electrostatic properties (a net loss of two positively charged residues and a 
gain of a negative charge) in this region as seen in the modelled variant form (Figure 
4.11b). Additionally, any change in the linker residue KI 590 could alter the junction 
orientation between CCPs 24 and 25. This suggests further mutagenesis experiments 
for understanding the CR1 -PfEMP 1 interaction that would target surrounding surface 
residues. 
Even though increased frequency of phenotypes in African populations 
suggest that epitopes in CCP 25 protect against severe malaria, the interaction site 
between CR1 and PfEMP1 has been mapped directly to functional site 2 - i.e. CCPs 
8-10 and CCPs 15-17 of CR1, with modules 10 and 17 playing a major role (Rowe et 
al. 2000). How then do mutations in module 25, affect the interaction of CR1 and 
PfEMP1 (which lie in CCPs 15-17)? A possible explanation lies in the potential 
flexibility of the 30 module CR1 structure. It is seen in crystal structures of the intact, 
shorter, RCA proteins DAF (Lukacik et al. 2004) and VCP (Murthy et al. 2001; 
Ganesh et al. 2004; Ganesh et al. 2005) that their four CCP modules are arranged 
linearly in a head-to-tail fashion, with not much flexibility between neighbouring 
modules (Chapter 2) - their short linker lengths (3 to 4 amino acids) preclude that. On 
the other hand, however, the existence of a longer eight residue linker between CCPs 
1 and 2 in another complement receptor, CR2, conferred on the module pair a unique 
side-by-side arrangement (Chapter 2) with respect to each other, resulting in a 
shaped" arrangement seen in the crystal structure (Szakonyi et al. 2001; Prota et al. 
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2002). This arrangement between two adjacent modules buries the largest surface 
area for any known module pair (Chapter 2). Other low resolution studies on factor H 
(Aslam and Perkins 2001), also suggested a "bent-back-upon-itself' folded protein, 
made possible through the longer linkers present between modules 10 and 15 (6 to 8 
amino acids). It is thus plausible that in CR1, CCPs 17 and 25 are brought close in 
3D-space facilitated by the long eight-residue linker (longest for any neighbouring 
pair of CCP modules; see Chapter 2) between modules 21 and 22 (Figure 4.12), 
ideally located four modules away from CCP 17 in site 2 and three modules prior to 
CCP 25. 
CR1 
4 5 6 	7 	...8.... 9.......10... 1112 13 14 	.1..16....1.7... 1819 20 21 
Site 1 	 Site 
30 29 28 27 2625 24 23 22 
Figure 4.12: Schematic to illustrate module and linker lengths in CR1. This figure is drawn on a 
distorted scale to emphasise the variation in length among CR1 CCP modules (56-67 residues) and of 
the linkers (3-8 residues) between them. Figure adapted from chapter 2. For convenience the first and 
last residues of a module are defined as Cys 1 and Cys 1v of the consensus sequence, and linkers are 
defined as the sequences lying between Cys of the N-tenTninal module and Cys of the C-terminal 
module. Modules are numbered and functional sites 1 and 2 labelled. Site 2 binds PfEMP1. CCP 25, 
which contains the antigen seen in some African-specific populations, is coloured blue, and the eight 
residue linker length between CCPs 21 and 22 proposed to contain the bend coloured red. 
However, this conformation cannot explain how CCP 25 can be brought into 
close proximity with the other copy of Site 2 (i.e. CCPs 8-10) as to be able to effect an 
interaction? The answer could lie in an "avidity" effect as seen in the case of another 
CCP-containing protein, 02GPI (Cucnik et al. 2004a; Cucnik et al. 2004b; Bozic et al. 
2005; Cucnik et al. 2005). 
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4.3.4 Insights from the model of the first CCP module of human SRPX2 
C 
Cys7 









Figure 4.13: 3D-model of SRPX2, CCP 1. Cartoon representation of the model of CCP1 of SRPX2 
coloured from blue to red (N- to C-terminus). Secondary structure elements have been assigned by 
default settings in PyMol (http://www.pymol.org). The location of the side-chains of the three putative 
disulfide bonds, conserved tryptophan, Y72 and K75 are indicated as stick-representations and labelled. 
The model of the first CCP module of human SRPX2 confirms an additional putative 
disulfide bridge (Cys7l-Cys87), atypical of the classical CCP-module fold (Figure 
4.13). As discussed in previous chapters, among all CCP modules, a loop, highly 
variable in length, sequence and conformation called the hypervariable loop is present 
between the typically occurring strands 2 and 3 (according to the Wiles et al. 
convention for numbering strands; Chapter 2, Section 2.5) (Wiles et al. 1997). 
Depending on its length, this projects laterally from the module and forms an obvious 
candidate surface for protein-protein recognition. Indeed, the hypervariable loop has 
been implicated as a "hot-spot" for several protein-protein interactions and disease-
causing SNPs in other CCP-containing complement proteins (Richards et al. 2003; 
171 
Herbert et al. 2006a; Herbert et al. 2006b; Jenkins et al. 2006). Cys7l lies at the 
beginning of the hypervariable loop that is exceptionally long in CCP1. The 
hypervariable loop is thus forced to form a prominent protruding extension towards 
the N-terminus of the module (Figure 4.13). This feature has not been seen in any 
experimentally determined CCP module to date, nor is predicted to occur in other D-
cluster members (Weyer et al. 2004; Soares et al. 2005) (except SRPX, which contain 
the same number of amino acids between the two additional cysteine residues). It is 
noteworthy, that the stretch of sequence between Cys59 and Cys7 1 does not contain 
any proline residues, and could correspond to a short helical segment, as seen in a 
percentage of module structures in the ensemble of GABABRIU CCP2 (Blein et al. 
2004). 
The Y72S disease-causing mutation (Roll et al. 2006) is largely solvent 
exposed and located within the hypervariable loop, adjacent to Cys7l that participates 
in the non-typical, third, disulfide (Figure 4.13). This change from a large aromatic 
side-chain to a small, polar one at position 72 will have a profound effect on the 
surface properties of this region that is close to the aforementioned prominent 
protrusion - so an effect on function of such a mutation is plausible. The R75K 
mutation is located nearby, within the protrusion, and its side-chain is exposed (Figure 
4.13). It is reasonable to suggest that the unique structural feature formed by the 
hypervariable loop of CCP1 performs some role that is specific to the protein. 
Presumably, it is not a coincidence that it is also the site of a human-specific change. 
An R75K substitution is a conservative one; the substitution of one exposed, 
positively charged residue for another can easily be accommodated by small atom 
shifts in surrounding side-chains, and is not likely to affect the structure of the CCP 
module. Such a change might have a small but not a dramatic functional effect. 
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Hence it fits well with positive selection, according to the neo-Darwinian view of 
evolution, as it would lead to a small step rather than to a giant leap (Wyckoff et al. 
2000). Moreover, conservative R-to-K and K-to-R substitutions can result in the 
altered properties of either secreted proteins (Higuchi et al. 1991) or the extracellular 
domains of some plasma membrane proteins (Vinson etal. 1996; Rodien et al. 1998), 
including a member of the selectin family (Erbe et al. 1992). 
There exists an N-terminal 34 amino acid sequence prior to the first CCP 
module (Figure 4.3a). Its conformation and location with respect to K75 and Y72 is 
speculative and hence cannot be commented upon. 
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4.4 Concluding remarks 
The utility of the homology-based models for interpretation of various evolutionary 
and disease-associated polymorphisms is evident from this exercise. Another 
example where application of the created here models have proven useful, but in work 
by others, was in site-directed mutagenesis experiments guided by the models in 
delineation of the binding site (functional site 1) in CR1 (Krych-Goldberg et al. 
2005). More recently, the individual CCP-module models from CR2 deposited on the 
website were used to discern the potential overall arrangement of its 15 CCP modules 
in solution, using a combination of X-ray scattering, and analytical ultracentrifugation 
(Gilbert et al. 2006b). Several potentially interesting cases for use of models among 
other non-complement CCP-module-containing proteins remain. An example is the 
interaction of the sole CCP module in neurocan with a glycosaminoglycan and its 
consequences for Ll-binding which was previously reported (Oleszewski et al. 2000). 
A surface representation of its CCP-module model revealed a large basic patch, with 
intriguing possibilities for interactions with GAGs. Another demonstration of model-
application could involve the prediction of complement regulatory sites within the 
giant protein CSMD 1 in rat (Kraus et al. 2006) - its human homologue has the same 
domain architecture. 
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Structural and functional insights from models of C5 
and C5b: insight into the latter stages of complement 
assembly 
5.1 Introduction 
5. 1.1 Background 
Central to the complement pathway are three large, paralogous, plasma proteins C3, 
C4 and C5. How the clear functional distinctions amongst this set of paralogues 
relate to their differences at the structural level is not known. Structural knowledge of 
these large proteins had, until recently, been limited to the 8-kDa C3a (Huber et al. 
1980) and C5a (Zhang et al. 1997) fragments, the '-'38-kDa C3d (Nagar et al. 1998; 
Szakonyi et al. 2001) and C4d (van den Elsen et al. 2002) fragments (that are cleaved 
from C3b and C4b respectively), and the —18-kDa C345C domain of C5 (Bramham et 
al. 2005b). Even though crystallisation of CS was reported (Discipio et al. 1998), no 
structure has been forthcoming. In the then absence of complete 3D structures of any 
of C3, C4 or C5, some previous attempts to assign specific amino acid residues to the 
various protein-protein interaction sites were based on sequence comparisons. This 
approach focussed on the identification of regions of insertion or deletion - i.e. 
"indels" - between C3, C4 and CS (Section 5.3.3). In addition, several binding sites 
on C3b for factor B, properdin (Daoudaki et al. 1988) and the RCAs (factor H, CR1) 
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(Lambris et al. 1988; Oran and Isenman 1999) were suggested on the basis of 
mutagenesis and peptide studies. Recently, hydrogen/deuterium exchange and mass 
spectrometry was used to map regions of conformational change that occur upon 
transition of C3 to C3(H20) (Winters et al. 2005). 
The recent landmark publications of the 3D-structures of human C3 and C3b 
(Janssen et al. 2005; Abdul Ajees et al. 2006; Janssen et al. 2006; Wiesmann et al. 
2006) now shed considerable extra light on these previous peptide-based and 
mutagenesis results. In particular the new structures provide the opportunity to 
construct 3D structural models of CS and CSb that can be used to reanalyse many of 
the previous functional studies of this protein. C3, C4 and CS have similarities in 
their subunit and precursor composition, protease sensitivities, and other properties, 
which suggest that they possess very similar 3D structures despite having distinct 
functions and binding specificities (Low et al. 1999). Thus, even though complement 
C5 lacks the thioester moiety, it might adopt a 0-like overall native fold. This 
notion is borne out by experiments where mutation of the thioester moiety in C3 
resulted in it retaining its native-like C3 conformation (Isaac et al. 1998). Various 
low-resolution experimental evidence for CS (DiScipio et al. 1983), and other 
modelling-based lines of evidence (Janssen et al. 2005; Fredslund et al. 2006; Janssen 
et al. 2006) suggest that even the more distant homologues, host-defence-like o2-
macroglobulin (a2M) proteins, exhibit similar ultrastructure, domain arrangements, 
and conformations to those of C3. Thus, the C3 and C3b structures would appear to 
represent good templates for homology modelling of CS and C5b. 
In this chapter, the modelling by homology of CS and CSb is described along 




models of C4 and C4b have also been created, although this are not discussed here. 
All the models (C4, C4b and C5, C5b) are available online. 
5.1.2 The a2-macroglobulin (a2M) family 
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Figure 5.1: Domain organisation of the a2M family deduced from the C3 structure. Members of 
the a2-macroglobulin (a2M) family are shown schematically; TEPs = thioester-containing proteins; 
other abbreviations as in Table 5.1. The family is characterised by homologous sequence features, 
including a unique thioester motif "GCGEQ" (absent in CS and some TEPs (Blandin and Levashina 
2004)). The domain organisation of C3 and CS are identical. The differences among the remaining 
members are highlighted. Native C4 has an additional tetra-arginine (RIRRR) processing site that 
occurs in an insert of 46 residues (within MG8, see alignment in Figure 5.4). CD109 (Solomon et al. 
2004) has a tetra-arginine site in the linker between CUB and MG8. Only C3, C4 and C5 have the 
C345C domain since a2M and TEPs lack this domain, and CD 109 has a GPI-anchor instead. Figure 
created on the basis of Janssen et al. (2005). 
Complement component C3, C4, and CS belong to the a2-macroglobulin (a2M) 
family, whose other members include the proteinase inhibitor a2M, the insect and 
nematode thioester-containing proteins (TEPs), and CD 109 (Figure 5.1). These 
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proteins (1400 - 1800 amino acid-residues) are characterised by homologous 
sequence features, including a unique thioester motif (not present in C5 and some 
TEPs); and they have important roles in the immune response in metazoans, predating 















C3: 187 kDa 
5.1.3 Structural insights gained from C3, C3b and C3c 
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Figure 5.2: Structures of human C3, C3b and C3c. (a) Cartoon representations of native C3 (13 
domains) (PDB ID: 2A73) (left panel) (Janssen et al. 2005), C3b (12 domains) (PDB ID: 2107) (middle 
panel) (Janssen et al. 2006), C3c (10 domains) (PDB ID: 2A74) (right panel) (Janssen et al. 2005) are 
shown and domains coloured [MG-domains (cyan), ANA (red), LNK (dark green), TED (purple), CUB 
(light green), C345C (yellow)]. (b) The schematic domain arrangements in C3, C3b and C3c are 
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shown. C3 was found to contain multiple immunoglobulin-like domains that have been called 
macroglobulin (MG) domains. Upon cleavage, C3 undergoes conformational changes to C3b and C3c. 
Domains in C3b and C3c exhibit almost identical conformations with each other, when compared with 
C3 (Wiesmann et al. 2006). (c) Shown on the linear sequence/domain arrangement is the thioester site 
(white triangle) in TED, disulfide bridges, glycan positions and cleavage sites (see text). Sequential 
proteolysis from C3 -* C3b -* C3c is indicated. MG6 intertwines the - and u-chain of mature C3; 
while CUB is also formed from intertwined regions (named 	and CUB). Figures created on the 
basis of (Janssen et al. 2005; Janssen et al. 2006). 
Domain PDB Chain Domain residue range 
MG1 A 1-104 
MG2 A 105-209 
MG3 A 210-328 
MG4 A 329-426 
MG5 A 427-534 
MG6P A 535-577 
LNK A 578-645 
ANA B 650-726 
ct'NT B 727-745 
MG6a B 746 -806 
MG7 B 807-911 
CUBE B 912-962 
TED B 963-1268 
CUB B 1269-1330 
MG8 B 1331-1474 
Anchor B 1475-1495 
C345C B 1496-1641 
Table 5.1: C3 domains and boundaries. Domain lengths for C3 as deduced by (Janssen et al. 2005) 
from the structure (PDB ID: 2A73) - Chain A: 1-645, Chain B: 650-1641 (Figure 5.2). Abbreviations 
used in table: MG = macroglobulin; LNK = linker; ANA = anaphylatoxin; NT = N-terminal; CUB = 
domain first found in Cir, CIs, uEGF, and bone morphogenetic protein; TED = thioester-containing 
domain; C345C = domain present in human complement components C3, C4 and CS. 
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The 3D structures of C3, C3b and C3c were recently determined (Janssen et al. 2005; 
Abdul Ajees et al. 2006; Janssen et al. 2006; Wiesmann et al. 2006), providing the 
first insights into the native overall arrangement of a2M family members. The two 
chains of C3 - a 13-chain made up from residues 1-645, and an a-chain made up of 
residues 650-1641 - together form 13 domains. In C3b, 12 domains are present within 
a complete 13-chain and an a-chain that lacks the ANA domain (ANA gets cleaved off 
as C3a). C3c on the other hand consists of three chains; the 13-chain, and two 
fragments of the a-chain (TED and CUB are cleaved off from C3b) that form ten 
domains (Figure 5.2). 
From the C3 structure (Janssen et al. 2005) it can be seen that one of the 
domains is formed by parts of both the 13- and a-chains (Figure 5.2, Table 5.1). In 
addition, each chain forms six domains by itself. Out of these, eight domains (5.5 of 
13 and 2.5 of a) show a fibronectin-type-3-like (immunoglobulin-like) core fold, even 
though there is no sequence homology apparent amongst them. These domains were 
termed macroglobulin (MG) domains and form a f3-ring like scaffold. Residues 1-534 
form five MG domains (MG1-MG5) and residues 535-577 form one half, denoted 
MG6, of a 13-chain!a-chain intertwined MG6 domain. Finally, residues 578-645 of 
the 13-chain form a linker domain, termed LNK. The a-chain begins with (residues 
650-726) the anaphylatoxin (ANA) domain (which when cleaved off forms the C3a 
fragment). Loop 727-745 connects ANA to MG6, and forms the N-terminal region of 
the cleaved (in C3b) a-chain, a'NT. Residues 746-806 form MG6', which 
complements MG6. This is followed by MG7 (residues 807-911). The polypeptide 
chain that may be excised by factor I to yield the 40-kd fragment C3dg and 2-kd 
fragment CH is located between MG7 and MG8 (residues 1331-1474). The cleavage 
sites that yield C3g, CM and C3f (Harrison and Lachmann 1980; Lachmann et al. 
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1982) do not fully coincide with domain boundaries. Residues 912-962 and 1269-
1330, i.e. 63% of C3g and all of Of, contribute two halves (approximately) of one 
CUB domain and have been named CUB9 and CUBE, respectively. The remaining 
parts of C3g and C3d (residues 963-1268) together form the thioester-containing 
domain (TED). Finally, residues 1496-1641 form the carboxy-terminal C345C 
domain. This domain is covalently linked to MG8 by the polypeptide chain and to 
MG7 by a disulfide bond (Thomas et al. 1982), in what was called an anchor region 
(residues 1475-1495). In total, nine of the thirteen domains were unpredicted (MGI-
MG7, LNK and CUB). All the domains together formed an irregular shaped C3. 
The structures of C3b (Abdul Ajees et al. 2006; Janssen et al. 2006; Wiesmann 
et al. 2006), revealed the conforrnational changes that accompany loss of the ANA 
domain to expose multiple-binding sites for factor B and RCA proteins previously 
hidden in intact native C3. In these structures, the thioester in TED is completely 
exposed for covalent attachment to target surfaces. It lies 80 A away from the 
buried site in native C3, since the TED has been relocated to the bottom of the MG-
domain n-ring (Figure 5.2). Significant further domain rearrangements (that result in 
loss and gain of domain-domain interactions in C3b) accompany activation 
particularly in the a-chain; while the 3-ring like scaffold remains almost intact 
(Figures 5.2a, 5.2b). In one of the published C3b structures (Abdul Ajees et al. 2006), 
however, there occurs a marked loss of secondary structure and unfolding of the CUB 
domain (not shown). Following cleavage of CUB and TED, to form the C3c fragment 
structure (Janssen et al. 2005), no major additional conformational changes are seen 
(Figure 5.2b), indicating that the main conformational rearrangements occur in the 
first activation step from C3 to Ob. Apart from the relocation of TED, MG7 and 
MG8 almost swap places in the overall structure; the C345C domain swivels 32 and 
moves 10.1 A; and the anchor region alters its conformation from an u-helix in C3 to 
a 3-hairpin in C3b and C3c (Janssen et al. 2005). 
5.2 Materials and Methods 
5.2.1 Template selection and sequence alignments 
Three-dimensional modelling of the amino acid sequences of human C5 (SWISS-
PROT entry: C05 HUMAN), was based upon two templates: the intact native human 
C3 crystal structure [PDB ID: 2A73 (Janssen et al. 2005)]; and the solution structure 
of the closest-to-mean C5-C345C domain, model 13 from PDB ID: 1XWE (Bramham 
et al. 2005b). The experimentally solved structure of isolated C5a (Zuiderweg et al. 
1989) was not employed on the grounds that the structure of its equivalent, free C3a, 
did not match to the structure of C3a in the context of intact C3. The C345C domain 
was inferred to be a more independent unit, exhibiting few interactions with other 
domains in C3. 
For modelling C5b, the crystal structure template PDB ID: 2107 (Janssen et al. 
2006) of unliganded C3b was employed, along with the C5-C345C domain. This 
unliganded C3b structure, was solved at higher resolution (PDB ID: 2107; 4 A) than 
the liganded structure determined by Wiesmann et al. (PDB ID: 2ICF; 4.1 A) and was 
hence the preferred template. Both these C3b structures exhibit almost identical 
conformations (Nishida et al. 2006). The aberrant C3b structure, PDB ID: 2HRO 
(Abdul Ajees et al. 2006), which exhibits a different conformation to 2107 and 2ICF, 
was ignored for purposes of the modelling work. 
The optimal target-template alignments were based upon initial multiple 
sequence alignments from Ogata and Low, 1998; Levashina et al., 2001 and 
Bramham et al., 2005 (Ogata and Low 1997; Levashina et al. 2001; Bramham et al. 
2005b). The alignment was subjected to further manual editing, guided by secondary 
structure as defined on the basis of the C3 crystal structure (Janssen et al. 2005) or 
predicted by PsiPred (McGuffin et al. 2000) for the target C5 sequence, in order to 
place conserved amino acid residues, and indels, most appropriately. 
5.2.2 Comparative modelling, evaluation and data analysis 
Figure 5.3: Overlay of templates for model building. The experimentally determined C5-C345C 
domain (blue) superposed on C3-C345C (red) using all equivalent secondary structure elements under 
INSIGHTII (Accelrys Inc., San Diego, CA, USA). This overlay ensures that during model building, 
the same inter-domain orientation is preserved in the model of C5. The C5-C345C domain is modelled 
upon itself and reflects the original experimentally solved structure. 
For modelling of C5, the previously solved solution structure of the recombinantly 
expressed C5-C345C domain was first superposed on C3-C345C (Figure 5.3), as it 
appeared in the crystal structures of C3, using all equivalent elements of secondary 
structure, under INSIGHT II (Accelrys Inc., San Diego, CA, USA). An equivalent 
operation was performed for modelling of C5b. This ensures that the relative 
orientation of this domain as observed in C3 (or C3b) is potentially preserved (fixed) 
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during subsequent model building of C5 or C5b. The C5-C345C (C5b-C345C) 
domain structure was then simply modelled upon its self, i.e. the original NMR-
derived solution structure. The appropriate inputs, including the PDB template files 
and the optimal target-template alignments, were provided to the comparative 
modelling program, Modeller release 8 version 1 (Sali and Blundell 1993). 
The twenty-six cysteine residues conserved between C3 and C5 that formed 
thirteen disulfide bridges in C3 were automatically restrained and created for C5 
during model building. Twenty models were generated, and the one with the lowest 
objective function score (Sali and Blundell 1993) selected as the representative model. 
It was noticed in this representative 3D-model that, apart from the expected thirteen 
disulfide bridges (as occur in the C3 structure used as a template), two additional 
cysteine residues (Cys838 and Cys865) occur close in space on neighbouring 
antiparallel 3-strands within the MG7 domain. The orientations of all side-chains in 
the representative model of the target, that are not identical to equivalents in the 
template structure (including the two abovementioned cysteine residues) were 
optimised using the side-chain replacement program SCWRL version 3 (Bower et al. 
1997; Canutescu et al. 2003). This automatically detected and created an additional 
disulfide bridge in the C5 model. 
The model of C5 was then protonated under SYBYL version 6.9 (Tripos 
Associates, St. Louis, MO, USA), and subject to brief energy minimisation employing 
the Tripos forcefield (Clark et al. 1989) using 100 steps of the Powell algorithm (the 
C5-C345C domain residues 1514-1658 were excluded from this) to remove clashes 
and bad geometries. 	The model structure was finally checked for valid 
stereochemistry using PROCHECK version 3.5.4 (Laskowski et al. 1993) (Table 
5.2a). Additionally, the packing quality of individual domains was checked using 
WHATIF (http://swift.cmbi.kun.nl/WIWWW1/) (Vriend 1990; Vriend and Sander 
1993) (Table 5.2b). An analogous set of procedures was employed to build and 
evaluate the model of C5b. 








C5 model 83.1% 14.1% 1.8% 1% 
C5b model 83.5% 13.2% 2% 1.2% 
(B) Domain Average packing quality 
control score in CS (C3) 
Average packing quality 
control score in C5b (C3b) 
ANA -1.667 (-1,946) Absent in C5b 
MGi -2.364 (-1.856) -1.962 (-0.895) 
MG2 -1.476 (-0.970) -1.258 (-0.626) 
MG3 -1.221 (-1.042) -0.991 (-0.627) 
MG4 -2.117 (-1.862) -2.095 (-1.535) 
MG5 -1.746 (-1.352) -1.558 (-0.861) 
MG6 -1.742 (-1.311) -1.498 (-1.106) 
MG7 -1.278 (-0.786) -1.423 (-0.955) 
MG8 -1.207 (-1.090) -1.585 (-1.162) 
CUB -2.000 (-1.209) -1.959 (-1.416) 
LNK -2.538 (-2.527) -2.336 (-2.407) 
TED -1.461 (4936) -1.333 (-1.054) 
C345C -1.324 (4889) -1.354 (-0.972) 
Table 5.2: Quality analysis for models. (a) 'Ihe PRUUHLUK. Kamachanclran plot statistics are given 
for the models of CS and C5b. (b) The average packing quality score for each domain in the models 
of CS and C5b, and the corresponding templates (in brackets), are reported. To place the values in 
context, a molecule is certain to be incorrect if the score is less than -3.0. Poorly refined molecules, 
extensively energy minimised misthreaded molecules, and low resolution homology models give 
values between -2.0 and -3.0. The average quality control score obtained by 200 highly refined X-ray 
structures was -0.5 ± 0.4 (Vriend 1990). The two halves of MG6 and CUB were evaluated together. 
Electrostatic surface representations were created using GRASP (Nicholls et al. 
1991). Lipophilic surface representations were created using MOLCAD (Heiden et 
al. 1993). 
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5.2.3 Domain-domain interaction identification and analysis 
Domain-domain interactions were compared between the crystal structure of C3/C3b 
and the modelled structures of C5/C5b. First, domain-domain interactions were 
identified for both the template and model structures using the program, Structural 
Classification of Protein-Protein Interfaces (SCOPPI) (Winter et al. 2006). Identified 
interacting domains were subsequently extracted individually, saved into separate 
PDB files, and then converted into their corresponding PQR format employing the 
PDB2PQR version 1.0.1 server (Dolinsky et al. 2004) (http://nbcr.sdsc.edu/pdb2pqr/)  
using default parameters. PQR files are simply PDB files where the occupancy and 
B-factor columns have been replaced by atom charge and radius. The PQR files for 
each interacting pair of domains were then submitted to the MolSurfer server 
(http ://proj ects.villa-bosch.de/dbase/molsurfer/submit-elec.html) (Gabdoulline et al. 
1999; 2003) and analysed using default parameters. 
MolSurfer links the 3D structure of a protein-protein complex to a 2D 
projection map using graphical outputs. Interface properties, including electrostatic 
and hydrophobic interactions, are projected to the two, symmetrical, 2D interface 
maps, and cross-correlation coefficients of surface properties between these two 
interface maps are then calculated. Because electrostatic and hydrophobic 
interactions are considered to be major factors that stabilise complexes, Molsurfer is 
particularly helpful in exploring complementarities at macromolecular interfaces 
(Gabdoulline et al. 2003) - cross-correlation coefficients of the mapped interfaces can 
be computed for electrostatic and hydrophobic components; these are ideal for 
comparison. Thus MolSurfer was used to calculate the "electrostatic correlation 
coefficient" (ECC) and "hydrophobic correlation coefficient" (HCC) for each 
domain-domain interaction in the C5/C5b models, and likewise for the corresponding 
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interactions in C3/C3b. In addition, the buried surface area (BSA) was calculated for 
each pair using the GETAREA version 1.1 server (http://www.scsb.utmb.edu/cgi-
binlget_a_forrn.tcl) (Fraczkiewicz and Braun 1998). The BSA was calculated as: 
[(SA domain  ) + (SAd0mauh12)I - (sAdomahhhl2); where SA = surface area; SAd0mah1l2 
surface area of combined domain-domain pair). 
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5.3 Results and Discussion 
5.3.1 Domain composition and organisation of C5 and C5b 
Inc/el I 
CO3-HUMAN 	1 -SPMYSIITNILRLESTMVLEABDAI-QGD-VPVTVTVHDFGKKL-VLSEXTVLTP 
C048-HUMAN 1 -KPRLLLFSDSVVBLGVPLSVGVQLQDVPRGQWVXGSVFLRN- SRN-NVPcPKVDFTL 
COS-HUMAN 	1 QEQTYVIsAIFRVGASENIVIQVYGr--EDATISIKSYD1UcFSY-SDGHVHL--  
Inde/2 	MGI 
CO3-HUMAN 	57 ATNN-MG-NVTFTIPANEFKS ----------- EKGRNKFVTVQATFG-TQVVEKVVLVS 
CO4B_MUMAN 58 SSERDTA-LLSLQVpL-1DAKSCGLHQLLRGPEVQLVAHSPWLKDSLS(TTNIQGINLLF 
C05 HUMAN 	56 SSENKTQNSAILTIQP-1cQL ----------- PGGQNVSYVYLEVVSKNFSKSKRMPITY 
Inc/el 3 
CO3 HUMAN 	103 
C04B_HUMAN 116 SSRRN 
C05-HUMAN 	104 DN--F 
CO3 HUMAN 	162 NQLG-VLPLSWDFjLVNMQ 	RYYENSPQQVFSTE 	E 	•SEVETEXT 
C04BHUMAN 176 SS---IFQDDFISEPTSRFSDGLESNSSTQ EKITGKPY 
C05 HUMAN 	160 DHIGIISFPDFNPRY 4 TRKKYKDPSTTGTAY 	E 	HSSIEEYNF 
Indel4 	 MG2 
--- 
0O3 HUMAN 	221 YYIJY--NEKGLEVTET 	 EGTAFVIZIQLI IQ:_.EQRISLPEsLKRIPIED 
C04B HUMAN 233 ILVPG18LDMQLDQ YIGP-QGVAYV 	LLDE--GKKT9'SRGLESQTKLVN 
C05_HUMAN 	220 IG4X--)FKNFEITfl YFNVTEADVYIT IRDLCDQKEMMQTAMQNTMLIN 
Inc/el 6 	MG3 
CO3 HUMAN 275 SGEVVLSRKVLLDGVQNiL--RE OKS 	SATVLHSSDMVIQF;GIPI4UT
VJ 
 T YQ 
C042-HUMAN 290 QSHXSLSKAEFQDALEK'LNMGIT. QGL AAAIBESPGEMEESWYSS s's
C05EUMAN 	278 IAQVTFDSETAVLSYfr--SLK. NKY IAVTVESTGFSEEPGIKYL •yx 
Inc/el 7 
CO3 HUMAN 	333 I'TKPKYFKMFDI.MVFNPDGSPAYRAi VQG;ITV'QGDGVAKLSINTH 
CO4B_NUMAN 350 LDLSKKRHLVALLQALRKMSGSPASGKVSAVS-1-SPcSVPEVQDIQQNTD 
C05_RUI4AN 	336 LNLVASPLFLK IYPIKVQKDSLDQIVGCILNAQTIDVNQTSDLDPSKSVTRV 
MG4 	 Indel/i 
CO3 HUMAN 	393 P-SQKPLSITVRTXKQESEAE-----------QTRTMQLPiYTVGNSNNYHLSVLR 
C04BHUMAN 408 
C05-HUMAN 396 
Inc/el 9 	 Inc/el 10 
CO3 HUMAN 	441 
C042-HUMAN 461 	 1 	ITYff 	I 
C05_NU14AN 454 
7cielI1 	MG5 
CO3 HUMAN 499 ITTOFI' LVATLIASRZADDVWVDVKD-
UELSVDG--AKQYRN 
KSGQSEDRQPVPQ 
CO4B_HUMAN 514 VDHHL 	FYFVAFYH-D---i-H9ANflLRVDVQAG
CO5HUMAN 	512 VTQNM SRLLVYIVTEQ-1AEDSD6VWLNIEE- NLSP-DADAYSPQ I 	I 
- - Inc/el 12 	 MG6 
CO3 HUMAN 558 
QMI..A  
KXEGDR 	.xGvFvLNxNg--LrQsxIwDvvExAEI TPESKDYAG 
C04BHUMAN 567 SVHLETDSLAL G L.TALYAAGKSlKPLNMGKVFtAMNSY•L GPGDSALQ
COS_HUMAN 	569 TVNMATGMDSW 	.SAVYGVQjGA(KP--LERVFQFLEKS.T GAGLNNAN 
LNK 
CO3 HUMAN 	616 	SD 	 K 
C04B_HUMAN 627 Q QSDGD-QWTLSPKRLSPKEKTTKKNVNFQKAINEKLGQAS2IAK Q 
C05 HUMAN 	627  	Y 
CO3-HUMAN 674 	 INYITERQNARASHLGASN---LD 
C04E_HUMAN 686 QFAESKKSRDKGQAGQALEILQE 
C05-HUMAN 	683 	 VVASQANISMK-DMQG ---- LNM 
Inc/el 13 	 ANA 	Inc/el 14 
CO3-HUMAN 731 EDIIEZNIVSEI 	 _LAVS)DK 
C04B_HUMAN 745 EDILIEDDXPVF NRKTVDR-------iFQILTLWP. L_HGLSLKT 
C05-HUMAN 737 KLLVSKPEIIY 	 LVPR------RXQLQ?AP. 	QGIGXN- 












CO4B_HUMAN 798 KL 	TPVQLRFREFHLMLRLM RFLELRPVL 	LD-KNLTVS}lVSPVEGL 




CO3_BUMAN 	851 SLAT 	- TKRHQQTMTIPPK6SLSPYVIVLKTGLQEVEVKAAVYHHFISOG 
C04B_EUMAN 857 LAGG--------- 
C05-HUMAN 848 
- - - 
1nLI I5 
CO3 HUMAN 	903 VRS2KVVP IRMNKTVAVRTLDRLCEGQKEDIIPADLSDQ DTESETRILLQG 
C04B_WUMAN 908 VSVQINI( AINREELVYELNP---LDRG-4RTLEX GNSOPNMI DGDFNSYVRVTA 
C05_HUMAN 	905 LVTRVVP - VKRESYSGVTLDPRGIYG'TI-RRKEF YRIPLUL KTEXKRILSVKG 
	
I 	 - 
I/1/E/ 17 
CO3 HUMAN 	963 -TPVAQMTEDA- 	RLKHrPIVTS CjG11 NMIGMTTVIAVH DETEQEKF--L 
C042_HUMAN 964 SDPLDTLGSEGLS1PGCVAS,LRL RCTMIYLATLAASP. oKTEQSrL---Bp 
C05_HUMAN 	964 LL--VGEILSALOQECIN
I 	 am 
LK SELMSVVVFYVFH ETGNHNIFISDL 
CO3 HUMAN 1018 EKRQGALELIKKYTQQLAFIQPSSAFAAFV APF_PyYVVKFSLAVNLIAIDSQV 
C04B_HUMAN 1021 ETKOHAVDLIQKYMRIQQF 
C05 HUMAN 1022 IEKQKLXKKLKEMLSIMSYNADYSYSVWKGGSA1 4'FALRLGQVNKYVEQNQNS 
CO3-HUMAN 1078 LCGAVKILEKKPDVDQEDAPVIHQEMIC0RNNN-EKDMA 	
V 
AKDIC 
C04B_NUMAN 1081 	 GLAVF 
C05 HUMAN 1082 T AFOIC 
1 - 	 --,.------- 	 -- 
Inc/el /9 TED 
CO3-HUMAN 1137 EEQ-- i---VNSLPGSITGD EANYMN-LQRSYTV 	0 	Q MGR --- LKGPLLNK 
CO4B_HUMAN 1138 QDEGAEPI4KQRVEASISNS GEKASAGLLGAHAA T $LTKAPVDLLGVAHNN 
C05_HUMAN 1142 ------4PIjV-KIDTALID 	LENTLP-AQSTFTL S 	SLGDKTBPQFRSIVSA 
mdcl 20 
CO3 HUMAN 1188 FLTTEDKNR------E0- -------------------DG-KQLYNVDAS&AL
CO4B_HUMAN 1198 
C05 HUMAN 1194 LKRELVKGNPPIYRFK0N--QHKDSS -----------VTGTARNVT  
CO3 HUMAN 1219L
LX-DINYVNPVI SEEQRYG 
LK-DFDFVPPVVR NEQR'IYG Y 	• 
I
FMVFQARAQQKDAPDHQELNLDVSLQ 
C04B HUMAN 1254 	HEGKAEMADQASATRQGSFQ 	•DVIALUA5SAWIASHTTEERGLNVTLS 
C05-HUMAN 1241 E Y •DINAIEGTESLLVKQLR-LSMDIDVS 
CO3 HUMAN 1278 LPSRSSKITERINWESAS-LLRSETKEN---EGFTVTAEKGQGI.SVTMYEAKAKDQ 
C 04B_HUMAN 1314 STGRNGFKSBALQLN-NRQXRGLEELQFSLGSKINVKVGNSKGLKLRTYNVLDMKN 
C05-HUMAN 1299 YKNX_GALHNYKNTGKN-FLGRPVVLLN0--DLIVSTGFSGLAEVHTTVVHKTSTSE 
CUBt 	 Indel2I 
CO3_HUMAN 1334 LTNKFDLKVTIKPAPETEKP -------------------------------------- 
C04B_HUMAN 1373 TTQDLQIEVTVKGHVEYTMEiANEDYEDYEYDELPAKDGPDAPLQPVTPLQLFEGRRNRRI 
C05-HUMAN 1355 EVS-FYLKIDTQDIEASHYNG -------------------------------------- 
------7TcTeT!2 	-
J CO3HUMAN 13561 --------DAKNTMILErTRyRGoQD----:-ATMsILIsMMTFAPoT ,
- - - - 
J 
- - -  
D. KQANG 
C04B_HUMAN 1433 	 . EKTSL 
C05-HUMAN 1376;-------- 	 KAVEG 
Inc/el 23 	MG8 
CO3 HUMAN 1403 
C043_HUMAN 1489 
V. RYISKYELDKAFSDRI; I TL 
IYLD. S. 
[DD 	V.Q.IIVFPNI. 1§GAVKMYN 
COS_HUMAN 1428 V.QLFTDYQIKDG ----- 
Inc/el 24 - - 	 Inc/el 25 














C04B_HUMAN 1543 PERRSV 	 YY 
COS_HUMAN 1483 PDKQTM 
L' 
anchor 
CO3-HUMAN 1518 GVDVYKTRLVKVQLSNDDDEYIMAIEQTIKSGSD-EVQVGQQRTDISPIKREALKEE 
C04B_HUMAN 1603 RVEGFQVKVLREDSRAARLFETKITQVLHFTKDVKAAANQMRNDLVRASR--LREP 
C05-HUMAN 1538 EIAAYKVSITSITVENVVKYKATLLDIYKTG-EAVAEKDSEITDIKKVTTNAEVK 
IndeI26a 	Inc/el 26b 	I7deI27 
CO3 HUMAN 1577 KKH EDE 
C043-HUMAN 1661 OKE 	 fS'ETENQ.""IA----Q







QIK NFSF 	 -----QAFLAND 
C345C 




C05-HUMAN 1648 EAEDIFLN -- 
Figure 5.4: Sequence alignment between C3, C4, and C5. The optimal structure-guided sequence 
alignment between C3 (SwissProt entry name: CO3 HUMAN), C4 (SwissProt entry name: 
C04BHIJMAN) and CS (SwissProt entry name: C05 HUMAN), as used for modelling, is shown 
using BOXSHADE version 3.21 (http://www.ch.embnet.org/software/BOX—form.html). It should be 
noted that two polymorphic C4 sequences exist - C04A_HUMAN and C0413—HUMAN (Yu et al. 
1986); the latter is more common. Completely conserved (dark shading) and conservatively substituted 
(light shading) residues are depicted on the alignment; domain boundaries are also indicated and 
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labelled (Refer to text for abbreviations). The indels proposed on the basis of the original (pre-
structure) alignment (Ogata and Low 1997; Ogata etal. 1998; Low etal. 1999) are also indicated. 
Domain Chain CS domain residue 
range 
C5 vs. C3 domain-domain 
% sequence identity 
MGI A 1-105 18% 
MG2 A 106-208 36% 
MG3 A 209-331 32% 
MG4 A 332-440 23% 
MG5 A 441-546 30% 
MG6P A 547 -588 29% 
LNK A 589-655 31% 
ANA B 660-733 34% 
aNT B 734-751 22% 
MG60' B 752 -804 45% 
MG7 B 805-913 29% 
B 914-963 20% 
TED B 964-1290 29% 
CUB B 1291-1351 22% 
MG8 B 1352-1494 25% 
Anchor B 1495-1513 32% 
C345C B 1514-1658 29% 
'[able 5.3: CS domain boundaries and comparison witn Li. uomam iengtns ior 	as uewrmizieu 
from the alignment in Figure 5.4 - Chain A: 1-655, Chain B: 660-1658. The percentage sequence 
identity between individual domains in C5 and C3 was derived using the percentage identity matrix 
option under ClustalX (Thompson et al. 1997). The overall percentage sequence identity between C5 
and C3 is 29%. 
That the domain composition of C3 is conserved in CS is evident from the sequence 
similarity between the two proteins (sequence identities at the domain-level vary from 
18% in MGi to 45% in MG6') (Table 5.3). CS consists of two chains, 0 (residues 1 - 
655) and a (residues 660 - 1658) that, unsurprisingly, fold, with error-free packing 
194 
scores (Table 5.2b), into the same 13 domains in the modelled structure as were 
described for C3 (Table 5.1). The modelling protocol dictates a similar organisation 
of domains in the model to that of the template. It is noteworthy, however, that the 
crystal structures showed C3 and its major fragments C3b and C3c to significantly 
differ in the spatial configuration of the 10 component domains they have in common 
(Figure 5.2). This evidence for conformational versatility suggests that the spatial 
arrangement of domains within CS could, in principal, differ from that of C3. To 
assess the likelihood of this possibility, and as an additional test of the quality and 
reliability of the new CS model, the interfaces between the 13 domains of the 
modelled structure were compared to the equivalent domain-domain interfaces in C3 
with respect to the extent of buried surface area, and conservation of favourable 
contacts (Figure 5.5). 
As in C3, the 13-chain is made up from five-and-a-half MG domains and a 
LNK domain (see Section 5.1.3). The a-chain is made up from the ANA domain 
(which upon cleavage forms the C5a anaphylatoxin domain), a short a'NT region, 
two-and-a-half MG domains, a TED and a CUB domain. Its C-terminus consists of 
an anchor region followed by the C345C domain. Thus, one MG domain (MG6) is 
formed from parts of both the a- and 13-chains; critically, in the CS model these two 
parts bury approximately the same large surface area and make contacts that are 
equally as favourable as those in the C3 crystal structure (Figure 5.5). The CUB 
domain in the a-chain is also composed from two parts, with the TED domain inserted 
between them; again, the two parts interact just as favourably as in C3. Many of the 
other interdomain interactions within the CS structure likewise match their 
counterparts in C3, while the exceptions might reveal any differences in the 
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MG60 20 30 
LNK 9 16 26 	28 33 
oNT 32 
MG6a 19 23 29 34 8 	2 
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CUBg 14 38 
TED 43 7 
CUBf 12 37 5 	42 
MGS 21 25 39 6 	 3 
Anchor 35 4 	 40 
C345C 36 41 
Figure 5.5: Domain interface analysis for C5, C3 and C51i, C3b. In each panel (A and B), the 
electrostatic correlation coefficient (ECC) (top panel), hydrophobic correlation coefficient (HCC) 
(middle panel) (Gabdoulline et al. 2003) and buried surface area (BSA) (lower panel) (Fraczkiewicz 
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and Braun 1998) for all interacting domain-domain pairs in (a) C5 (blue symbol) vs. C3 (pink 
rectangle) and (b) C5b (blue symbol) vs. C3b (pink rectangle) are plotted. ECC, HCC and BSA values 
are plotted on the y-axis, while domain-domain interacting pairs are shown on the x-axis according to 
the table numbers shown below the respective graphs. Some outliers (but only those with largish BSA) 
are labelled. Position for the two half domains of MG6 and CUB are also indicated with a solid black 
arrow at the top of the graph. Raw data may be viewed on Appendix CD, A.5.1 and A.5.2. 
In some cases (see Figure 5.5) there are differences in one or other of buried 
surface area, 11CC or ECC values, but in general these compensate for one another. 
Some major differences in buried surface area and energetically favoured contacts 
suggest that the arrangements of the anchor (32% identical) and C345C (29% 
identical) domains at the "top" of C3 are not necessarily emulated in C5 and therefore 
the model is possibly unreliable with respect to the precise positioning of these 
domains. It is interesting that these domains are amongst those rearranged upon 
cleavage of C3 to 0b. Overall, the analysis supports a very similar arrangement of 
domains in CS to that in C3, in agreement with other experimental observations 
(DiScipio et al. 1983) as discussed in the Introduction (Section 5.1.1). 
Turning to the C5b model, it is again apparent that most domain-domain 
interactions are as favourable as their counterparts in C3b. On the other hand, several 
of the new interdomain contacts that arise from domain rearrangements during the CS 
to C5b transition appear less convincing. In comparison with the equivalent interface 
in 0b, the TED-MG 1 interface has poorer electrostatic and hydrophobic contacts but 
only a slightly larger buried surface area. The nascent TED-CUBE and MG3-MG7 
interactions in C5b also appear weaker than those in 0b. Therefore, confidence in 
the model of C5b is lower and it is possible that the conformational transition upon 










5.3.2 The mode! of C5 reveals a novel putative disulfide bridge 
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MJU C04BHUMAN 	1 HLH ERPV 	fD-KNLTSNVSPEGL LAGS--
A2M_HUMAN 1 ET 1TL P-KCIRSQZASPA--LAVPVEKEQAPHCI 
C0109_HUMAN 	1 	FP 	i1AEI IF 	K-DATEKIIEKSIDK--0ILMTSNEINA--- 
TEPI_Anopheles 	1 ' E19 I 	VQF  F N G-AEYIADTYNANQ-TEFVGRPDT ------ 
C 
C05-HUMAN 	56 -TKSSI(CVRQKEGS I S 
CO3HUMAN 50 -TKRRliQTTI 





A2M HUMAN 58 CANGRQTVSW T - LGMN' TVSAEA ESQELCGTEVPSVPEHGP.].T IPLE 
C0109 HUMAN 	55 ---TGHQTLL •SEDGATL' PIPTE ZIPITTLSPTA----S. TQMILTK - 
TEPI_Anopheles 	53 --DLSYTKSS 	GVPIS LIKAR EMAVRRSIMLGH--ET EVI 
Figure 5.6: Novel disulfide bond in human CS. (a) Sequence alignment of MG7 among A2M family 
members. The MG7 domains from C5 (C05 HUMAN), C3 (CO3 HUMAN), C4 (C04 HUMAN), 
a2-macroglobulin (A2M HUMAN), CD 109 (CD IO9 HUMAN) from human and thioester-containing 
protein I (TEPI Anopheles) from Anopheles gambiae are shown using BOXSHADE version 3.21 
colouring (http:!!www.ch.embnet.org/software/BOX_form.html). The two cysteine residues in C5 
involved in the extra disulfide bond are marked on the alignment (connected with a yellow dashed 
line), and the location of the loop containing the trypsin cleavage site (K861) in C5 is indicated (red 
arrow). (b) MG7 domain, highlighting the location of the C5-specific disulfide bond. The MG7 
domain (marked within the dashed oval and labelled), depicting the location of the additional disulfide 
bond in C5 (Cys838-Cys865), on adjacent neighbouring antiparallel 3-strands. Also indicated is the 
location of the trypsin cleavage site at position Lys861, whose side-chain (blue) is highly exposed. 
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The crystal structure of C3 revealed thirteen disulfide bridges - eleven in the a-chain, 
one in the 13-chain, and one inter-chain disulfide in MG6" - all of which are 
predicted by conservation/homology to occur in related components C4 and C5. The 
model of CS, however, revealed a fourteenth disulfide bridge, not obvious previously, 
formed by residues Cys838 and Cys865 in its MG7 domain (Figure 5.6). This 
disulfide was calculated and built by the side-chain replacement program, SCWRL 
(Bower et al. 1997; Canutescu et al. 2003), which confirmed that these Cys side-
chains were in allowed rotamer conformations to form a disulfide bond. The 
measured Ca-Ca, and Sy-Sy atom distances between these Cys residues for the two 
models are as follows: C5-model: 6.55 A, 3.10 A; C5b-model: 6.61 A, 3.11 A. 
Disulfide bonds may be assumed to exist between two cysteine residues if their Sy-Sy 
atoms are < 3.5 A apart (Cheek et al. 2006) (and Ca-Ca atoms are approximately < 8 
A). 
The existence of this additional disulfide, not present in C3, C4 or other 
members of the a2M family (Figure 5.6a), raises several important questions. Was 
this disulfide bridge present in an ancestral protein but lost by each of the other A2M-
family members, during evolution, due to a lack of importance? Or has CS evolved a 
new disulfide because it is needed to fulfil an important specific role? It is interesting 
to note that a trypsin cleavage site (Lys 861) (Wetsel and Kolb 1982) lies in the loop 
connecting the two antiparallel 13-strands that are held together by this disulfide bond. 
Additionally, it is worth pointing out absence of an otherwise conserved disulfide 
bond within the TED domain in C4 and the a2M-family member Anopheles-TEP 
(Callister, Soares et. al., unpublished). In TED the two cysteine residues involved are 
strictly conserved in CM (Cys 1079, Cys 1136) for a range of species (mouse, 
chicken, cobra, trout, lamprey, and hagfish) (Nagar et al. 1998). 
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5.3.3 Location of indels and active sites mapped onto the models of C5 
and C5b 
Previous experimental studies on structure-function relationships in C5 focussed on 
indels - regions of deletion or insertion - between C3, C4 and C5 (Ogata and Low 
1997; Ogata et al. 1998; Low et al. 1999). The authors reasoned that regions of a 
protein near indels were good candidates for protein-protein interactions, because they 
would usually be expected to appear on the protein surface as loops. A series of 
indel-based mutational experiments and indel-derived peptide inhibitor studies were 
carried out on C5 (Low et al. 1999). This mutagenesis strategy reversed deletion and 
insertion sites in C5 relative to C3 or C4 at each of 27 indels in the C3/C4/C5 family, 
based upon inspection of a previously created multiple sequence alignment (Ogata 
and Low 1997). For example, if the indel were a putative insertion in C5 relative to 
C3 and or C4, those residues were deleted in the mutant; for a deletion in C5 relative 
to C3 and or C4, the corresponding residues from C3 or C4 were inserted. To further 
assess the usefulness of the indel strategy, the authors designed 23 peptides with 
indel-proximal sequences. Peptide sequences of about 14 residues in length, spanning 
an indel, were usually chosen. The precise length, sequence, and presence or absence 
of terminal amidationlacetylatiori were selected primarily to optimise peptide 
solubility (Low et al. 1999). The resulting panel of synthetic peptides was tested for 
their capacity to inhibit specific C5 and C5b-mediated protein-protein interactions. 
The availability of the C5 and C5b models now sheds fresh light on these 
studies. In particular they allow judgement of the likelihood that a particular mutation 
will cause localised structural perturbation or more general disruption of the structure. 
Moreover they allow each mutation to be considered in the context of its position on 
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the 3D structure relative to other domains and or residues implicated in function. 
mdcl 	 Mutant Sequences 	 mdcl 	 Mutant Sequences 
3-ch.in 
1 	 5-1 	 46 2 
hC5 VIQVYGYT* 	 hCS 
C5/Idl ------ VPRG ----------------- 	C5/1d2 
E??E 
3 5-3 169 
hC5 FIDPEGSEV* *DJEEIflHIGIISFpD 
C5/1d3 --------- KQ---------------- 
B-?B-- 
5 272 
hC5 DVYITFG I REDLKDDQKEMMQTAMQNT 
C5/1d5 
7 5-73 	5-7A 398 
hC5 L.NAOTIDVNOETSDL.DPSKSVTRVDDG 
C5/1d7 BEB EEE: BBffB ---------- 
9 5-9 483 
105 LVGEHLNIIVTPKSP_*yDjfNy 
C5/1c19 --------------- RA---------- 
13. 5-11 553 
hC5 IV'rGEOTAELVSDSVWL.NI EEKCGNQL 
C5/Idl1 -------- 	------------------ 
EE-BBB 






hC5 VSXEPEYNF IGYK * * NFK1'JFEITI KARY 
CS / 1d4 




5-6 	 307 








10 5-10 513 
hC5 L.SKGKI IHFGTREKSDASYOSINI PVT 
C5/IdlO ----------BEBEEE 
12 5-12 616 
hC5 AVYGVQRG * * ARK PLERFOFLEKSDLGC 
C5/1d12 -------- SH------------------ 
a-chain 
13/14 	 5-13/14 	 776 
hC5 GRLHMX1L * LPVSKPEI RSYFPESWLWE'/HLVPRR*****KQL.QFALPDSL. 
C5/1d13 --------QE 
CS/1d14 -------- f7 
E??BB--E-EBB 	 EEE-EB- 
15 	 5-15A t 	5-15B 879 16 	 947 
hC5 SESPVIDHOGTKSSKCVROKVEGSSHLVT }CS GVTLaDPRGIYGTISRRKEFPYRIPL 
C5/Idl5 -------------------------- C5/1d16 ------------------------- --BEEEEE-EEE --- E-EB  	 BEE-B 
17 	 5-17 986 18 	 5-18 	1035 
hC5 KGLL.VGEIL* *SAJL5pEGIHILTHLp hC5 ETGNH'JNIFHSDPLIEKOKLKXKLKEGM 
C5/1d17 ---------PG----------------C5/1d18 ---------------------------- 
19 	 1157 20 	 1226 
hC5 KAFDICP*****L.VKID'rALIX.ADNFL hC5 PIYRFWXDNL******QHKDSSVPNTGT 
C5/1d19 ------- EGAEP --------------- C5/1d20 ---------- SQSNAV------------ 
E?????E 	 -E--BBBBB- ?????? BEE-EE-B-BBB 
22. 	 1386 22 	 5-22A 	5-223 1418 
hC5 TQDIEASHYRG*****YGNSDYKRIVA hC5 KPSREESSSGSSI1VMDISL.P1'GI5ANE 
C5/Id2lA ----------- EDVED ----------- C5/Id.22 -------------- 
C5/Id218 -----------RARE 	 -BBBBBBB 
B????? - 
23 	 5-23 	1452 24 	 5-24 	 1509 
hC5 QL.FTDYOIKDGH* * * *VILOLNSIPSS hC5 DKQCTMVYSTS* *NIKIpJCECKC 
C5/1d23 ------------ SDRN ----------- C5/1d24 ----------- XE--------------- 
-E-BBB 
25 	 1537 26 	 5-26a 5-26 	 1627 
hC5 EADCGQMQEELDLTISAETRKQ'IACKP hC5 LIZKEALOIKYNFSEYIYPLDSLTWI 
C5/1d25 --------------------------- C5/Id26A ---------------------------- 
EEEBEEBEBEEB 	C5/Id26B ------- I3FWGE---------------- 
	
BB-EE 	-E-B 
27 	 1653 	 E-BEEEEEEEEEE- 
hC5 VWPRDTTCS * * SCQAFLANLDEFAEDI 
C5/1d27 --------- DE---------------- 
EEEE 
Figure 5.7: Exposure or burial of residues in human CS or C3 identified on the basis of a 
previous indel-driven mutagenesis strategy. The figure has been adapted from (Low et at. 1999) to 
show regions of the 27 originally identified indels (Idi, 1d2, 1d3 etc.), along with their accessibility 
according to the 3D-model of C5 and structure of C3. Dashes indicate identity of the indel sequence 
with the human C5 sequence. Asterisks indicate absent residues (gaps) in the indel relative to the CS 
sequence, or vice versa (i.e. deletion or insertion mutants respectively). Sequences of the 23 synthetic 
C5-derived peptides are underlined; double underlining indicates overlaps between synthetic peptides. 
Lys861, which is the primary trypsin cleavage site in C5, is labelled with a 't' near indel 15. The 
surface accessibility (Fraczkiewicz and Braun 1998) of indel residue side-chains, and some flanking 
residues, is indicated below the sequence: 'E' = exposed; 'B' = buried; '-.' = neither exposed nor 
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buried; '?' = relative to C4; red labelling indicates C5 model accessibility; blue labelling indicates C3 
structure residue accessibility. 
Indel Confirmed 	Low 	Cleaved by Category 	Poor activity 
indel? expression convertase? (A, B, C or D) 
1 No D 
2 No 	Yes No data 
3 No C 	 Yes 
4 Yes 	Yes No data 
S Yes B 
6 Yes 	Yes A 	 Yes 
7 No D 
8 No 	Yes D 
9 Yes Yes A 	 Yes 
10 Yes A Yes 
11 No 	Yes No data 
12 No D 
13 No D 
14 Yes 	 Poor B 
15 No Poor Special 	Yes 
16 No C Yes 
17 No D 
18 No D 
19 No D 
20 No D 
21 Yes B 
22 Yes B 
23 Yes A 	 Yes 
24 Yes B 
25 Yes B 
26a No D 
26b No C 	 Yes 
27 Yes B 
Table 5.4: Indels categorised on basis of activity: Indels enumerated in the previous study (Low et 
al. 	1999) are categorised according to the new structure-based sequence alignment as "confirmed 
indels", i.e. an appropriate insertion or deletion, expression levels, activity in MAC formation, along 
with susceptibility to convertase cleavage are indicated. 	Note (cobra venom factor.Bb) CVF.Bb was 
used as the convertase, rather than a true C5 convertase; CVF.Bb cleaves both C3 and C5. 
The C3 structure allows structure-guided sequence alignment and hence more 
accurate identification of indels. Many of these match to the previously proposed 
ones (Figure 5.7, which also summarise whether the residues concerned are exposed 
or buried within the structure of the parent protein). Thus of the mutations in the 
paper (identified as "indel 1" through "indel 27"), the following correspond to 
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deletions of residues that are located in loops within the modelled C5 structure, or 
insertions of residues corresponding to loops in the C3 structure: indels 4, 5, 6, 9, 10, 
14, 21a, 21b, 22, 23, 24, 25 and 27 (Table 5.4). Despite their presence in loops, not 
all of the residues concerned are in fact exposed (due to the multiple domain nature of 
the protein), but at the domain level these mutations should have only a localised 
structural effect. Other deletion mutations performed in the original work correspond 
to non-loop residues that are generally (but not always) buried in CS, while in some 
cases insertions were made between a pair of buried residues (Figure 5.7). These 
could prevent correct folding of a domain or have a wider structural impact. Poor 
expression levels were obtained for mutants with the following mutations: indels 2, 4 
and 11, and no functional data could be obtained for these. 
In the light of the CS structure it is possible to group these mutations into four 
categories as follows. A: appropriate mutations with regard to an indel-based strategy 
(using the new alignment) that cause reduced haemolytic activity (i.e. a reduction in 
the ability of the mutated CS to participate in terminal steps of the complement 
cascade); B: appropriate mutations as in category A but resulting in no loss of activity; 
C: mutations that don't match insertions or deletions according to the new alignment 
and that result in lowered haemolytic activity; and finally D: inappropriate mutations 
as in category C but not associated with significant loss of activity. The positions of 
residues corresponding to the various mutations were mapped onto the 3D structures 
of CS and CSb and are illustrated in Figures 5.8 and 5.9. Note that mutations 
identified as indel numbers 14 and 15 were found to be poor substrates for CS (CVF) 
convertase, while all the other expressed mutants were cleaved nearly as efficiently as 
the wild type (Table 5.4). Note that there is a trypsin cleavage site in CS at Lys 861, 
in the sequence 'QGTKSS' (while the convertase cleavage site is located at Arg 733, 
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in the sequence 'LGLH'). Trypsin cleavage is also blocked by Alexion's inhibitory 
antibodies (Alexion Pharmaceuticals, Cheshire, CT, USA), eculizumab and 
pexelizumab (Kaplan 2002; Whiss 2002), humanised monoclonal antibodies that 
prevents the cleavage of human complement component CS into its pro-inflammatory 
components (see Chapter 1, Section 1.5.1.2). Within the modelled CS structure, Lys 
861 occurs in the protruding loop in the MG7 domain, in between two disulfide 
bridges (one of which is unique to CS) (Figure 5.6b). This residue lies approximately 
48 A (Ca-to-Ca) from the convertase cleavage site at Arg 733. 
Those mutations that reduce haemolytic activity will be considered first. 
These might prevent productive interaction with C6 or C7, either in the C5:C6 or 
C5:C7 pre-activation complexes, or the C5b:C6 post-cleavage complex (Thai and 
Ogata 2004), although they might also interfere with subsequent steps in assembly of 
the MAC (see Section 5.3.4). Mutations might also perturb the mechanisms involved 
in the extensive domain-domain rearrangements that are required for the transition 
from CS to C5b. Indels 6, 9, 10 and 23 belong to category A (i.e. domain structures 
are likely retained). Indels 9 and 10, both in MGS, correspond to proximal loops at 
the base of the molecule (in the conventional view with C345C at the top, Figure 5.8) 
and together constitute an excellent candidate for a protein-protein recognition patch. 
Since this part of the molecule is completely unaffected by the conformational 
changes accompanying activation (cleavage of C5 to C5b) it could be involved in 
forming the pre-activation complexes. hdel 6 (MG3) lies on the side on the 0 ring 
and is also unaffected by activation since it is positioned far from the nascent 
interaction site for the displaced TED (in C5b). Despite the fact that they are —51 A 
(in CS) and -55 A (in C5b) apart, all three of these indels could contribute to the same 
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surprisingly involved insertion of several buried residues. Intriguingly, it lies on the 
face of MG8 close to the interface with the TED domain (with residue 11e1443, buried 
at the interface). Thus this mutation likely disrupts the arrangement of TED with 
respect 	to 	the 	rest 	of 	the 	C5 	protein. 
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Figure 5.8: Mutant mapping on C5 and C5b models that reduce haemolytic activity. Two views 
rotated by 1800  about the y-axis, showing C5/C5b surface mapping of mutant (indel) residues with 
reduced haemolytic activity (Low et al. 1999), i.e. categories A (red) and C (violet); also mapped in 
yellow is indel 15. Their corresponding domains are shown within square brackets. 
In category C, indel 3 also lies in the n-ring, within MG2 and near the 
interface with TED in C5, and with CUB in C5b. So this mutation might also disrupt 
the activation mechanism. Indels 16 (CUB) and 26b (C345C), correspond to two 
regions on the ct-chain, and exist in close proximity at the top of the structure (as 
viewed in Figure 5.8). Indel 16 involves deletion of three residues, Thr-Ile-Ser, which 
are exposed and lie in a loop of CUB (even though they do not correspond to an indel) 
and hence this mutation may in fact cause little structural change. The CUB domain 
undergoes a major orientation upon activation and in C5b, indel 16 appears to be 
exposed on the far side of CUB where it could form part of a nascent interaction site 
for C6. Indel 26b corresponds to a prominent feature of C345C that has been 
discussed elsewhere (Bramham et al. 2005b) (discussed further in Section 5.3.4). 
Categories B and D - that have no significant functional consequences - are 
distributed widely over the structure (Figure 5.9). Note, however, that no such 
mutants were found in MGS, MG7, or CUB. Although this could be a coincidence, it 
is interesting to note that the face of MGS between indels 9 and 10 (which are 
proximal) and indel 6 remains a very good candidate for C6 interactions and hence for 
future mutagenesis studies. One obvious difference between C5 and C5b is the 
prominence of indel 21 in the activated structure. The fact that insertion of a multiple 
residue sequence in this loop has no functional effects, however, implies that it is not 
critical for MAC formation. 
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Figure 5.9: Mutant mapping on C5 and C5b models that cause no loss of activity. Two views 
rotated by 1800 about the y-axis, showing C5/C5b surface mapping of mutant (indel) residues that 
cause no loss of haemolytic activity (Low et al. 1999), i.e. categories B (blue) and D (cyan). Their 
corresponding domains are shown within brackets. 
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Figure 5.10: Peptide mapping on C5 and C5b models. Two views rotated by 1800  about they-axis, 
showing surface mapping of peptide residues that cause 50% inhibition of both haemolytic and 
bactericidal activities at <=100yM in CS and C5b (Low et al. 1999); indels 4, 13/14 and 26 coloured 
differently. Their corresponding domains are shown within square brackets. 
A review of the peptide studies in the 3D structural context is, unfortunately, 
less illuminating (Figure 5.10). Only peptide 26 coincides with a category A or C 
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mutation, thus confirming this prominent feature of C345C as of significant functional 
interest. Peptide 4 corresponds with indel 4, which was not expressed well and 
therefore not investigated - nonetheless the equivalent sequence of residues (to 
peptide 4) lies close to indel 6 (Figure 5.10) that was previously identified as 
potentially important (see above). 	The lack of any significant functional 
consequences for indels 13 and 14 is not irreconcilable with the observation that a 
peptide selected from a region between these two indels (Figure 5.10) inhibited 
haemolysis. This peptide corresponds to the C-terminal part of a'NT and could 
participate in protein-protein interactions independently of indels 13 and 14, although 
none of the other experiments had identified this region as important. 
5.3.4 The functional role of the C345C domain revisited in view of the 
intact C5 model 
The C-terminal —150 amino acid residue portions of the u-chains of C3 and CS and of 
the y-chain of C4 had been anticipated to form independently folded units prior to 
determination of the C3 structure (Ishii et al. 1992; Banyai and Patthy 1999; 
Brainham et al. 2005b). These regions not only exhibit high sequence-similarity with 
one another (Table 5.3) but their sequences also resemble those of the C-terminal 
segment of the Caenorhabditis elegans UNC-6, procollagen C-proteinase enhancer 
proteins and secreted frizzled-related proteins among others. This family of domains 
has been named the netrin-like (NTR) module (Banyai and Patthy 1999). 
It is notable that C5-C345C, unlike the C345C domain of C3, can bind to both 
C6 and C7 in surface plasmon resonance-based assays (Thai and Ogata 2003). 
Furthermore C5-C345C can inhibit recruitment of C7 by C5b.C6 through an 
interaction between C5-C345C and the pair of factor I membrane attack complex 
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(FIIVIAC) domains, (also called Factor-I-modules (Filvis)), at the C-terminus of C7. 
Thus the C5-C345C domain provides at least part of the interacting surface between 
C5b and C7 in formation of the MAC. The C345C domain also harbours a region that 
interacts with the C5 convertase (Sandoval et al. 2000), although the cleavage site 
itself lies some 800 residues away towards the N-terminus of the a-chain of C5 (-45 
A from the cleavage site). Expression of the segment of C5 corresponding to its 
C345C domain (C5-C345C) resulted in a full 3D solution structure (Bramham et al. 
2005b). The NMR-derived structure helped to identify functionally important patches 
on C5-C345C but the orientation of C5-C345C relative to the remainder of C5/C5b 
was not known and this limited the usefulness of structure-function analysis. The new 
homology models for C5 and C5b partially make good this knowledge deficit 
(although there is some uncertainty about the reliability of the modelling in terms of 
placing this domain accurately - see Section 5.3.1). 
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Figure 5.11: Position of C345C within intact Cs model. A cartoon representation of the C345C 
domain is shown in yellow along with neighbouring and interacting domains - CUB (blue), MG7 (hot 
pink), MG8 (cyan) and the anchor region (light green). The assigned secondary structure in C345C is 
labelled according to Bramham et al. (Bramharn et al. 2005b). A surface representation of the same 
view is shown on the right hand panel. 
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The core of C345C is a barrel composed from two orthogonal, three-stranded, 
antiparallel twisted 13-sheets made up from strands ACBC  and strands ANDE 
(where the superscripts N and C denote the N- and the C- terminal halves of strand A) 
(Figure 5.11). Two adjacent a-helices - a shorter more N-terminal one (helix-1) and a 
longer C-terminal helix-2 - are essentially aligned with, and lie against, the convex 
face of the ANDE  sheet. The N-terminal segment of the domain runs above one end 
of the barrel, from Cys 1514 to the top of helix-1. Cys 1514 is disulfide-linked to Cys 
1588, which is located in the long CD-loop; the CD loop crosses over the otherwise 
open end of the barrel from the ACBC  sheet to the ANDE  sheet. At the bottom of 
the short helix-I the transition to the long strand A contains Cys 1535, which is linked 
to Cys 1658, the C-terminal residue of the module. The BC-loop caps off the other 
end of the barrel. The long DE-loop protrudes prominently from the more open side 
of the barrel-like structure, opposite to the pair of helices. After strand E, a stretch of 
13 residues makes the transition to the top of helix-2. From residue 1634 onwards 
this region forms a bulge above helix-2 (Figure 5.11). Most of the solvent-exposed 
hydrophobic residues lie in the DE loop, while Phe 1654 and Leu 1655 are exposed 
near the C-terminus. Adjacent to this exposed pair of side-chains is a patch of 
negatively charged side-chains (Glu 1528, 1648 and 1651; Asp 1647 and 1652) that 
dominate the electrostatic surface of C5-C345C (see below) (Bramham et al. 2005b). 
In the typical view of C3/C5 (Figures 5.2 and 5.8), the C345C domain is a 
clearly defined structural entity perched prominently atop the a chain exposing a large 
surface area for potential protein-protein interactions. This remains true upon 
transition to C3b/C5b, even though C345C swivels 32° and moves 10.1 A in C3b 
(Janssen et al. 2005; Janssen et al. 2006). The face of C345C that contacts the body 
of CS is made up from the AB loop, along with the CD loop that is disulfide linked to 
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the N-terminal residue of the domain (Figure 5.11). This leaves the two (X-helices 
facing away from the rest of CS, and the aforementioned negative patch and adjacent 
Phe 1654-Leu 1655 pair are well placed to make intermolecular contacts. This part of 
the structure exhibits structural differences from other NTR modules, and diversity in 
terms of chemical character amongst C3, C4 and CS. The C345C domain of C3 has 
many more Asp and Glu residues than either the C4 or CS equivalents, and 
consequently has an overall electronegative character - but C3 lacks the patch of five 
negatively charged side chains that occur next to the exposed hydrophobic side-chains 
near the C-terminus of CS (Bramham et al. 2005b). Note that C5-C345C, but not the 
equivalent domain from C3, binds reversibly to C6 and C7 (the p1 of C7-FIMAC-I is 
9.5 consistent with a strong ionic component in recognition of the highly acidic C5-
C345C domain). 
The very long DE loop (14 residues, Ala 1606-to-Tyr 1619) is also exposed 
and is not involved in the interface with the rest of CS or CSb according to the 
models. This is surprising given its high content of hydrophobic residues, and (if the 
model is accurate) enhances the value of previous mutagenesis work on this region 
(Low et al. 1999). Substitution of Leu 1607-Tyr 1611 - a poorly structured region of 
the DE loop with no buried side-chains - by the sequence DFWGE (indel 26b, 
discussed above) destroyed haemolytic activity. Subsequent substitutions of Ile 1609 
or Tyr 1611 by Ala had little effect on haemolytic activity or proteolytic 
susceptibility. Substitution of the exposed Lys 1610, on the other hand, produced 
mutant CS molecules with both low haemolytic activity and decreased sensitivity to 
proteolytic activation. This pinpoints Lys 1610 as the functionally critical residue in 
the indel 26b pentapeptide. Substitution of Phe 1613 and Phe 1615 also perturbed 
haemolytic activity and decreased proteolytic susceptibility to the classical pathway 
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convertase (but not cobra venom factor, which presumably has a different recognition 
mechanism). Comparison of HSQC spectra for the wild-type and Phe1613AIa 
versions of C5-C345C has proved that this mutation exerts no non-local structural 
effects at the domain level (Bramham et at. 2005b), and the intact model suggests no 
effects on interdomain orientations; Phe 1615 is also exposed, and mutation to Ala 
would be equally unlikely to disrupt structure. Therefore these mutagenesis results, 
considered in the context of the model of C5, clearly identify three exposed side-
chains (1610, 1613 and 1615) on the DE extension as being specifically involved in 
an interaction with the convertase that is critical for function. 
This is reinforced (see above) by the observation that a peptide extending from 
Lys 1604 to Arg 1616 inhibited complement haemolytic activity and activation of C5 
by the convertase pathway CS convertase (but not cobra venom factor) (Sandoval et 
al. 2000). 	Furthermore, the consequences for inhibitory activity of alanine 
substitution within the peptide reflected alanine-scanning mutagenesis results. The 
peptide studies therefore provide additional evidence for a direct interaction between 
the DE extension and the classical pathway convertase. Based on the structure of CS, 
the C345C module is -45 A from the convertase cleavage site, implying an extended 
interaction surface. An extended interaction surface between CS and its convertase is 
not surprising, since the convertase is a huge complex (>400 kDa). 
5.3.5 Electrostatic and lipophilic surface analysis of C5 and C5b 
Negative charge dominates the surfaces of the models of CS and C5b (Figure 5.12). 
This is consistent with their calculated theoretical p1 values derived from their 
sequence (Bjellqvist et al. 1993). The p1 of CS is 6.07, and it is 5.85 for CSb. The 
ANA domain, which gets cleaved off as C5a on the other hand, is basic (p1 = 8.93). 
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Prominent charged features in the model of C5, involve the J3-chain MG-ring-like 
scaffold that appears to contain a highly acidic patch, while regions on TED remain 
largely neutral. Upon activation, conformationally different C5b reveals a more 






























Figure 5.12: GRASP surface representations of CS and C5b models. Two views rotated by 1800 
about the y-axis depicting the electrostatic surface representation of C5 (left panel) and C5b (right 
panel) models, respectively. Scale shown on the right-hand side; coloured from red (acidic) to blue 
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Figure 5.13: MOLCAD surface representations of CS and C51J models. Two views rotated by 1800 
about the y-axis depicting the lipophilic surface representation of models C5 and C5b, coloured from 
brown (hydrophobic) to blue (hydrophilic) - scale shown on the right-hand side. 
The conformational change that accompanies activation of C5 to C5b is 
central to the formation of the membrane attack complex. Upon activation, a transient 
hydrophobic patch appears in C5b that binds irreversibly to C6 (Muller-Eberhard 
1985; 1986), creating a nucleation site (C5bC6, the post-activation complex) that 
proceeds to accrete components C7, C8 and multiple copies of C9, leading to 
formation of the MAC. The lipophilic surface analysis (Figure 5.13) of the model of 
C5b now allows proposal of candidate sites. Interesting among them are exposed 
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patches of hydrophobic residues on CUB, TED - particularly near their interface - and 
as discussed earlier (Section 5.3.4) in the DE-loop of C345C. 
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Figure 5.14: Hypothetical model for assembly of terminal pathway interactions. The models of 
C5 and C5b are shown along with potential regions of interaction with the large convertase (in C5), C6 
and C7 (in both) - not drawn to scale. According to this model, in C5, indels 6, 9, 10 and 26b 
potentially participate in protein-protein interactions along with the region above helix-i of C345C. 
The convertase cleavage site (Arg 733) is indicated in green. The right hand panel shows indels 16 and 
26b in C5b now contributing to the interaction site with C6, while the interaction with C7 remains 
unchanged. 
In the work described in this chapter, a model of CS has been built by homology with 
the C3 structure and evaluated. The C5 model reveals the presence of a previously 
unrecognised disulfide. A model of C5b was also built that is probably valid at the 
domain level. These models are not inconsistent with conformational changes upon 
activation that generally emulate those seen in C3. But analysis of domain-domain 
interactions revealed uncertainty in the precise orientation of domains in the activated 
structure. In particular, the model did not provide support for the newly positioned 
TED in C5b adopting the same orientation as in C3b. That the TED in C5b could be 
twisted, for example, is not unreasonable since the CS TED contains no thioester and 
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must perform a different role to the C3/C4 TEDs. Inspection of previous indel-based 
mutagenesis data allows construction of a hypothetical model. This is illustrated in 
Figure 5.14. Models such as this are useful as hypothesis generators and can be tested 
experimentally by mutagenesis or by biophysical methods such as SAXS or FRET. 
The model predicts that C6 associates differently with CS (pre-activation complex) 
and C5b (post-activation complex), while C7 remains attached to the C345C domain. 
In the activation complex, C6 and C7 could be brought into proximity creating a 
novel site for C8. 
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